



hmrn

Haematological Malignancy
Research Network

First report to the clinical network
-2011-

Haematological Malignancy Research Network: first report to the clinical network

Background

The Haematological Malignancy Research Network (HMRN) was established to provide robust, generalizable data to inform clinical practice and research; it is a collaborative project between the clinical network, the Haematological Malignancy Diagnostic Service (HMDS) and the Epidemiology & Cancer Statistics Unit (ESCG) at the University of York. Since September 2004, all new diagnoses made by HMDS from patients across the Yorkshire and Humber & Yorkshire Coast Cancer Networks who had no prior record of a haematological malignancy have been included in HMRN. For these patients, demographic and clinical data have been abstracted from their medical records by ESCG research nurses, and these data have been added to the diagnostic information obtained from HMDS. This initial report is based on 10,729 diagnoses from 10,306 patients newly diagnosed in the first five years of HMRN: 1st September 2004 to 31st August 2009.

Methods & Interpretation

Death certificate data for all patients is obtained from the NHS Central Register (NHSCR) and the analysis presented here includes all deaths up to the 31st May 2011. Overall survival and 1-year survival have been calculated using time to event analyses, including Kaplan-Meier and Cox proportional hazard regression. Relative survival, which takes into account the background mortality rate in the general population, has also been estimated.

Comparisons between hospitals and MDTs were made using the organisation (hospital or MDT) with the largest number of patients as the baseline: Leeds Teaching Hospitals in the case of the former and Humber Yorkshire Coast Cancer Network (HYCCN) in the case of the latter. Risk estimates are reported for hospitals with 10 or more diagnoses.

To adjust for differences in case-mix, diagnostic age and sex were routinely included in the models. These adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) are reported alongside the unadjusted estimates. Where appropriate, further adjustments were

made for prognostic factors, for example International Prognostic Index (IPI) for diffuse large B-cell lymphoma (DLBCL). More information about the data presented is provided in the figure overleaf. For hospitals where only one patient was diagnosed or recorded, information has been removed from the rows to protect patient confidentiality; hence some tables may not sum to the total presented. With respect to interpretation, an important caveat is that due to the large number of comparisons made, some associations may have occurred by chance alone. Future reports will allow the use of different statistical techniques as the number of diagnoses will increase, thus avoiding the need to make comparisons to one institution.

A HR of 1.91 (1.29 – 2.82) means patients are nearly twice as likely to die compared to the baseline group. However, when the analysis is repeated taking into account differences in case-mix by hospital (age at diagnosis and sex) there is no longer any difference in survival: 1.15 (0.77 - 1.70).

Table 42: AML Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	717 (100)	68.8 (0.2 - 97.2)	155 (21.6)	562 (78.4)	-	-
Hospital:						
Airedale	36 (5.0)	73.4 (0.2 - 91.4)	3 (8.3)	33 (91.7)	1.91 (1.29 - 2.82)	1.15 (0.77 - 1.70)
Bradford Royal	59 (8.2)	70.5 (17.5 - 89.3)	12 (20.3)	47 (79.7)	1.60 (1.14 - 2.25)	1.27 (0.90 - 1.79)
Calderdale & Huddersfield	58 (8.1)	71.2 (24.6 - 90.9)	8 (13.8)	50 (86.2)	1.56 (1.11 - 2.18)	1.04 (0.74 - 1.46)
Leeds Teaching	162 (22.6)	58.8 (0.5 - 94.9)	52 (32.1)	110 (67.9)	1	1
Harrogate & District	28 (3.9)	73.0 (55.2 - 96.3)	2 (7.1)	26 (92.9)	1.92 (1.25 - 2.95)	1.02 (0.66 - 1.56)
York Teaching	54 (7.5)	70.8 (17.7 - 90.7)	14 (25.9)	40 (74.1)	1.09 (0.76 - 1.56)	0.69 (0.47 - 1.00)
Dewsbury & District	25 (3.5)	77.0 (25.8 - 97.2)	4 (16.0)	21 (84.0)	1.50 (0.94 - 2.40)	1.00 (0.63 - 1.61)
Pinderfields General	38 (5.3)	64.8 (17.0 - 86.4)	11 (29.0)	27 (71.1)	1.10 (0.72 - 1.67)	1.04 (0.68 - 1.59)
Pontefract General	32 (4.5)	74.3 (22.5 - 94.3)	5 (15.6)	27 (84.4)	1.55 (1.02 - 2.37)	0.98 (0.64 - 1.50)
Hull & East Yorkshire	125 (17.5)	65.3 (16.9 - 93.9)	34 (27.2)	91 (72.8)	1.17 (0.89 - 1.55)	0.92 (0.69 - 1.21)
Scarborough	21 (2.9)	76.7 (17.4 - 95.7)	3 (14.3)	18 (85.7)	1.80 (1.08 - 2.96)	1.06 (0.64 - 1.75)
Grimsby (DPOW)	24 (3.4)	73.7 (34.4 - 86.7)	3 (12.5)	21 (87.5)	1.63 (1.02 - 2.60)	1.13 (0.71 - 1.81)
Scunthorpe General	53 (7.4)	76.3 (13.9 - 89.8)	3 (5.7)	50 (94.3)	2.25 (1.61 - 3.15)	1.33 (0.95 - 1.87)
Private	1 (0.1)	72.9 (-)	1 (100)	-	-	-
No Haematology Referral	1 (0.1)	79.7 (-)	-	1 (100)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	95 (13.3)	71.2 (0.2 - 91.4)	15 (15.8)	80 (84.2)	1.17 (0.90 - 1.52)	1.18 (0.90 - 1.53)
Leeds	220 (30.7)	63.3 (0.5 - 94.9)	60 (27.3)	160 (72.7)	0.77 (0.62 - 0.95)	0.98 (0.79 - 1.22)
Harrogate/York	82 (11.5)	71.2 (17.7 - 96.3)	16 (19.5)	66 (80.5)	0.89 (0.67 - 1.18)	0.76 (0.57 - 1.02)
Mid-Yorks	95 (13.3)	70.2 (17.0 - 97.2)	20 (21.0)	75 (79.0)	0.91 (0.70 - 1.20)	0.97 (0.74 - 1.28)
HYCCN ³	223 (31.2)	70.5 (13.9 - 95.7)	43 (19.3)	180 (80.7)	1	1
Private	1 (0.1)	72.9 (-)	1 (100)	-	-	-
No Haematology Referral	1 (0.1)	79.7 (-)	-	1 (100)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Baseline group

Hazard ratios (HR) are only reported for groups with 10 or more patients.

Baseline group

Statistical significance can be inferred from the confidence intervals. If the 95% Confidence Intervals do not include 1, the effect is statistically significant at the 5% level (p<0.05)

A HR of 0.77 (0.62 - 0.95) means that there is a statistically significant (p<0.05) increase in survival by 23% for patients in the Leeds MDT compared to the baseline group - HYCCN. However, when the analysis is repeated taking into account differences in case-mix by MDT (age at diagnosis and sex) there are no longer any differences: 0.98 (0.79 - 1.22).

HMRN First Report to the Clinical Network

Review by Audit Committee

The HMRN audit committee reviewed this report on the 9th of March 2012, the purpose being to determine:

- 1. That the data was valid and presented in a way that could reasonably be interpreted by all members of the network and the public.*
- 2. To identify any areas of concern with regard to clinical practice that would require further investigation.*
- 3. To agree the communication policy for the report.*

With respect to the first objective the committee were impressed by the depth and quality of the information. They were satisfied that the processes for collection and analysis of the data were robust and presented in a form that could easily be interpreted by readers.

To identify areas of clinical concern the committee reviewed all of the comparative data presented in the report. The committee received support in their interpretation of the data from members of staff at the Epidemiology and Cancer Statistics Group (ECSG). They were particularly mindful of the fact that when analysing such large numbers of variables it was highly likely that the 95% confidence intervals used would lead to a number of "statistically significant" results being produced that were due to chance rather than real variances.

Overall the committee were impressed by the consistency of performance between different units and MDTs across the spectrum of haematological malignancies. They felt that this reflected the effective MDT structure, the high quality diagnostic service and robust treatment guidelines in operation across the clinical network.

The committee identified only 2 areas of potential variation that they considered may required further investigation. All other identified variances were felt to be of such a minor degree or to relate to such small numbers that they were almost certainly related to chance. The 2 areas identified were DLBCL and Myeloma.

An initial inspection of DLBCL data appeared to demonstrate comparatively poor performance at Leeds Teaching Hospitals. However, further analysis revealed that the result could be explained by the high proportion of patients with CNS involvement that were treated in LTH in accordance with network guidelines. These patients have a particularly poor outcome, and when this was taken into account no evidence of significant variation in outcomes remained. The committee accepted this explanation and did not consider any further action was required.

The committee felt that the myeloma analysis demonstrated significant variation in outcome with respect to patients diagnosed in Pontefract and to a lesser extent in Scunthorpe. In both units the poor performance appeared to have no obvious explanation. The committee were advised that a more detailed myeloma audit, which would provide a greater level of detail on prognostic factors and therapy across the network, was already being undertaken. The committee agreed that a more detailed analysis was the appropriate action; and also advised that because of the large apparent variance, the Mid Yorkshire MDT should review the cases treated at Pontefract. It was agreed that the identity of the patients would be made available to the MDT for this purpose.

The committee agreed that the report should be disseminated widely to both commissioners and provider organisations across the network and that it would be made available on the public area of the HMRN website. It was agreed that all network clinicians would be informed prior to circulation.

Russell Patmore

Chair, HMRN Audit Committee

Contents

Table 1: Number of Diagnoses - Total.....	8
Hospital	9
Table 2: Number of Diagnoses - Airedale	9
Table 3: Number of Diagnoses - Bradford Royal.....	10
Table 4: Number of Diagnoses - Calderdale & Huddersfield	11
Table 5: Number of Diagnoses - Leeds Teaching Hospitals	12
Table 6: Number of Diagnoses - Harrogate & District	13
Table 7: Number of Diagnoses - York Teaching Hospital.....	14
Table 8: Number of Diagnoses - Dewsbury & District	15
Table 9: Number of Diagnoses - Pinderfields General.....	16
Table 10: Number of Diagnoses - Pontefract General	17
Table 11: Number of Diagnoses - Hull & East Yorkshire Hospitals	18
Table 12: Number of Diagnoses - Scarborough	19
Table 13: Number of Diagnoses - Grimsby (Diana Princess of Wales).....	20
Table 14: Number of Diagnoses - Scunthorpe General	21
Multi-Disciplinary Team	22
Table 15: Number of Diagnoses - Airedale / Bradford.....	22
Table 16: Number of Diagnoses - Leeds	23
Table 17: Number of Diagnoses - Harrogate / York.....	24
Table 18: Number of Diagnoses - Mid-Yorks	25
Table 19: Number of Diagnoses - Humber Yorkshire Coast Cancer Network	26
Primary Care Trusts.....	27
Table 20: Number of Diagnoses - Bradford & Airedale Teaching.....	27
Table 21: Number of Diagnoses - Calderdale	28
Table 22: Number of Diagnoses - Leeds	29
Table 23: Number of Diagnoses - Kirklees	30
Table 24: Number of Diagnoses - Wakefield District.....	31
Table 25: Number of Diagnoses - North Yorks & York.....	32
Table 26: Number of Diagnoses - East Riding	33
Table 27: Number of Diagnoses - Hull Teaching	34
Table 28: Number of Diagnoses - North East Lincolnshire	35
Table 29: Number of Diagnoses - Lincolnshire Teaching.....	36

Table 30: Number of Diagnoses - East Lincolnshire Teaching	37
Table 31: Number of Diagnoses - North Lincolnshire	38
Chronic Myeloid Leukaemia (CML)	39
Table 32: CML Patient Demographics and Overall Survival	39
Table 33: CML Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	40
Figure 1: CML Overall Survival	41
Figure 2: CML Relative Survival	41
Figure 3: CML Survival by Age (Years)	42
Myeloproliferative Neoplasms (MPN)	43
Table 34: MPN Patient Demographics and Overall Survival	43
Table 35: MPN Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	44
Figure 4: MPN Overall Survival	45
Figure 5: MPN Relative Survival	45
Figure 6: MPN Survival by Age at Diagnosis (Years)	46
Primary Myelofibrosis	47
Table 36: Primary myelofibrosis Patient Demographics and Overall Survival	47
Table 37: Primary myelofibrosis Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	48
Figure 7: Primary myelofibrosis Overall Survival	49
Figure 8: Primary myelofibrosis Relative Survival	49
Figure 9: Primary myelofibrosis Survival by Age at Diagnosis (Years)	50
Chronic Myelomonocytic Leukaemia (CMML)	51
Table 38: CMML Patient Demographics and Overall Survival	51
Table 39: CMML Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	52
Figure 10: CMML Overall Survival	53
Figure 11: CMML Relative Survival	53
Figure 12: CMML Survival by Age at Diagnosis (Years)	54
Myelodysplastic Syndrome (MDS)	55
Figure 13: MDS Subtypes	55
Table 40: MDS Patient Demographics and Overall Survival	55
Table 41: MDS Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	56
Figure 14: MDS Overall Survival	57
Figure 15: MDS Relative Survival	57
Figure 16: MDS Survival by Age at Diagnosis (Years)	58

Figure 17: MDS Survival by International Prognostic Scoring System Score	58
Figure 18: MDS Survival by Disease Subtype	59
Acute Myeloid Leukaemia (AML).....	60
Figure 19: AML Subtypes	60
Table 42: AML Patient Demographics and Overall Survival.....	60
Table 43: AML Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	61
Table 44: AML Overall Survival by Treating Hospital.....	62
Table 45: AML Patient Demographics and 1-year Survival.....	63
Table 46: AML - 1 Year Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	64
Table 47: AML 1-year Survival by Treating Hospital	65
Figure 20: AML Overall Survival	66
Figure 21: AML Relative Survival.....	66
Figure 22: AML Survival by Age at Diagnosis (Years)	67
Figure 23: AML Survival by Subtype.....	67
Precursor Acute Lymphoblastic Leukaemia (ALL).....	68
Figure 24: ALL Subtypes	68
Table 48: ALL Patient Demographics and Overall Survival	68
Table 49: ALL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	69
Table 50: ALL Overall Survival by Treating Hospital.....	70
Figure 25: ALL Overall Survival.....	71
Figure 26: ALL Relative Survival	71
Figure 27: ALL Survival by Age at Diagnosis (Years).....	72
Figure 28: ALL Survival by Age at Diagnosis (Years).....	72
Monoclonal B-cell lymphocytosis (MBL).....	73
Table 51: MBL Patient Demographics and Overall Survival.....	73
Table 52: MBL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	74
Figure 29: MBL Overall Survival	75
Figure 30: MBL Relative Survival.....	75
Figure 31: MBL Survival by Age at Diagnosis (Years)	76
Chronic Lymphocytic Leukaemia	77
Table 53: CLL Patient Demographics and Overall Survival.....	77
Table 54: CLL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	78
Figure 32: CLL Overall Survival.....	79
Figure 33: CLL Relative Survival.....	79

Figure 34: CLL Survival by Age at Diagnosis (Years)	80
Figure 35: CLL Survival by Binet Score	80
Hairy Cell Leukaemia (HCL)	81
Table 55: HCL Patient Demographics and Overall Survival.....	81
Table 56: HCL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	82
Figure 36: HCL Overall Survival	83
Figure 37: HCL Relative Survival.....	83
Monoclonal Gammopathy of Undetermined Significance (MGUS).....	84
Table 57: MGUS Patient Demographics and Overall Survival.....	84
Table 58: MGUS Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	85
Figure 38: MGUS Overall Survival	86
Figure 39: MGUS Relative Survival.....	86
Figure 40: MGUS Survival by Age at Diagnosis (Years)	87
Myeloma	88
Table 59: Myeloma Patient Demographics and Overall Survival.....	88
Table 60: Myeloma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	89
Table 61: Myeloma Overall Survival by Treating Hospital	90
Table 62: Myeloma Patient Demographics and 1 - Year Survival	91
Table 63: Myeloma - 1-Year Survival by Diagnostic Hospital and MDT.....	92
Table 64: Myeloma 1- Year Overall Survival by Treating Hospital.....	93
Figure 41: Myeloma Overall Survival	94
Figure 42: Myeloma Relative Survival.....	94
Figure 43: Myeloma Survival by Age.....	95
Figure 44: Myeloma Relative Survival by Age	95
Figure 45: Myeloma Survival by B ² M (mg/L)	96
Plasmacytoma.....	97
Table 65: Plasmacytoma Patient Demographics and Overall Survival	97
Table 66: Plasmacytoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	98
Figure 46: Plasmacytoma Overall Survival.....	99
Figure 47: Plasmacytoma Relative Survival	99
Figure 48: Plasmacytoma Survival by Age at Diagnosis	100
Follicular Lymphoma.....	101
Table 67: Follicular Lymphoma Patient Demographics and Overall Survival	101

Table 68: Follicular Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	102
Figure 49: Follicular Lymphoma Overall Survival.....	103
Figure 50: Follicular Lymphoma Relative Survival	103
Figure 51: Follicular Lymphoma Survival by Age at Diagnosis (Years).....	104
Marginal Zone Lymphoma (MZL).....	105
Figure 52: MZL Subtypes.....	105
Table 69: Total MZL Patient Demographics and Overall Survival.....	105
Table 70: Systemic MZL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	106
Table 71: Extranodal MZL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team ..	107
Figure 53: MZL Overall Survival	108
Figure 54: MZL Survival by Disease Subtype.....	108
Figure 55: MZL Relative Survival.....	109
Figure 56: Systemic MZL Relative Survival.....	109
Figure 57: Extranodal MZL Relative Survival.....	110
Figure 58: MZL Survival by Age (Years).....	110
Mantle Cell Lymphoma	111
Table 72: MCL Patient Demographics and Overall Survival.....	111
Table 73: MCL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	112
Figure 59: MCL Overall Survival	113
Figure 60: MCL Relative Survival.....	113
Figure 61: MCL Survival by Age at Diagnosis (Years)	114
Diffuse Large B - Cell Lymphoma (DLBCL).....	115
Figure 62: DLBCL Subtypes.....	115
Table 74: DLBCL Patient Demographics and Overall Survival.....	115
Table 75: DLBCL Overall Survival by Hospital and Multi-Disciplinary Team	116
Table 76: DLBCL Overall Survival by Treating Hospital	117
Table 77: DLBCL by International Prognostic Index (IPI).....	118
Table 78: DLBCL 1-Year Survival by Hospital and Multi-Disciplinary Team	119
Table 79: DLBCL 1-Year Survival by Treating Hospital	120
Figure 63: DLBCL Overall Survival	121
Figure 64: DLBCL Relative Survival.....	121
Figure 65: DLBCL Survival by Age at Diagnosis (Years)	122
Figure 66: DLBCL Relative Survival by Age at Diagnosis (Years)	122

Figure 67: DLBCL Survival by IPI Score	123
Figure 68: DLBCL Survival by CNS Involvement	123
Burkitt Lymphoma	124
Table 80: Burkitt Lymphoma Patient Demographics and Overall Survival	124
Table 81: Burkitt Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	125
Table 82: Burkitt Lymphoma Overall Survival by Treating Hospital	126
Figure 69: Burkitt Lymphoma Overall Survival	127
Figure 70: Burkitt Lymphoma Survival by Age at Diagnosis (Years)	127
Lymphoproliferative Disorder, NOS.....	128
Table 83: LPD NOS Patient Demographics and Overall Survival	128
Table 84: LPD NOS Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	129
Figure 71: LPD NOS Overall Survival	130
Figure 72: LPD NOS Relative Survival.....	130
Figure 73: LPD NOS Survival by Age at Diagnosis (Years)	131
Hodgkin Lymphoma	132
Figure 74: Hodgkin Lymphoma Subtypes	132
Table 85: Hodgkin Lymphoma Patient Demographics and Overall Survival.....	132
Table 86: Hodgkin Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team	133
Table 87: Classical Hodgkin Lymphoma Patient Demographics and Overall Survival	134
Table 88: Classical Hodgkin Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team.....	135
Table 89: Classical Hodgkin Lymphoma by Treating Hospital.....	136
Figure 75: Hodgkin Lymphoma Overall Survival	137
Figure 76: Hodgkin Lymphoma Relative Survival.....	137
Figure 77: Hodgkin Lymphoma Survival by Age (Years).....	138
Figure 78: Hodgkin Lymphoma Survival by IPI Score.....	138
Figure 79: Hodgkin Lymphoma Survival by Disease Subtype	139
T-cell Disorders	140
Figure 80: T-cell Disorders	140
Table 90: T-cell Disorders Patient Demographics.....	140
Table 91: T-cell Disorders by Diagnostic, Treating Hospital and Multi-Disciplinary Team	141
Figure 81: T-cell Disorders Overall Survival	142
Figure 82: T-cell Disorders Relative Survival	142

Figure 83: T-cell Prolymphocytic Leukaemia Overall Survival	143
Figure 84: T-cell or NK - cell Large Granular Lymphocytosis Overall Survival.....	143
Figure 85: Extranodal NK/T-cell Lymphoma, Nasal Type Overall Survival.....	144
Figure 86: Enteropathy - type T-cell Lymphoma Overall Survival.....	144
Figure 87: Mycosis Fungoides Overall Survival	145
Figure 88: Primary Cutaneous CD30 Positive T-cell Overall Survival	145
Figure 89: Anaplastic Large Cell Lymphoma of T/Null Type Overall Survival	146
Figure 90: Peripheral T-cell Lymphoma - Common; Unspecified Overall Survival	146

Table 1: Number of Diagnoses - Total

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	651	1,908	2,092	2,180	2,378	1,520	10,729
Chronic myeloid leukaemia	10	25	29	43	35	23	165
Myeloproliferative neoplasms	34	117	209	242	205	154	961
Primary myelofibrosis	2	11	10	14	25	11	73
Chronic myelomonocytic leukaemia	6	9	14	24	26	19	98
Myelodysplastic syndromes	43	101	116	141	145	107	653
Acute myeloid leukaemia	34	126	162	157	134	104	717
Precursor lymphoblastic leukaemia	14	48	46	36	52	21	217
Monoclonal B-cell lymphocytosis	25	90	88	89	105	48	445
MGUS	99	221	222	189	239	165	1,135
Chronic lymphocytic leukaemia	82	209	226	213	241	173	1,144
Hairy cell leukaemia	5	10	7	16	10	7	55
Plasma cell myeloma	57	213	208	232	254	163	1,127
Plasmacytoma	6	17	15	17	29	15	99
Marginal zone lymphoma	25	77	97	104	146	81	530
Follicular lymphoma	37	112	81	111	141	64	546
Mantle cell lymphoma	8	25	23	25	35	28	144
Diffuse large B - cell lymphoma	91	238	285	291	325	189	1,419
Burkitt lymphoma	3	13	11	12	19	8	66
Lymphoproliferative disorder NOS	25	74	75	67	64	25	330
T-cell Disorders	15	56	60	49	40	32	252
Lymphocyte predominant nodular Hodgkin	3	11	10	12	9	5	50
Classical Hodgkin Lymphoma	25	101	90	90	89	69	464
Hypereosinophilic syndrome ¹	1	1	3	3	6	8	22
Systemic mastocytosis ¹	-	1	4	2	3	1	11
Atypical chronic myeloid leukaemia ¹	1	2	1	1	1	-	6

¹These diagnoses are excluded from later sections of the document on account of small number of patients.

Hospital

Table 2: Number of Diagnoses - Airedale

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	34	107	100	124	140	70	575
Chronic myeloid leukaemia	-	-	-	5	1	-	6
Myeloproliferative neoplasms	2	13	13	16	18	6	68
Primary myelofibrosis	-	1	-	-	2	1	4
Chronic myelomonocytic leukaemia	-	-	-	-	3	-	3
Myelodysplastic syndromes	3	6	9	9	14	4	45
Acute myeloid leukaemia	4	7	6	8	9	2	36
Precursor lymphoblastic leukaemia	-	-	1	3	2	-	6
Monoclonal B-cell lymphocytosis	1	11	4	6	6	5	33
MGUS	2	9	12	15	16	7	61
Chronic lymphocytic leukaemia	9	14	10	12	13	11	69
Hairy cell leukaemia	-	-	-	-	-	-	-
Plasma cell myeloma	4	15	12	6	18	8	63
Plasmacytoma	-	-	1	1	5	1	8
Marginal zone lymphoma	1	3	4	12	9	6	35
Follicular lymphoma	3	3	1	5	7	4	23
Mantle cell lymphoma	-	-	-	-	-	2	2
Diffuse large B - cell lymphoma	4	7	13	11	8	8	51
Burkitt lymphoma	-	-	-	1	1	-	2
Lymphoproliferative disorder NOS	1	8	6	5	1	3	24
T-cell Disorders	-	4	3	4	5	-	16
Lymphocyte predominant nodular Hodgkin	-	1	-	1	-	-	2
Classical Hodgkin Lymphoma	-	5	5	4	2	2	18

Table 3: Number of Diagnoses - Bradford Royal

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	50	152	149	188	190	122	851
Chronic myeloid leukaemia	2	4	-	5	6	3	20
Myeloproliferative neoplasms	4	12	12	24	21	15	88
Primary myelofibrosis	-	3	1	-	3	-	7
Chronic myelomonocytic leukaemia	-	2	-	-	1	3	6
Myelodysplastic syndromes	3	7	6	9	8	5	38
Acute myeloid leukaemia	5	11	15	7	13	8	59
Precursor lymphoblastic leukaemia	-	2	3	2	4	-	11
Monoclonal B-cell lymphocytosis	-	2	2	5	3	-	12
MGUS	7	12	12	10	25	18	84
Chronic lymphocytic leukaemia	5	14	15	15	16	17	82
Hairy cell leukaemia	-	1	-	-	-	-	1
Plasma cell myeloma	3	15	12	21	19	10	80
Plasmacytoma	-	-	-	1	4	1	6
Marginal zone lymphoma	1	6	9	10	10	6	42
Follicular lymphoma	6	11	14	18	12	6	67
Mantle cell lymphoma	-	3	2	1	1	3	10
Diffuse large B - cell lymphoma	7	21	23	35	28	13	127
Burkitt lymphoma	-	-	-	1	1	1	3
Lymphoproliferative disorder NOS	1	4	6	8	4	1	24
T-cell Disorders	1	6	5	5	3	4	24
Lymphocyte predominant nodular Hodgkin	-	2	-	3	1	2	8
Classical Hodgkin Lymphoma	5	14	12	8	7	6	52

Table 4: Number of Diagnoses - Calderdale & Huddersfield

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	50	164	157	155	189	136	851
Chronic myeloid leukaemia	-	2	3	4	2	1	12
Myeloproliferative neoplasms	3	20	7	20	15	11	76
Primary myelofibrosis	-	1	2	3	3	3	12
Chronic myelomonocytic leukaemia	-	2	-	2	2	1	7
Myelodysplastic syndromes	3	10	12	6	11	9	51
Acute myeloid leukaemia	3	7	10	12	10	16	58
Precursor lymphoblastic leukaemia	1	2	3	2	3	4	15
Monoclonal B-cell lymphocytosis	5	4	8	7	2	2	28
MGUS	8	14	15	4	10	8	59
Chronic lymphocytic leukaemia	6	14	19	19	22	14	94
Hairy cell leukaemia	-	2	-	1	3	1	7
Plasma cell myeloma	4	16	17	16	22	18	93
Plasmacytoma	-	1	1	3	3	1	9
Marginal zone lymphoma	1	7	7	5	9	7	36
Follicular lymphoma	2	17	5	11	15	5	55
Mantle cell lymphoma	2	3	4	2	1	2	14
Diffuse large B - cell lymphoma	9	21	31	17	33	17	128
Burkitt lymphoma	-	1	1	2	1	-	5
Lymphoproliferative disorder NOS	1	5	4	6	5	3	24
T-cell Disorders	1	6	3	6	4	5	25
Lymphocyte predominant nodular Hodgkin	-	-	-	-	-	-	-
Classical Hodgkin Lymphoma	1	9	5	7	13	8	43

Table 5: Number of Diagnoses - Leeds Teaching Hospitals

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	128	386	428	417	448	273	2,080
Chronic myeloid leukaemia	3	6	6	10	7	6	38
Myeloproliferative neoplasms	7	12	39	41	41	24	164
Primary myelofibrosis	-	-	1	3	4	1	9
Chronic myelomonocytic leukaemia	1	1	-	4	4	2	12
Myelodysplastic syndromes	7	26	18	25	29	25	130
Acute myeloid leukaemia	5	33	34	36	34	20	162
Precursor lymphoblastic leukaemia	9	25	27	17	21	11	110
Monoclonal B-cell lymphocytosis	5	9	8	12	12	5	51
MGUS	15	38	49	32	40	26	200
Chronic lymphocytic leukaemia	16	28	35	27	40	24	170
Hairy cell leukaemia	1	1	1	3	-	1	7
Plasma cell myeloma	11	40	41	44	50	26	212
Plasmacytoma	2	9	7	6	2	5	31
Marginal zone lymphoma	4	15	24	23	25	15	106
Follicular lymphoma	6	13	15	20	18	10	82
Mantle cell lymphoma	4	6	8	5	7	4	34
Diffuse large B - cell lymphoma	18	60	68	59	65	35	305
Burkitt lymphoma	2	7	3	5	8	3	28
Lymphoproliferative disorder NOS	6	10	10	15	10	6	57
T-cell Disorders	4	8	12	10	5	3	42
Lymphocyte predominant nodular Hodgkin	1	5	-	1	4	1	12
Classical Hodgkin Lymphoma	1	34	22	19	22	20	118

Table 6: Number of Diagnoses - Harrogate & District

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	30	77	93	92	111	71	474
Chronic myeloid leukaemia	1	-	1	1	1	-	4
Myeloproliferative neoplasms	1	1	14	21	6	9	52
Primary myelofibrosis	-	1	1	3	1	1	7
Chronic myelomonocytic leukaemia	-	-	-	1	-	-	1
Myelodysplastic syndromes	3	4	4	2	5	6	24
Acute myeloid leukaemia	1	7	9	6	3	2	28
Precursor lymphoblastic leukaemia	-	-	-	-	1	-	1
Monoclonal B-cell lymphocytosis	1	4	5	1	3	-	14
MGUS	5	4	8	2	9	5	33
Chronic lymphocytic leukaemia	3	8	11	9	22	12	65
Hairy cell leukaemia	1	1	-	-	-	-	2
Plasma cell myeloma	3	8	10	11	10	7	49
Plasmacytoma	-	1	1	2	2	-	6
Marginal zone lymphoma	1	6	5	4	9	5	30
Follicular lymphoma	1	3	7	3	5	2	21
Mantle cell lymphoma	-	1	1	1	2	3	8
Diffuse large B - cell lymphoma	4	16	9	18	18	12	77
Burkitt lymphoma	-	-	-	-	3	-	3
Lymphoproliferative disorder NOS	2	4	2	3	3	1	15
T-cell Disorders	1	6	2	-	3	5	17
Lymphocyte predominant nodular Hodgkin	-	-	1	-	1	-	2
Classical Hodgkin Lymphoma	2	2	2	4	4	1	15

Table 7: Number of Diagnoses - York Teaching Hospital

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	60	192	228	219	238	140	1,077
Chronic myeloid leukaemia	1	2	4	-	2	1	10
Myeloproliferative neoplasms	-	6	29	21	13	12	81
Primary myelofibrosis	-	-	1	-	1	3	5
Chronic myelomonocytic leukaemia	1	1	-	5	1	3	11
Myelodysplastic syndromes	3	13	13	13	11	10	63
Acute myeloid leukaemia	2	8	12	12	14	6	54
Precursor lymphoblastic leukaemia	-	4	3	2	1	2	12
Monoclonal B-cell lymphocytosis	4	10	18	13	16	9	70
MGUS	19	36	22	16	32	13	138
Chronic lymphocytic leukaemia	5	24	24	25	17	14	109
Hairy cell leukaemia	-	1	1	1	1	-	4
Plasma cell myeloma	4	22	24	25	26	19	120
Plasmacytoma	-	1	1	2	5	3	12
Marginal zone lymphoma	1	9	7	18	18	6	59
Follicular lymphoma	4	10	11	13	22	5	65
Mantle cell lymphoma	-	2	1	2	2	7	14
Diffuse large B - cell lymphoma	11	23	34	27	32	18	145
Burkitt lymphoma	-	-	1	1	1	1	4
Lymphoproliferative disorder NOS	1	8	9	7	6	1	32
T-cell Disorders	1	4	6	2	2	2	17
Lymphocyte predominant nodular Hodgkin	-	1	3	2	1	-	7
Classical Hodgkin Lymphoma	3	7	4	12	14	5	45

Table 8: Number of Diagnoses - Dewsbury & District

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	30	57	67	73	100	67	394
Chronic myeloid leukaemia	1	3	2	-	4	2	12
Myeloproliferative neoplasms	3	4	11	10	11	10	49
Primary myelofibrosis	-	-	1	-	3	-	4
Chronic myelomonocytic leukaemia	-	-	-	1	-	1	2
Myelodysplastic syndromes	6	4	5	6	4	4	29
Acute myeloid leukaemia	2	3	9	5	3	3	25
Precursor lymphoblastic leukaemia	1	1	-	-	-	1	3
Monoclonal B-cell lymphocytosis	1	2	5	2	5	4	19
MGUS	-	6	1	7	6	4	24
Chronic lymphocytic leukaemia	4	10	8	11	7	8	48
Hairy cell leukaemia	-	-	-	2	1	-	3
Plasma cell myeloma	3	8	8	5	10	8	42
Plasmacytoma	1	1	-	-	-	-	2
Marginal zone lymphoma	-	-	2	4	3	2	11
Follicular lymphoma	3	5	-	2	9	4	23
Mantle cell lymphoma	1	-	1	-	1	-	3
Diffuse large B - cell lymphoma	2	4	7	11	23	13	60
Burkitt lymphoma	-	1	1	-	-	-	2
Lymphoproliferative disorder NOS	1	-	3	1	6	2	13
T-cell Disorders	1	4	2	1	2	-	10
Lymphocyte predominant nodular Hodgkin	-	-	-	-	-	-	-
Classical Hodgkin Lymphoma	-	1	1	5	2	1	10

Table 9: Number of Diagnoses - Pinderfields General

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	28	96	127	128	127	83	589
Chronic myeloid leukaemia	-	1	-	2	-	4	7
Myeloproliferative neoplasms	2	9	10	17	15	8	61
Primary myelofibrosis	-	-	-	-	3	-	3
Chronic myelomonocytic leukaemia	1	-	3	1	5	1	11
Myelodysplastic syndromes	2	-	3	8	9	4	26
Acute myeloid leukaemia	1	7	12	6	8	4	38
Precursor lymphoblastic leukaemia	-	3	2	2	1	1	9
Monoclonal B-cell lymphocytosis	3	5	7	3	3	6	27
MGUS	-	11	22	17	18	15	83
Chronic lymphocytic leukaemia	3	12	18	11	15	11	70
Hairy cell leukaemia	1	-	-	1	1	1	4
Plasma cell myeloma	3	5	7	11	9	8	43
Plasmacytoma	1	-	-	-	1	-	2
Marginal zone lymphoma	-	7	3	4	9	3	26
Follicular lymphoma	-	8	4	4	3	4	23
Mantle cell lymphoma	1	1	-	-	6	1	9
Diffuse large B - cell lymphoma	6	17	15	19	9	6	72
Burkitt lymphoma	1	-	1	1	1	-	4
Lymphoproliferative disorder NOS	1	6	6	5	3	2	23
T-cell Disorders	-	3	6	3	2	-	14
Lymphocyte predominant nodular Hodgkin	-	-	-	2	-	-	2
Classical Hodgkin Lymphoma	2	1	8	11	6	4	32

Table 10: Number of Diagnoses - Pontefract General

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	18	73	73	83	80	52	379
Chronic myeloid leukaemia	1	-	1	1	3	2	8
Myeloproliferative neoplasms	2	3	9	14	3	6	37
Primary myelofibrosis	1	2	-	1	1	-	5
Chronic myelomonocytic leukaemia	-	-	1	1	2	1	5
Myelodysplastic syndromes	2	5	8	8	8	7	38
Acute myeloid leukaemia	1	4	10	9	5	3	32
Precursor lymphoblastic leukaemia	-	1	1	-	2	-	4
Monoclonal B-cell lymphocytosis	-	12	6	6	7	1	32
MGUS	3	12	9	11	15	7	57
Chronic lymphocytic leukaemia	2	9	12	15	8	6	52
Hairy cell leukaemia	-	1	-	-	-	1	2
Plasma cell myeloma	2	7	7	4	8	7	35
Plasmacytoma	-	1	-	-	-	-	1
Marginal zone lymphoma	-	2	1	2	2	2	9
Follicular lymphoma	-	4	2	2	4	1	13
Mantle cell lymphoma	-	-	-	1	1	-	2
Diffuse large B - cell lymphoma	2	3	2	4	3	4	18
Burkitt lymphoma	-	-	-	-	-	1	1
Lymphoproliferative disorder NOS	1	3	2	2	4	-	12
T-cell Disorders	-	1	2	-	2	3	8
Lymphocyte predominant nodular Hodgkin	1	-	-	1	-	-	2
Classical Hodgkin Lymphoma	-	3	-	1	2	-	6

Table 11: Number of Diagnoses - Hull & East Yorkshire Hospitals

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	112	314	332	354	360	241	1,713
Chronic myeloid leukaemia	1	4	6	10	5	1	27
Myeloproliferative neoplasms	3	15	28	29	25	23	123
Primary myelofibrosis	-	2	3	3	3	-	11
Chronic myelomonocytic leukaemia	1	1	4	5	5	3	19
Myelodysplastic syndromes	6	15	17	29	17	19	103
Acute myeloid leukaemia	3	21	23	27	21	30	125
Precursor lymphoblastic leukaemia	2	5	2	6	11	2	28
Monoclonal B-cell lymphocytosis	3	19	15	20	17	8	82
MGUS	25	53	34	34	36	26	208
Chronic lymphocytic leukaemia	9	29	26	33	30	17	144
Hairy cell leukaemia	1	1	2	6	2	2	14
Plasma cell myeloma	11	38	40	42	41	28	200
Plasmacytoma	2	3	2	1	5	2	15
Marginal zone lymphoma	11	7	10	9	27	16	80
Follicular lymphoma	3	20	9	18	22	11	83
Mantle cell lymphoma	-	5	3	8	6	1	23
Diffuse large B - cell lymphoma	15	37	52	48	58	30	240
Burkitt lymphoma	-	2	3	-	2	2	9
Lymphoproliferative disorder NOS	5	13	17	4	11	2	52
T-cell Disorders	2	7	9	10	6	4	38
Lymphocyte predominant nodular Hodgkin	1	2	5	2	-	-	10
Classical Hodgkin Lymphoma	8	15	22	10	10	14	79

Table 12: Number of Diagnoses - Scarborough

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	42	80	104	75	94	61	456
Chronic myeloid leukaemia	-	-	1	-	-	2	3
Myeloproliferative neoplasms	3	5	14	9	11	7	49
Primary myelofibrosis	-	-	-	-	-	-	-
Chronic myelomonocytic leukaemia	-	-	4	1	1	1	7
Myelodysplastic syndromes	3	1	3	9	7	7	30
Acute myeloid leukaemia	2	4	5	2	4	4	21
Precursor lymphoblastic leukaemia	-	2	-	-	1	-	3
Monoclonal B-cell lymphocytosis	1	5	4	4	6	2	22
MGUS	3	6	8	9	11	8	45
Chronic lymphocytic leukaemia	9	18	26	11	13	4	81
Hairy cell leukaemia	1	-	2	-	-	-	3
Plasma cell myeloma	1	12	7	11	7	2	40
Plasmacytoma	-	-	1	-	-	1	2
Marginal zone lymphoma	1	2	3	2	5	4	17
Follicular lymphoma	5	5	1	2	8	3	24
Mantle cell lymphoma	-	1	1	-	4	1	7
Diffuse large B - cell lymphoma	7	8	10	13	11	10	59
Burkitt lymphoma	-	1	-	1	1	-	3
Lymphoproliferative disorder NOS	2	5	4	-	2	1	14
T-cell Disorders	2	4	4	1	1	-	12
Lymphocyte predominant nodular Hodgkin	-	-	-	-	1	-	1
Classical Hodgkin Lymphoma	2	1	6	-	-	4	13

Table 13: Number of Diagnoses - Grimsby (Diana Princess of Wales)

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)		Total
Total	20	96	105	126	119	76		542
Chronic myeloid leukaemia	-	1	3	4	3	1		12
Myeloproliferative neoplasms	-	9	8	11	10	9		47
Primary myelofibrosis	-	-	-	-	-	1		1
Chronic myelomonocytic leukaemia	1	1	1	-	-	1		4
Myelodysplastic syndromes	1	6	7	10	3	2		29
Acute myeloid leukaemia	1	4	5	9	4	1		24
Precursor lymphoblastic leukaemia	-	1	1	2	2	-		6
Monoclonal B-cell lymphocytosis	1	1	2	-	3	1		8
MGUS	5	10	18	24	15	17		89
Chronic lymphocytic leukaemia	4	11	10	12	18	10		65
Hairy cell leukaemia	-	2	1	-	-	-		3
Plasma cell myeloma	3	15	15	23	20	12		88
Plasmacytoma	-	-	-	-	1	1		2
Marginal zone lymphoma	-	7	11	5	5	3		31
Follicular lymphoma	3	9	4	4	6	-		26
Mantle cell lymphoma	-	3	1	3	1	3		11
Diffuse large B - cell lymphoma	1	10	12	10	20	10		63
Burkitt lymphoma	-	-	-	-	-	-		-
Lymphoproliferative disorder NOS	-	2	4	4	3	-		13
T-cell Disorders	-	1	2	2	1	2		8
Lymphocyte predominant nodular Hodgkin	-	-	-	-	-	2		2
Classical Hodgkin Lymphoma	-	3	-	3	4	-		10

Table 14: Number of Diagnoses - Scunthorpe General

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	39	91	92	104	114	83	523
Chronic myeloid leukaemia	-	2	1	1	1	-	5
Myeloproliferative neoplasms	3	6	12	9	10	10	50
Primary myelofibrosis	1	1	-	-	1	1	4
Chronic myelomonocytic leukaemia	1	1	1	2	1	2	8
Myelodysplastic syndromes	1	3	8	7	16	4	39
Acute myeloid leukaemia	4	10	12	18	5	4	53
Precursor lymphoblastic leukaemia	1	2	3	-	3	-	9
Monoclonal B-cell lymphocytosis	-	6	2	2	2	1	13
MGUS	5	9	10	7	4	7	42
Chronic lymphocytic leukaemia	5	12	8	7	14	12	58
Hairy cell leukaemia	-	-	-	1	2	1	4
Plasma cell myeloma	5	10	7	12	13	9	56
Plasmacytoma	-	-	-	1	1	-	2
Marginal zone lymphoma	3	5	8	3	11	5	35
Follicular lymphoma	1	3	5	6	7	7	29
Mantle cell lymphoma	-	-	1	2	2	1	6
Diffuse large B - cell lymphoma	4	8	8	15	14	12	61
Burkitt lymphoma	-	1	1	-	-	-	2
Lymphoproliferative disorder NOS	2	5	-	3	2	1	13
T-cell Disorders	2	2	2	4	4	2	16
Lymphocyte predominant nodular Hodgkin	-	-	1	-	-	-	1
Classical Hodgkin Lymphoma	1	5	2	4	1	4	17

Multi-Disciplinary Team

Table 15: Number of Diagnoses - Airedale / Bradford

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	84	259	249	312	330	192	1,426
Chronic myeloid leukaemia	2	4	-	10	7	3	26
Myeloproliferative neoplasms	6	25	25	40	39	21	156
Primary myelofibrosis	-	4	1	-	5	1	11
Chronic myelomonocytic leukaemia	-	2	-	-	4	3	9
Myelodysplastic syndromes	6	13	15	18	22	9	83
Acute myeloid leukaemia	9	18	21	15	22	10	95
Precursor lymphoblastic leukaemia	-	2	4	5	6	-	17
Monoclonal B-cell lymphocytosis	1	13	6	11	9	5	45
MGUS	9	21	24	25	41	25	145
Chronic lymphocytic leukaemia	14	28	25	27	29	28	151
Hairy cell leukaemia	-	1	-	-	-	-	1
Plasma cell myeloma	7	30	24	27	37	18	143
Plasmacytoma	-	-	1	2	9	2	14
Marginal zone lymphoma	2	9	13	22	19	12	77
Follicular lymphoma	9	14	15	23	19	10	90
Mantle cell lymphoma	-	3	2	1	1	5	12
Diffuse large B - cell lymphoma	11	28	36	46	36	21	178
Burkitt lymphoma	-	-	-	2	2	1	5
Lymphoproliferative disorder NOS	2	12	12	13	5	4	48
T-cell Disorders	1	10	8	9	8	4	40
Lymphocyte predominant nodular Hodgkin	-	3	-	4	1	2	10
Classical Hodgkin Lymphoma	5	19	17	12	9	8	70

Table 16: Number of Diagnoses - Leeds

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	178	550	585	572	637	409	2,931
Chronic myeloid leukaemia	3	8	9	14	9	7	50
Myeloproliferative neoplasms	10	32	46	61	56	35	240
Primary myelofibrosis	0	1	3	6	7	4	21
Chronic myelomonocytic leukaemia	1	3	0	6	6	3	19
Myelodysplastic syndromes	10	36	30	31	40	34	181
Acute myeloid leukaemia	8	40	44	48	44	36	220
Precursor lymphoblastic leukaemia	10	27	30	19	24	15	125
Monoclonal B-cell lymphocytosis	10	13	16	19	14	7	79
MGUS	23	52	64	36	50	34	259
Chronic lymphocytic leukaemia	22	42	54	46	62	38	264
Hairy cell leukaemia	1	3	1	4	3	2	14
Plasma cell myeloma	15	56	58	60	72	44	305
Plasmacytoma	2	10	8	9	5	6	40
Marginal zone lymphoma	5	22	31	28	34	22	142
Follicular lymphoma	8	30	20	31	33	15	137
Mantle cell lymphoma	6	9	12	7	8	6	48
Diffuse large B - cell lymphoma	27	81	99	76	98	52	433
Burkitt lymphoma	2	8	4	7	9	3	33
Lymphoproliferative disorder NOS	7	15	14	21	15	9	81
T-cell Disorders	5	14	15	16	9	8	67
Lymphocyte predominant nodular Hodgkin	1	5	0	1	4	1	12
Classical Hodgkin Lymphoma	2	43	27	26	35	28	161

Table 17: Number of Diagnoses - Harrogate / York

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	90	269	321	311	349	211	1,551
Chronic myeloid leukaemia	2	2	5	1	3	1	14
Myeloproliferative neoplasms	1	7	43	42	19	21	133
Primary myelofibrosis	-	1	2	3	2	4	12
Chronic myelomonocytic leukaemia	1	1	-	6	1	3	12
Myelodysplastic syndromes	6	17	17	15	16	16	87
Acute myeloid leukaemia	3	15	21	18	17	8	82
Precursor lymphoblastic leukaemia	-	4	3	2	2	2	13
Monoclonal B-cell lymphocytosis	5	14	23	14	19	9	84
MGUS	24	40	30	18	41	18	171
Chronic lymphocytic leukaemia	8	32	35	34	39	26	174
Hairy cell leukaemia	1	2	1	1	1	-	6
Plasma cell myeloma	7	30	34	36	36	26	169
Plasmacytoma	-	2	2	4	7	3	18
Marginal zone lymphoma	2	15	12	22	27	11	89
Follicular lymphoma	5	13	18	16	27	7	86
Mantle cell lymphoma	-	3	2	3	4	10	22
Diffuse large B - cell lymphoma	15	39	43	45	50	30	222
Burkitt lymphoma	-	-	1	1	4	1	7
Lymphoproliferative disorder NOS	3	12	11	10	9	2	47
T-cell Disorders	2	10	8	2	5	7	34
Lymphocyte predominant nodular Hodgkin	-	1	4	2	2	-	9
Classical Hodgkin Lymphoma	5	9	6	16	18	6	60

Table 18: Number of Diagnoses - Mid-Yorks

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	76	226	267	284	307	202	1,362
Chronic myeloid leukaemia	2	4	3	3	7	8	27
Myeloproliferative neoplasms	7	16	30	41	29	24	147
Primary myelofibrosis	1	2	1	1	7	-	12
Chronic myelomonocytic leukaemia	1	-	4	3	7	3	18
Myelodysplastic syndromes	10	9	16	22	21	15	93
Acute myeloid leukaemia	4	14	31	20	16	10	95
Precursor lymphoblastic leukaemia	1	5	3	2	3	2	16
Monoclonal B-cell lymphocytosis	4	19	18	11	15	11	78
MGUS	3	29	32	35	39	26	164
Chronic lymphocytic leukaemia	9	31	38	37	30	26	170
Hairy cell leukaemia	1	1	-	3	2	2	9
Plasma cell myeloma	8	20	22	20	27	23	120
Plasmacytoma	2	2	-	-	1	-	5
Marginal zone lymphoma	-	9	6	10	14	8	46
Follicular lymphoma	3	17	6	8	16	9	59
Mantle cell lymphoma	2	1	1	1	8	1	14
Diffuse large B - cell lymphoma	10	24	24	34	35	23	150
Burkitt lymphoma	1	1	2	1	1	1	7
Lymphoproliferative disorder NOS	3	9	11	8	13	4	48
T-cell Disorders	1	8	10	4	6	3	32
Lymphocyte predominant nodular Hodgkin	1	-	-	3	-	-	4
Classical Hodgkin Lymphoma	2	5	9	17	10	5	48

Table 19: Number of Diagnoses - Humber Yorkshire Coast Cancer Network

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	213	581	633	659	687	461	3,234
Chronic myeloid leukaemia	1	7	11	15	9	4	47
Myeloproliferative neoplasms	9	35	62	58	56	49	269
Primary myelofibrosis	1	3	3	3	4	2	16
Chronic myelomonocytic leukaemia	3	3	10	8	7	7	38
Myelodysplastic syndromes	11	25	35	55	43	32	201
Acute myeloid leukaemia	10	39	45	56	34	39	223
Precursor lymphoblastic leukaemia	3	10	6	8	17	2	46
Monoclonal B-cell lymphocytosis	5	31	23	26	28	12	125
MGUS	38	78	70	74	66	58	384
Chronic lymphocytic leukaemia	27	70	70	63	75	43	348
Hairy cell leukaemia	2	3	5	7	4	3	24
Plasma cell myeloma	20	75	69	88	81	51	384
Plasmacytoma	2	3	3	2	7	4	21
Marginal zone lymphoma	15	21	32	19	48	28	163
Follicular lymphoma	12	37	19	30	43	21	162
Mantle cell lymphoma	0	9	6	13	13	6	47
Diffuse large B - cell lymphoma	27	63	82	86	103	62	423
Burkitt lymphoma	0	4	4	1	3	2	14
Lymphoproliferative disorder NOS	9	25	25	11	18	4	92
T-cell Disorders	6	14	17	17	12	8	74
Lymphocyte predominant nodular Hodgkin	1	2	6	2	1	2	14
Classical Hodgkin Lymphoma	11	24	30	17	15	22	119

Primary Care Trusts

Table 20: Number of Diagnoses - Bradford & Airedale Teaching

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	68	212	221	278	275	170	1,224
Chronic myeloid leukaemia	3	4	-	10	6	3	26
Myeloproliferative neoplasms	5	18	24	37	30	19	133
Primary myelofibrosis	-	3	1	1	4	-	9
Chronic myelomonocytic leukaemia	-	1	-	-	2	2	5
Myelodysplastic syndromes	3	14	11	15	15	10	68
Acute myeloid leukaemia	8	14	19	16	17	9	83
Precursor lymphoblastic leukaemia	2	4	7	7	10	-	30
Monoclonal B - cell Lymphocytosis	1	9	5	12	5	5	37
MGUS	8	18	21	21	35	24	127
Chronic lymphocytic leukaemia	8	23	18	23	26	26	124
Hairy cell leukaemia	-	1	-	-	-	-	1
Plasma cell myeloma	6	24	22	25	26	13	116
Plasmacytoma	-	1	1	2	9	2	15
Marginal zone lymphoma	1	8	11	21	14	6	61
Follicular lymphoma	8	13	14	18	16	10	79
Mantle cell lymphoma	-	3	2	1	2	4	12
Diffuse large B - cell lymphoma	8	21	31	39	35	20	154
Burkitt lymphoma	-	1	-	1	2	1	5
Lymphoproliferative disorder NOS	1	6	11	12	5	4	39
T-cell Disorders	1	7	6	4	5	3	26
Lymphocyte predominant nodular Hodgkin	-	2	-	2	1	2	7
Classical Hodgkin Lymphoma	5	17	17	11	10	7	67

Table 21: Number of Diagnoses - Calderdale

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	25	79	84	97	91	74	450
Chronic myeloid leukaemia	-	2	2	2	1	1	8
Myeloproliferative neoplasms	1	6	3	15	9	9	43
Primary myelofibrosis	-	1	1	1	1	2	6
Chronic myelomonocytic leukaemia	-	-	-	2	1	2	5
Myelodysplastic syndromes	1	5	5	5	2	6	24
Acute myeloid leukaemia	-	8	10	7	4	10	39
Precursor lymphoblastic leukaemia	1	2	2	4	2	2	13
Monoclonal B - cell Lymphocytosis	-	-	1	4	1	1	7
MGUS	4	4	7	4	4	5	28
Chronic lymphocytic leukaemia	3	3	8	10	5	4	33
Hairy cell leukaemia	-	1	-	-	1	-	2
Plasma cell myeloma	4	11	13	9	12	11	60
Plasmacytoma	1	3	-	2	-	1	7
Marginal zone lymphoma	-	1	1	3	8	2	15
Follicular lymphoma	1	4	2	5	7	2	21
Mantle cell lymphoma	2	2	1	1	-	-	6
Diffuse large B - cell lymphoma	6	11	17	11	17	7	69
Burkitt lymphoma	-	2	-	4	2	-	8
Lymphoproliferative disorder NOS	-	3	2	2	2	3	12
T-cell Disorders	1	3	2	3	2	1	12
Lymphocyte predominant nodular Hodgkin	-	-	-	-	-	-	-
Classical Hodgkin Lymphoma	-	7	7	3	10	5	32

Table 22: Number of Diagnoses - Leeds

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	118	324	368	372	411	240	1,833
Chronic myeloid leukaemia	2	6	7	10	6	6	37
Myeloproliferative neoplasms	9	13	38	45	45	24	174
Primary myelofibrosis	-	1	1	3	4	1	10
Chronic myelomonocytic leukaemia	1	-	-	3	5	2	11
Myelodysplastic syndromes	9	21	17	24	27	22	120
Acute myeloid leukaemia	2	26	27	33	27	17	132
Precursor lymphoblastic leukaemia	4	9	11	6	6	4	40
Monoclonal B - cell Lymphocytosis	5	9	8	11	14	5	52
MGUS	13	34	42	31	46	24	190
Chronic lymphocytic leukaemia	16	30	39	27	39	24	175
Hairy cell leukaemia	1	1	1	3	-	1	7
Plasma cell myeloma	12	31	39	37	47	26	192
Plasmacytoma	1	7	6	4	2	3	23
Marginal zone lymphoma	4	19	24	24	25	18	114
Follicular lymphoma	6	14	16	21	19	10	86
Mantle cell lymphoma	4	6	7	5	5	4	31
Diffuse large B - cell lymphoma	17	51	46	45	52	23	234
Burkitt lymphoma	1	3	1	2	6	2	15
Lymphoproliferative disorder NOS	6	10	12	14	9	6	57
T-cell Disorders	3	7	11	7	6	1	35
Lymphocyte predominant nodular Hodgkin	1	5	1	1	4	1	13
Classical Hodgkin Lymphoma	1	21	14	16	17	16	85

Table 23: Number of Diagnoses - Kirklees

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	63	185	187	164	197	135	931
Chronic myeloid leukaemia	1	3	3	2	5	1	15
Myeloproliferative neoplasms	5	19	13	16	13	8	74
Primary myelofibrosis	-	-	2	1	4	1	8
Chronic myelomonocytic leukaemia	-	2	-	1	1	1	5
Myelodysplastic syndromes	9	8	13	8	14	10	62
Acute myeloid leukaemia	8	7	19	11	13	11	69
Precursor lymphoblastic leukaemia	1	6	4	4	6	5	26
Monoclonal B - cell Lymphocytosis	6	7	13	5	5	5	41
MGUS	3	19	12	6	12	6	58
Chronic lymphocytic leukaemia	8	21	21	21	26	19	116
Hairy cell leukaemia	-	1	-	3	3	1	8
Plasma cell myeloma	4	18	14	18	24	18	96
Plasmacytoma	2	-	1	2	3	1	9
Marginal zone lymphoma	1	8	10	8	7	6	40
Follicular lymphoma	4	17	3	10	11	4	49
Mantle cell lymphoma	2	1	4	1	2	2	12
Diffuse large B - cell lymphoma	5	22	36	25	30	25	143
Burkitt lymphoma	1	1	1	-	-	-	3
Lymphoproliferative disorder NOS	1	2	5	5	8	1	22
T-cell Disorders	1	11	5	6	3	5	31
Lymphocyte predominant nodular Hodgkin	-	-	-	1	-	-	1
Classical Hodgkin Lymphoma	1	12	8	10	7	5	43

Table 24: Number of Diagnoses - Wakefield District

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	40	148	174	191	221	136	910
Chronic myeloid leukaemia	1	1	-	2	2	7	13
Myeloproliferative neoplasms	2	8	20	27	20	14	91
Primary myelofibrosis	1	2	-	1	5	-	9
Chronic myelomonocytic leukaemia	1	-	4	3	6	2	16
Myelodysplastic syndromes	2	3	12	14	16	9	56
Acute myeloid leukaemia	1	9	18	11	13	7	59
Precursor lymphoblastic leukaemia	-	7	4	1	3	1	16
Monoclonal B - cell Lymphocytosis	3	15	10	9	10	7	54
MGUS	2	24	30	28	29	22	135
Chronic lymphocytic leukaemia	6	17	24	21	22	11	101
Hairy cell leukaemia	1	1	-	1	1	2	6
Plasma cell myeloma	3	12	12	15	17	15	74
Plasmacytoma	1	1	-	1	1	1	5
Marginal zone lymphoma	-	4	3	6	11	4	28
Follicular lymphoma	-	13	4	2	11	7	37
Mantle cell lymphoma	-	1	-	1	7	1	10
Diffuse large B - cell lymphoma	9	16	16	27	26	14	108
Burkitt lymphoma	1	-	2	1	1	1	6
Lymphoproliferative disorder NOS	3	8	6	6	7	3	33
T-cell Disorders	-	2	6	2	4	3	17
Lymphocyte predominant nodular Hodgkin	1	-	-	2	-	-	3
Classical Hodgkin Lymphoma	2	4	3	10	9	5	33

Table 25: Number of Diagnoses - North Yorks & York

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	129	370	426	408	480	266	2,079
Chronic myeloid leukaemia	2	2	6	4	6	2	22
Myeloproliferative neoplasms	3	16	54	48	31	28	180
Primary myelofibrosis	-	1	2	3	4	4	14
Chronic myelomonocytic leukaemia	1	1	2	6	3	4	17
Myelodysplastic syndromes	10	22	19	26	32	16	125
Acute myeloid leukaemia	6	22	31	24	27	17	127
Precursor lymphoblastic leukaemia	2	11	6	4	9	3	35
Monoclonal B - cell Lymphocytosis	3	17	23	15	21	9	88
MGUS	26	41	41	27	52	25	212
Chronic lymphocytic leukaemia	17	51	54	44	49	30	245
Hairy cell leukaemia	2	2	2	1	1	-	8
Plasma cell myeloma	7	46	39	47	50	28	217
Plasmacytoma	-	2	3	4	7	3	19
Marginal zone lymphoma	5	16	12	21	34	16	104
Follicular lymphoma	9	16	19	22	32	10	108
Mantle cell lymphoma	-	3	4	3	9	10	29
Diffuse large B - cell lymphoma	21	58	65	63	67	39	313
Burkitt lymphoma	-	-	1	3	6	1	11
Lymphoproliferative disorder NOS	4	17	14	11	11	1	58
T-cell Disorders	3	9	14	9	8	9	52
Lymphocyte predominant nodular Hodgkin	-	2	3	2	3	-	10
Classical Hodgkin Lymphoma	8	15	12	21	18	11	85

Table 26: Number of Diagnoses - East Riding

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	87	212	219	240	235	177	1,170
Chronic myeloid leukaemia	1	1	3	2	3	2	12
Myeloproliferative neoplasms	6	10	16	16	16	21	85
Primary myelofibrosis	1	1	1	2	1	1	7
Chronic myelomonocytic leukaemia	1	1	4	4	5	1	16
Myelodysplastic syndromes	6	8	10	24	12	19	79
Acute myeloid leukaemia	3	12	10	17	9	18	69
Precursor lymphoblastic leukaemia	2	2	4	6	1	3	18
Monoclonal B - cell Lymphocytosis	4	14	12	14	13	7	64
MGUS	17	36	22	21	25	17	138
Chronic lymphocytic leukaemia	6	23	19	22	20	10	100
Hairy cell leukaemia	1	1	2	5	2	1	12
Plasma cell myeloma	6	26	31	34	28	16	141
Plasmacytoma	-	3	2	1	3	2	11
Marginal zone lymphoma	6	4	5	8	18	10	51
Follicular lymphoma	3	10	9	12	16	10	60
Mantle cell lymphoma	-	5	3	3	5	2	18
Diffuse large B - cell lymphoma	13	29	28	31	37	19	157
Burkitt lymphoma	-	1	2	-	1	2	6
Lymphoproliferative disorder NOS	4	10	10	3	8	3	38
T-cell Disorders	2	5	8	7	8	3	33
Lymphocyte predominant nodular Hodgkin	1	1	3	1	-	-	6
Classical Hodgkin Lymphoma	4	9	15	7	4	10	49

Table 27: Number of Diagnoses - Hull Teaching

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)		Total
Total	40	131	153	139	137	96		696
Chronic myeloid leukaemia	-	3	3	6	1	-		13
Myeloproliferative neoplasms	-	7	17	16	15	10		65
Primary myelofibrosis	-	2	2	1	2	-		7
Chronic myelomonocytic leukaemia	-	1	2	2	1	2		8
Myelodysplastic syndromes	1	5	12	9	2	5		34
Acute myeloid leukaemia	2	7	7	10	5	7		38
Precursor lymphoblastic leukaemia	2	3	3	2	6	1		17
Monoclonal B - cell Lymphocytosis	1	10	7	8	9	2		37
MGUS	8	23	17	17	10	12		87
Chronic lymphocytic leukaemia	4	15	14	14	15	9		71
Hairy cell leukaemia	-	-	1	1	-	1		3
Plasma cell myeloma	6	14	12	11	17	11		71
Plasmacytoma	-	-	-	-	2	1		3
Marginal zone lymphoma	3	2	8	3	8	10		34
Follicular lymphoma	2	10	3	7	11	3		36
Mantle cell lymphoma	-	1	-	6	1	1		9
Diffuse large B - cell lymphoma	6	9	21	16	20	13		85
Burkitt lymphoma	-	3	3	-	1	-		7
Lymphoproliferative disorder NOS	2	5	8	2	5	1		23
T-cell Disorders	-	5	2	5	1	-		13
Lymphocyte predominant nodular Hodgkin	-	1	2	1	-	-		4
Classical Hodgkin Lymphoma	3	5	9	2	5	7		31

Table 28: Number of Diagnoses - North East Lincolnshire

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	17	75	77	96	101	66	432
Chronic myeloid leukaemia	-	-	2	3	2	1	8
Myeloproliferative neoplasms	-	7	3	9	6	8	33
Primary myelofibrosis	-	-	-	-	-	-	-
Chronic myelomonocytic leukaemia	1	-	-	-	-	1	2
Myelodysplastic syndromes	-	5	4	9	2	2	22
Acute myeloid leukaemia	1	5	7	5	6	2	26
Precursor lymphoblastic leukaemia	-	1	2	2	3	-	8
Monoclonal B - cell Lymphocytosis	1	1	1	-	2	1	6
MGUS	5	12	10	16	12	13	68
Chronic lymphocytic leukaemia	4	6	6	10	12	9	47
Hairy cell leukaemia	-	2	1	-	-	-	3
Plasma cell myeloma	1	10	9	16	16	13	65
Plasmacytoma	-	-	1	-	2	1	4
Marginal zone lymphoma	-	4	10	4	3	2	23
Follicular lymphoma	3	4	4	3	5	-	19
Mantle cell lymphoma	-	3	1	1	1	1	7
Diffuse large B - cell lymphoma	1	10	12	11	23	10	67
Burkitt lymphoma	-	-	-	-	-	-	-
Lymphoproliferative disorder NOS	-	1	3	2	3	-	9
T-cell Disorders	-	-	1	2	-	1	4
Lymphocyte predominant nodular Hodgkin	-	-	-	-	-	1	1
Classical Hodgkin Lymphoma	-	4	-	3	3	-	10

Table 29: Number of Diagnoses - Lincolnshire Teaching

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	7	32	41	40	42	19	181
Chronic myeloid leukaemia	-	1	1	1	1	-	4
Myeloproliferative neoplasms	1	2	5	2	4	2	16
Primary myelofibrosis	-	-	-	-	-	1	1
Chronic myelomonocytic leukaemia	-	1	1	-	-	-	2
Myelodysplastic syndromes	1	2	3	2	4	3	15
Acute myeloid leukaemia	-	1	2	6	3	-	12
Precursor lymphoblastic leukaemia	-	-	-	-	1	-	1
Monoclonal B - cell Lymphocytosis	-	-	-	-	1	-	1
MGUS	1	-	10	10	6	4	31
Chronic lymphocytic leukaemia	1	4	4	2	8	1	20
Hairy cell leukaemia	-	-	-	-	-	-	-
Plasma cell myeloma	2	8	9	9	6	1	35
Plasmacytoma	-	-	-	-	-	-	-
Marginal zone lymphoma	-	2	2	1	2	1	8
Follicular lymphoma	-	6	-	1	2	-	9
Mantle cell lymphoma	-	-	1	2	-	1	4
Diffuse large B - cell lymphoma	1	1	1	3	1	3	10
Burkitt lymphoma	-	-	-	-	-	-	-
Lymphoproliferative disorder NOS	-	1	1	1	-	-	3
T-cell Disorders	-	-	1	-	2	1	4
Lymphocyte predominant nodular Hodgkin	-	-	-	-	-	1	1
Classical Hodgkin Lymphoma	-	3	-	-	1	-	4

Table 30: Number of Diagnoses - East Lincolnshire Teaching

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	5	8	8	8	11	12	52
Chronic myeloid leukaemia	-	-	-	-	1	-	1
Myeloproliferative neoplasms	-	2	1	2	1	1	7
Primary myelofibrosis	-	-	-	-	-	-	-
Chronic myelomonocytic leukaemia	-	-	-	-	-	-	-
Myelodysplastic syndromes	1	-	1	-	1	-	3
Acute myeloid leukaemia	-	2	-	-	-	-	2
Precursor lymphoblastic leukaemia	-	-	-	-	1	1	2
Monoclonal B - cell Lymphocytosis	-	-	-	-	-	-	-
MGUS	1	1	1	1	1	1	6
Chronic lymphocytic leukaemia	1	-	-	-	-	2	3
Hairy cell leukaemia	-	-	-	-	-	-	-
Plasma cell myeloma	-	2	1	-	2	1	6
Plasmacytoma	-	-	-	-	-	-	-
Marginal zone lymphoma	1	1	1	-	-	2	5
Follicular lymphoma	-	-	1	1	1	-	3
Mantle cell lymphoma	-	-	-	-	-	-	-
Diffuse large B - cell lymphoma	-	-	1	1	2	4	8
Burkitt lymphoma	-	-	-	-	-	-	-
Lymphoproliferative disorder NOS	1	-	-	-	1	-	2
T-cell Disorders	-	-	-	-	-	-	-
Lymphocyte predominant nodular Hodgkin	-	-	-	1	-	-	1
Classical Hodgkin Lymphoma	-	-	1	2	-	-	3

Table 31: Number of Diagnoses - North Lincolnshire

	2004 (1 Sep - 31 Dec)	2005	2006	2007	2008	2009 (1 Jan - 31 Aug)	Total
Total	34	87	81	88	98	75	463
Chronic myeloid leukaemia	-	2	1	1	1	-	5
Myeloproliferative neoplasms	1	6	12	9	9	5	42
Primary myelofibrosis	-	-	-	-	-	1	1
Chronic myelomonocytic leukaemia	1	1	1	2	1	2	8
Myelodysplastic syndromes	-	4	6	5	15	4	34
Acute myeloid leukaemia	2	12	11	16	7	5	53
Precursor lymphoblastic leukaemia	-	3	2	-	4	-	9
Monoclonal B - cell Lymphocytosis	-	4	3	2	1	1	11
MGUS	6	7	7	6	4	7	37
Chronic lymphocytic leukaemia	4	10	9	6	11	12	52
Hairy cell leukaemia	-	-	-	1	2	1	4
Plasma cell myeloma	6	9	6	10	8	8	47
Plasmacytoma	1	-	-	1	-	-	2
Marginal zone lymphoma	3	7	8	2	12	3	35
Follicular lymphoma	-	4	2	6	5	6	23
Mantle cell lymphoma	-	-	-	1	2	2	5
Diffuse large B - cell lymphoma	3	6	6	13	11	11	50
Burkitt lymphoma	-	2	1	-	-	1	4
Lymphoproliferative disorder NOS	2	5	-	2	1	1	11
T-cell Disorders	4	2	2	2	1	2	13
Lymphocyte predominant nodular Hodgkin	-	-	1	-	-	-	1
Classical Hodgkin Lymphoma	1	3	3	3	3	3	16

Chronic Myeloid Leukaemia (CML)

Table 32: CML Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	165 (100)	133 (80.5)	32 (19.5)		
Follow up (years):					
Median (range)	3.4 (0 - 6.5)	3.8 (1.6-6.5)	1.7 (0-4.5)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	96 (58.2)	77 (80.2)	19 (19.8)	1	1
Female	69 (41.8)	56 (81.2)	13 (18.8)	0.92 (0.45 - 1.88)	0.70 (0.34 - 1.46)
Age at Diagnosis (years):					
Mean (sd)	57.8 (16.9)	55.3 (15.8)	68.6 (17.2)	-	-
Median (range)	59.1 (15.1 - 92.6)	57.6 (15.1 - 87.7)	74.2 (25.1 - 92.6)		
Age group					
<40	26 (15.8)	23 (88.5)	3 (11.5)	0.80 (0.19 - 3.33)	0.80 (0.19 - 3.35)
40 to 49	26 (15.8)	24 (92.3)	2 (7.7)	0.56 (0.11 - 2.86)	0.60 (0.12 - 3.08)
50 to 59	35 (21.2)	30 (85.7)	5 (14.3)	1	1
60 to 69	34 (20.6)	31 (91.2)	3 (8.8)	0.64 (0.15 - 2.69)	0.64 (0.15 - 2.69)
70 to 79	34 (20.6)	23 (67.7)	11 (32.4)	2.49 (0.86 - 7.17)	2.78 (0.96 - 8.06)
80+	10 (6.1)	2 (20.0)	8 (80.0)	9.84 (3.15 - 30.77)	15.67 (4.46 - 55.07)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 33: CML Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	165 (100)	59.1 (15.1 - 92.6)	133 (80.6)	32 (19.4)		
Hospital:						
Airedale	6 (3.6)	62.4 (51.9 - 71.2)	6 (100)	-	-	-
Bradford Royal	20 (12.1)	54.0 (22.3 - 84.0)	17 (85.0)	3 (15.0)	0.78 (0.21 - 2.93)	0.91 (0.24 - 3.45)
Calderdale & Huddersfield	12 (7.3)	58.3 (37.0 - 87.7)	12 (100)	-	-	-
Leeds Teaching	38 (23.0)	56.8 (15.1 - 92.6)	30 (79.0)	8 (21.1)	1	1
Harrogate & District	4 (2.4)	47.8 (36.5 - 74.0)	4 (100)	-	-	-
York Teaching	10 (6.1)	55.1 (25.1 - 79.8)	7 (70.0)	3 (30.0)	1.21 (0.32 - 4.57)	1.10 (0.29 - 4.17)
Dewsbury & District	12 (7.3)	62.1 (18.7 - 88.9)	7 (58.3)	5 (41.7)	2.34 (0.76 - 7.17)	1.65 (0.53 - 5.15)
Pinderfields General	7 (4.2)	57.6 (32.6 - 85.4)	7 (100)	-	-	-
Pontefract General	8 (4.9)	68.0 (41.5 - 86.9)	5 (62.5)	3 (37.5)	-	-
Hull & East Yorkshire	27 (16.4)	64.7 (23.2 - 82.8)	20 (74.1)	7 (25.9)	1.11 (0.40 - 3.06)	0.78 (0.28 - 2.18)
Scarborough	3 (1.8)	67.2 (62.4 - 77.5)	3 (100)	-	-	-
Grimsby (DPOW)	12 (7.3)	57.8 (36.1 - 79.8)	10 (83.3)	2 (16.7)	0.78 (0.16 - 3.65)	0.60 (0.13 - 2.82)
Scunthorpe General	5 (3.0)	52.7 (37.3 - 71.3)	4 (80.0)	1 (20.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	26 (15.8)	57.6 (22.3 - 84.0)	23 (88.5)	3 (11.5)	0.61 (0.17 - 2.21)	0.89 (0.24 - 3.30)
Leeds	50 (30.0)	57.6 (15.1 - 92.6)	42 (84.0)	8 (16.0)	0.77 (0.31 - 1.96)	1.02 (0.40 - 2.59)
Harrogate/York	14 (8.5)	50.5 (25.1 - 79.8)	11 (78.6)	3 (21.4)	0.90 (0.25 - 3.28)	1.12 (0.31 - 4.07)
Mid-Yorks	27 (16.4)	61.2 (18.7 - 88.9)	19 (70.4)	8 (29.6)	1.82 (0.72 - 4.63)	1.84 (0.72 - 4.71)
HYCCN ³	47 (28.5)	63.5 (23.2 - 82.8)	37 (78.7)	10 (21.3)	1	1

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 1: CML Overall Survival




Figure 2: CML Relative Survival




Figure 3: CML Survival by Age (Years)

Myeloproliferative Neoplasms (MPN)

Table 34: MPN Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	961 (100)	757 (78.8)	204 (21.3)		
Follow up (years):					
Median (range)	3.3 (0 - 6.5)	3.7 (1.6-6.5)	1.8 (0-6.4)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	413 (43.0)	314 (76.0)	99 (24.0)	1	1
Female	548 (57.0)	443 (80.8)	105 (19.2)	0.70 (0.53 - 0.93)	0.52 (0.39 - 0.68)
Age at Diagnosis (years):					
Mean (sd)	68.6 (15.0)	65.7 (14.6)	79.2 (9.5)		
Median (range)	71.1 (16.4 - 99.0)	68.2 (16.4 - 95.1)	80.5 (37.6 - 99.0)	-	-
Age group					
<40	56 (5.8)	55 (98.2)	1 (1.8)	0.38 (0.04 - 3.26)	0.39 (0.05 - 3.32)
40 to 49	73 (7.6)	72 (98.6)	1 (1.4)	0.31 (0.04 - 2.68)	0.30 (0.03 - 2.56)
50 to 59	109 (11.3)	104 (95.4)	5 (4.6)	1	1
60 to 69	210 (21.9)	183 (87.1)	27 (12.9)	3.23 (1.24 - 8.40)	2.96 (1.14 - 7.71)
70 to 79	282 (29.3)	221 (78.4)	61 (21.6)	5.42 (2.18 - 13.49)	5.81 (2.33 - 14.48)
80+	231 (24.0)	122 (52.8)	109 (47.2)	15.03 (6.12 - 36.90)	16.21 (6.60 - 39.82)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 35: MPN Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	961 (100)	71.1 (16.4 - 99.0)	757 (78.8)	204 (21.3)	-	-
Airedale	68 (7.1)	72.5 (32.1 - 94.3)	58 (85.3)	10 (14.7)	0.64 (0.32 - 1.30)	0.58 (0.29 - 1.18)
Bradford Royal	88 (9.2)	69.8 (27.3 - 96.1)	75 (85.2)	13 (14.8)	0.70 (0.37 - 1.32)	0.71 (0.38 - 1.35)
Calderdale & Huddersfield	76 (7.9)	68.2 (25.0 - 91.4)	58 (76.3)	18 (23.7)	1.12 (0.63 - 1.99)	1.36 (0.77 - 2.41)
Leeds Teaching	164 (17.1)	69.6 (16.4 - 94.6)	130 (79.3)	34 (20.7)	1	1
Harrogate & District	52 (5.4)	70.7 (40.8 - 92.9)	43 (82.7)	9 (17.3)	0.91 (0.44 - 1.90)	1.08 (0.52 - 2.27)
York Teaching	81 (8.4)	71.8 (26.3 - 94.9)	66 (81.5)	15 (18.5)	0.90 (0.49 - 1.65)	0.80 (0.44 - 1.48)
Dewsbury & District	49 (5.1)	65.5 (24.6 - 94.7)	38 (77.6)	11 (22.5)	1.15 (0.58 - 2.28)	1.56 (0.79 - 3.09)
Pinderfields General	61 (6.4)	73.4 (36.5 - 98.9)	46 (75.4)	15 (24.6)	1.27 (0.69 - 2.33)	1.20 (0.65 - 2.20)
Pontefract General	37 (3.9)	70.4 (25.2 - 96.8)	25 (67.6)	12 (32.4)	1.55 (0.80 - 3.00)	1.26 (0.65 - 2.43)
Hull & East Yorkshire	123 (12.8)	72.8 (17.0 - 94.0)	96 (78.1)	27 (22.0)	1.12 (0.68 - 1.86)	0.94 (0.57 - 1.56)
Scarborough	49 (5.1)	77.4 (41.8 - 87.3)	36 (73.5)	13 (26.5)	1.24 (0.66 - 2.36)	1.01 (0.53 - 1.93)
Grimsby (DPOW)	47 (4.9)	69.7 (19.5 - 95.5)	33 (70.2)	14 (29.8)	1.63 (0.87 - 3.04)	1.82 (0.97 - 3.39)
Scunthorpe General	50 (5.2)	71.9 (19.9 - 99.0)	39 (78.0)	11 (22.0)	0.99 (0.50 - 1.96)	0.92 (0.46 - 1.82)
Private	15 (1.6)	64.1 (28.0 - 94.7)	13 (86.7)	2 (13.3)	0.61 (0.15 - 2.53)	0.42 (0.10 - 1.77)
Multi-Disciplinary Team:						
Airedale/Bradford	156 (16.2)	71.1 (27.3 - 96.1)	133 (85.3)	23 (14.7)	0.56 (0.35 - 0.90)	0.61 (0.38 - 0.98)
Leeds	240 (24.9)	69.1 (16.4 - 94.6)	188 (78.3)	52 (21.7)	0.87 (0.60 - 1.25)	1.03 (0.72 - 1.49)
Harrogate/York	133 (13.8)	71.7 (26.3 - 94.9)	109 (82.0)	24 (18.1)	0.75 (0.47 - 1.20)	0.84 (0.52 - 1.33)
Mid-Yorks	147 (15.3)	71.1 (24.6 - 98.9)	109 (74.2)	38 (25.9)	1.09 (0.73 - 1.63)	1.22 (0.82 - 1.83)
HYCCN³	269 (28.0)	72.6 (17.0 - 99.0)	204 (75.8)	65 (24.2)	1	1
Private	15 (1.7)	64.0 (28.0 - 94.7)	13 (86.7)	2 (13.3)	0.51 (0.12 - 2.07)	0.40 (0.10 - 1.64)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 4: MPN Overall Survival




Figure 5: MPN Relative Survival




Figure 6: MPN Survival by Age at Diagnosis (Years)

Primary Myelofibrosis

Table 36: Primary myelofibrosis Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	73 (100)	37 (50.7)	36 (49.3)	-	-
Follow up (years): Median (range)	2.4 (0.07 - 6.4)	2.80 (1.7-6.4)	1.87 (0-4.6)	-	-
Survival (years): Median (95%CI)	3.8 (0.8 – 2.8)				
Sex:					
Male	48 (65.8)	22 (45.8)	26 (54.2)	1	1
Female	25 (34.3)	15 (60.0)	10 (40.0)	0.50 (0.23 - 1.01)	0.41 (0.19 - 0.86)
Age at Diagnosis (Years):					
Mean (sd)	72.0 (9.8)	68.4 (9.4)	75.6 (8.9)	-	-
Median (range)	73.0 (45.5 - 90.4)	69.9 (45.5 - 88.9)	76.4 (55.7 - 90.4)	-	-
Age group					
<40	-	-	-	-	-
40 to 49	1 (1.4)	1 (100)	-	-	-
50 to 59	9 (12.3)	5 (55.6)	4 (44.4)	1	1
60 to 69	17 (23.3)	13 (76.5)	4 (23.5)	0.71 (0.18 - 2.85)	0.70 (0.17 - 2.83)
70 to 79	33 (45.2)	15 (45.5)	18 (54.6)	1.63 (0.55 - 4.86)	1.72 (0.58 - 5.10)
80+	13 (17.8)	3 (23.1)	10 (76.9)	4.40 (1.31 - 14.82)	4.94 (1.47 - 16.54)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 37: Primary myelofibrosis Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	73 (100)	73.0 (45.5 - 90.4)	37 (50.7)	36 (49.3)	-	-
Hospital:						
Airedale	4 (5.5)	72.5 (67.8 - 75.8)	3 (75.0)	1 (25.0)	-	-
Bradford Royal	7 (9.6)	69.9 (57.0 - 87.3)	3 (42.9)	4 (57.1)	-	-
Calderdale & Huddersfield	12 (16.4)	79.7 (63.4 - 88.2)	5 (41.7)	7 (58.3)	-	-
Leeds Teaching	9 (12.3)	76.9 (45.5 - 90.4)	5 (55.6)	4 (44.4)	-	-
Harrogate & District	7 (9.6)	71.8 (57.1 - 88.9)	2 (28.6)	5 (71.4)	-	-
York Teaching	5 (6.9)	65.5 (54.2 - 87.3)	4 (80.0)	1 (20.0)	-	-
Dewsbury & District	4 (5.5)	72.3 (68.8 - 77.7)	-	4 (100)	-	-
Pinderfields General	3 (4.1)	61.6 (57.0 - 85.5)	3 (100)	-	-	-
Pontefract General	5 (6.9)	74.2 (59.4 - 85.6)	3 (60.0)	2 (40.0)	-	-
Hull & East Yorkshire	11 (15.1)	72.3 (55.6 - 79.0)	6 (54.6)	5 (45.5)	-	-
Scarborough	-	-	-	-	-	-
Scunthorpe General	4 (5.5)	69.9 (60.9 - 83.1)	2 (50.0)	2 (50.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	11 (15.1)	70.2 (57.0 - 87.3)	6 (54.6)	5 (45.5)	1.26 (0.41 - 3.85)	1.61 (0.52 - 4.99)
Leeds	21 (28.8)	78.8 (45.5 - 90.4)	10 (47.6)	11 (52.4)	1.71 (0.67 - 4.33)	1.72 (0.64 - 4.63)
Harrogate/York	12 (16.4)	70.9 (54.2 - 88.9)	6 (50.0)	6 (50.0)	1.53 (0.52 - 4.45)	1.47 (0.49 - 4.44)
Mid-Yorks	12 (16.4)	72.0 (57.0 - 85.6)	6 (50.0)	6 (50.0)	1.70 (0.59 - 4.94)	2.24 (0.75 - 6.77)
HYCCN ³	16 (21.9)	71.9 (55.6 - 83.1)	8 (50.0)	8 (50.0)	1	1

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 7: Primary myelofibrosis Overall Survival




Figure 8: Primary myelofibrosis Relative Survival




Figure 9: Primary myelofibrosis Survival by Age at Diagnosis (Years)

Chronic Myelomonocytic Leukaemia (CMML)

Table 38: CMML Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	98 (100)	30 (30.6)	68 (69.4)	-	-
Follow up (years):					
Median (range)	1.5 (0 - 6.4)	3.1 (1.6-6.4)	0.6 (0.02-4.21)	-	-
Survival (years):					
Median (95%CI)	1.5 (0.7 – 2.1)				
Sex:					
Male	65 (66.3)	20 (30.8)	45 (69.2)	1	1
Female	33 (33.7)	10 (30.3)	23 (69.7)	0.84 (0.50 - 1.38)	0.85 (0.51 - 1.41)
Age at Diagnosis (Years):					
Mean (sd)	73.7 (15.0)	69.5 (20.5)	75.5 (11.6)	-	-
Median (range)	75.9 (0.07 - 94.1)	75.3 (0.07 - 84.6)	76.4 (35.9 - 94.1)		
Age group					
<40	3 (3.1)	2 (66.7)	1 (33.3)	0.40 (0.04-3.63)	0.42 (0.05-3.80)
40 to 49	1 (1.0)	-	1 (100)	-	-
50 to 59	7 (7.1)	3 (42.9)	4 (57.1)	1	1
60 to 69	16 (16.3)	3 (18.8)	13 (81.3)	1.30 (0.42 - 3.99)	1.34 (0.43 - 4.13)
70 to 79	36 (36.7)	13 (36.1)	23 (63.9)	1.29 (0.45 - 3.74)	1.26 (0.44 - 3.67)
80+	35 (35.7)	9 (25.7)	26 (74.3)	1.71 (0.59 - 4.91)	1.74 (0.60 - 5.00)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 39: CMML Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	98 (100)	75.9 (0.07 - 94.1)	30 (30.6)	68 (69.4)	-	-
Hospital:						
Airedale	3 (3.1)	72.5 (61.6 - 81.1)	-	3 (100)	-	-
Bradford Royal	6 (6.1)	73.6 (53.7 - 78.3)	1 (16.7)	5 (83.3)	-	-
Calderdale & Huddersfield	7 (7.1)	76.3 (67.9 - 88.1)	2 (28.6)	5 (71.4)	-	-
Leeds Teaching	12 (12.2)	75.3 (0.1 - 91.5)	7 (58.3)	5 (41.7)	1	1
York Teaching	11 (11.2)	80.5 (72.6 - 83.6)	6 (54.6)	5 (45.5)	1.30 (0.38 - 4.51)	1.10 (0.31 - 3.86)
Dewsbury & District	2 (2.0)	75.8 (67.7 - 83.9)	1 (50.0)	1 (50.0)	-	-
Pinderfields General	11 (11.2)	79.8 (65.4 - 86.5)	4 (36.4)	7 (63.6)	1.67 (0.53 - 5.29)	1.49 (0.46 - 4.83)
Pontefract General	5 (5.1)	86.3 (77.4 - 94.1)	-	5 (100)	-	-
Hull & East Yorkshire	19 (19.4)	73.4 (35.9 - 93.7)	6 (31.6)	13 (68.4)	1.86 (0.66 - 5.23)	1.84 (0.64 - 5.27)
Scarborough	7 (7.1)	72.9 (54.2 - 85.9)	2 (28.6)	5 (71.4)	-	-
Grimsby (DPOW)	4 (4.1)	72.8 (54.2 - 85.9)	-	4 (100)	-	-
Scunthorpe General	8 (8.2)	76.3 (57.0 - 91.0)	-	8 (100)	-	-
Private	2 (2.0)	83.1 (-)	1 (50.0)	1 (50.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	9 (9.2)	72.5 (53.7 - 81.1)	1 (11.1)	8 (88.9)	1.71 (0.78 - 3.75)	2.10 (0.92 - 4.78)
Leeds	19 (19.4)	76.3 (0.1 - 91.5)	9 (47.4)	10 (52.6)	0.54 (0.26 - 1.10)	0.50 (0.24 - 1.04)
Harrogate/York	12 (12.2)	78.5 (68.4 - 83.6)	6 (50.0)	6 (50.0)	0.59 (0.24 - 1.41)	0.46 (0.19 - 1.34)
Mid-Yorks	18 (18.4)	81.1 (65.4 - 94.1)	5 (27.8)	13 (72.2)	0.91 (0.48 - 1.75)	0.81 (0.42 - 1.56)
HYCCN ³	38 (38.8)	73.7 (35.9 - 93.7)	8 (21.1)	30 (79.0)	1	1
Private	2 (2.0)	83.1 (-)	1 (50.0)	1 (50.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 10: CMML Overall Survival




Figure 11: CMML Relative Survival




Figure 12: CMML Survival by Age at Diagnosis (Years)

Myelodysplastic Syndrome (MDS)




Figure 13: MDS Subtypes

Table 40: MDS Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	653 (100)	167 (25.4)	486 (74.7)		
Follow up (years):					
Median (range)	1.3 (0 - 6.5)	3.0 (1.6-6.5)	0.8 (0-5.9)	-	-
Survival (years):					
Median (95%CI)	1.3 (1.2 - 1.6)				
Sex:					
Male	433 (66.3)	99 (22.9)	334 (77.1)	1	1
Female	220 (33.7)	68 (30.9)	152 (69.1)	0.81 (0.67 - 0.98)	0.80 (0.66 - 0.98)
Age at Diagnosis (Years):					
Mean (sd)	73.9 (12.1)	70.8 (13.5)	74.9 (11.4)	-	-
Median (range)	76.1 (3.8 - 96.3)	73.1 (10.1 - 95.4)	76.8 (3.8 - 96.3)	-	-
Age group					
<40	12 (1.8)	6 (50.0)	6 (50.0)	0.93 (0.38 - 2.28)	1.02 (0.41 - 2.51)
40 to 49	14 (2.1)	3 (21.4)	11 (78.6)	1.48 (0.72 - 3.03)	1.58 (0.77 - 3.24)
50 to 59	40 (6.1)	17 (42.5)	23 (57.5)	1	1
60 to 69	113 (17.3)	37 (32.7)	76 (67.3)	1.21 (0.76 - 1.93)	1.21 (0.76 - 1.93)
70 to 79	252 (38.6)	63 (25.0)	189 (75.0)	1.58 (1.03 - 2.44)	1.58 (1.03 - 2.44)
80+	222 (34.0)	41 (18.5)	181 (81.3)	1.86 (1.20 - 2.86)	1.91 (1.24 - 2.95)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex

Table 41: MDS Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	653 (100)	76.1 (3.8 - 96.3)	167 (25.4)	486 (74.7)	-	-
Hospital:						
Airedale	45 (6.9)	78.2 (45.3 - 89.7)	15 (33.3)	30 (66.7)	0.80 (0.53 - 1.21)	0.75 (0.50 - 1.14)
Bradford Royal	38 (5.8)	72.2 (40.5 - 96.3)	6 (15.8)	32 (84.2)	1.44 (0.96 - 2.15)	1.43 (0.96 - 2.15)
Calderdale & Huddersfield	51 (7.8)	78.9 (58.8 - 89.0)	8 (15.7)	43 (84.3)	1.13 (0.79 - 1.63)	1.01 (0.70 - 1.45)
Leeds Teaching	130 (19.9)	75.3 (3.8 - 95.4)	38 (29.3)	92 (70.8)	1	1
Harrogate & District	24 (3.7)	76.3 (56.4 - 92.0)	6 (25.0)	18 (75.0)	1.21 (0.73 - 2.01)	1.14 (0.68 - 1.89)
York Teaching	63 (9.7)	74.0 (44.6 - 91.8)	19 (30.2)	44 (69.8)	0.86 (0.60 - 1.24)	0.84 (0.59 - 1.20)
Dewsbury & District	29 (4.4)	80.7 (34.3 - 89.2)	5 (17.2)	24 (82.8)	1.33 (0.85 - 2.09)	1.24 (0.79 - 1.94)
Pinderfields General	26 (4.0)	70.8 (29.8 - 85.5)	6 (23.1)	20 (76.9)	1.10 (0.68 - 1.78)	1.13 (0.69 - 1.83)
Pontefract General	38 (5.8)	76.3 (40.8 - 88.9)	10 (26.3)	28 (73.7)	0.99 (0.65 - 1.52)	0.95 (0.62 - 1.45)
Hull & East Yorkshire	103 (15.8)	76.3 (40.2 - 88.8)	21 (20.4)	82 (79.6)	1.28 (0.95 - 1.72)	1.19 (0.88 - 1.60)
Scarborough	30 (4.6)	75.7 (41.1 - 92.5)	8 (26.7)	22 (73.3)	1.05 (0.66 - 1.67)	0.95 (0.60 - 1.52)
Grimsby (DPOW)	29 (4.4)	74.6 (53.1 - 91.2)	8 (27.6)	21 (72.4)	1.00 (0.62 - 1.61)	0.91 (0.57 - 1.47)
Scunthorpe General	39 (6.0)	76.3 (53.0 - 88.6)	13 (33.3)	26 (66.7)	0.96 (0.62 - 1.49)	0.91 (0.59 - 1.40)
Private	8 (1.2)	74.7 (69.1 - 85.7)	4 (50.0)	4 (50.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	83 (12.7)	75.8 (40.5 - 96.3)	21 (25.3)	62 (74.7)	0.92 (0.68 - 1.24)	0.96 (0.71 - 1.29)
Leeds	181 (27.4)	76.8 (3.8 - 95.4)	46 (25.4)	135 (75.6)	0.92 (0.73 - 1.16)	0.96 (0.76 - 1.21)
Harrogate/York	87 (13.3)	74.6 (44.6 - 92.0)	25 (28.7)	62 (71.3)	0.83 (0.62 - 1.12)	0.87 (0.65 - 1.17)
Mid-Yorks	93 (14.3)	77.0 (29.8 - 89.2)	21 (22.6)	72 (77.4)	0.99 (0.75 - 1.31)	1.04 (0.79 - 1.37)
HYCCN ³	201 (30.8)	75.8 (40.2 - 92.5)	50 (24.9)	151 (75.1)	1	1
Private	8 (1.2)	74.7 (69.1 - 85.7)	4 (50.0)	4 (50.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 14: MDS Overall Survival




Figure 15: MDS Relative Survival




Figure 16: MDS Survival by Age at Diagnosis (Years)




Figure 17: MDS Survival by International Prognostic Scoring System Score




Figure 18: MDS Survival by Disease Subtype

Acute Myeloid Leukaemia (AML)




Figure 19: AML Subtypes

Table 42: AML Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	717 (100)	155 (21.6)	562 (78.4)		
Follow up (years):				-	-
Median (range)	0.4 (0 - 6.5)	3.8 (1.6-6.5)	0.2 (0-6.2)		
Survival (years):					
Median (95%CI)	0.4 (0.3 - 0.6)				
Sex:					
Male	387 (54.0)	83 (21.5)	304 (78.6)	1	1
Female	330 (46.0)	72 (21.8)	258 (78.2)	0.96 (0.81 - 1.13)	0.86 (0.72 - 1.01)
Age at Diagnosis (Years):					
Mean (sd)	63.6 (20.6)	43.6 (20.9)	69.1 (16.8)	-	-
Median (range)	68.8 (0.2 - 97.2)	47.5 (0.54 - 86.34)	72.8 (0.14 - 97.21)	-	-
Age group					
<40	102 (14.2)	64 (62.8)	38 (37.3)	0.39 (0.26 - 0.58)	0.39 (0.26 - 0.58)
40 to 49	45 (6.3)	23 (51.1)	22 (48.9)	0.56 (0.34 - 0.91)	0.56 (0.34 - 0.91)
50 to 59	93 (13.0)	30 (32.3)	63 (67.7)	1	1
60 to 69	131 (18.3)	23 (17.6)	108 (82.4)	1.38 (1.01 - 1.88)	1.38 (1.01 - 1.88)
70 to 79	197 (27.5)	13 (6.6)	184 (93.4)	2.51 (1.88 - 3.36)	2.53 (1.89 - 3.37)
80+	149 (20.8)	2 (1.3)	147 (98.7)	4.26 (3.14 - 5.79)	4.39 (3.23 - 5.96)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 43: AML Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	717 (100)	68.8 (0.2 - 97.2)	155 (21.6)	562 (78.4)	-	-
Hospital:						
Airedale	36 (5.0)	73.4 (0.2 - 91.4)	3 (8.3)	33 (91.7)	1.91 (1.29 - 2.82)	1.15 (0.77 - 1.70)
Bradford Royal	59 (8.2)	70.5 (17.5 - 89.3)	12 (20.3)	47 (79.7)	1.60 (1.14 - 2.25)	1.27 (0.90 - 1.79)
Calderdale & Huddersfield	58 (8.1)	71.2 (24.6 - 90.9)	8 (13.8)	50 (86.2)	1.56 (1.11 - 2.18)	1.04 (0.74 - 1.46)
Leeds Teaching	162 (22.6)	58.8 (0.5 - 94.9)	52 (32.1)	110 (67.9)	1	1
Harrogate & District	28 (3.9)	73.0 (55.2 - 96.3)	2 (7.1)	26 (92.9)	1.92 (1.25 - 2.95)	1.02 (0.66 - 1.56)
York Teaching	54 (7.5)	70.8 (17.7 - 90.7)	14 (25.9)	40 (74.1)	1.09 (0.76 - 1.56)	0.69 (0.47 - 1.00)
Dewsbury & District	25 (3.5)	77.0 (25.8 - 97.2)	4 (16.0)	21 (84.0)	1.50 (0.94 - 2.40)	1.00 (0.63 - 1.61)
Pinderfields General	38 (5.3)	64.8 (17.0 - 86.4)	11 (29.0)	27 (71.1)	1.10 (0.72 - 1.67)	1.04 (0.68 - 1.59)
Pontefract General	32 (4.5)	74.3 (22.5 - 94.3)	5 (15.6)	27 (84.4)	1.55 (1.02 - 2.37)	0.98 (0.64 - 1.50)
Hull & East Yorkshire	125 (17.5)	65.3 (16.9 - 93.9)	34 (27.2)	91 (72.8)	1.17 (0.89 - 1.55)	0.92 (0.69 - 1.21)
Scarborough	21 (2.9)	76.7 (17.4 - 95.7)	3 (14.3)	18 (85.7)	1.80 (1.08 - 2.96)	1.06 (0.64 - 1.75)
Grimsby (DPOW)	24 (3.4)	73.7 (34.4 - 86.7)	3 (12.5)	21 (87.5)	1.63 (1.02 - 2.60)	1.13 (0.71 - 1.81)
Scunthorpe General	53 (7.4)	76.3 (13.9 - 89.8)	3 (5.7)	50 (94.3)	2.25 (1.61 - 3.15)	1.33 (0.95 - 1.87)
Multi-Disciplinary Team:						
Airedale/Bradford	95 (13.3)	71.2 (0.2 - 91.4)	15 (15.8)	80 (84.2)	1.17 (0.90 - 1.52)	1.18 (0.90 - 1.53)
Leeds	220 (30.7)	63.3 (0.5 - 94.9)	60 (27.3)	160 (72.7)	0.77 (0.62 - 0.95)	0.98 (0.79 - 1.22)
Harrogate/York	82 (11.5)	71.2 (17.7 - 96.3)	16 (19.5)	66 (80.5)	0.89 (0.67 - 1.18)	0.76 (0.57 - 1.02)
Mid-Yorks	95 (13.3)	70.2 (17.0 - 97.2)	20 (21.0)	75 (79.0)	0.91 (0.70 - 1.20)	0.97 (0.74 - 1.28)
HYCCN ³	223 (31.2)	70.5 (13.9 - 95.7)	43 (19.3)	180 (80.7)	1	1

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 44: AML Overall Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	717 (100)	68.8 (0.2 - 97.2)	155 (21.6)	562 (78.4)	-	-
Hospital:						
Airedale	30 (4.2)	74.0 (37.6 - 91.4)	2 (6.7)	28 (93.3)	2.29 (1.51 - 3.45)	1.19 (0.78 - 1.81)
Bradford Royal	64 (8.9)	69.1 (17.5 - 89.3)	13 (20.3)	51 (79.7)	1.67 (1.20 - 2.31)	1.26 (0.91 - 1.75)
Calderdale & Huddersfield	41 (5.7)	73.8 (51.8 - 90.9)	1 (2.4)	40 (97.6)	2.51 (1.76 - 3.60)	1.25 (0.87 - 1.80)
Leeds Teaching	187 (26.1)	57.3 (0.2 - 94.9)	64 (34.2)	123 (65.8)	1	1
Harrogate & District	23 (3.2)	77.4 (59.3 - 96.3)	1 (4.4)	22 (95.7)	2.61 (1.65 - 4.11)	1.14 (0.72 - 1.81)
York Teaching	52 (7.3)	71.1 (22.1 - 90.7)	12 (23.1)	40 (76.9)	1.25 (0.87 - 1.78)	0.73 (0.51 - 1.05)
Mid-Yorks	93 (13.0)	71.4 (17.9 - 97.2)	19 (20.4)	74 (79.6)	1.49 (1.11 - 1.98)	1.06 (0.79 - 1.42)
Hull & East Yorkshire	141 (19.7)	65.3 (16.9 - 93.9)	38 (27.0)	103 (73.1)	1.27 (0.97 - 1.64)	0.98 (0.75 - 1.27)
Scarborough	16 (2.2)	79.0 (70.1 - 95.7)	-	16 (100)	3.17 (1.88 - 5.36)	1.32 (0.77 - 2.24)
Grimsby (DPOW)	16 (2.2)	77.4 (55.6 - 86.7)	-	16 (100)	2.70 (1.60 - 4.55)	1.46 (0.86 - 2.47)
Scunthorpe General	42 (5.9)	79.2 (30.6 - 89.8)	2 (4.8)	40 (95.2)	2.59 (1.81 - 3.71)	1.25 (0.87 - 1.81)
No Haematology Referral ³	11 (1.5)	62.6 (13.9 - 83.9)	2 (18.2)	9 (81.8)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³No referral to haematology or treated outside the network

Table 45: AML Patient Demographics and 1-year Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	717 (100)	270 (37.6)	447 (62.3)	-	-
Sex:					
Male	387 (54.0)	146 (37.7)	241 (62.3)	1	1
Female	330 (46.0)	124 (37.6)	206 (62.4)	0.99 (0.82 - 1.19)	0.88 (0.73 - 1.06)
Age at Diagnosis (years):					
Mean (sd)	63.6 (20.6)	50.2 (21.1)	71.7 (15.5)	-	-
Median (Range)	68.8 (0.2-97.2)	55.3 (0.5-88.0)	75.8 (0.2-97.2)	-	-
Age group					
<40	102 (14.2)	80 (78.4)	22 (21.6)	0.39 (0.23 - 0.65)	0.39 (0.23-0.65)
40 to 49	45 (6.3)	34 (75.6)	11 (24.4)	0.45 (0.23 - 0.88)	0.45 (0.23-0.87)
50 to 59	93 (13.0)	50 (53.8)	43 (46.2)	1	1
60 to 69	131 (18.3)	58 (44.3)	73 (55.7)	1.25 (0.86 - 1.82)	1.24 (0.85-1.81)
70 to 79	197 (27.5)	39 (19.8)	158 (80.2)	2.61 (1.86 - 3.66)	2.62 (1.87-3.67)
80+	149 (20.8)	9 (6.0)	140 (94.0)	4.37 (3.09 - 6.18)	4.44 (3.14-6.30)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 46: AML - 1 Year Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	717 (100)	68.8 (0.2 - 97.2)	270 (37.7)	447 (62.3)	-	-
Hospital:						
Airedale	36 (5.0)	73.4 (0.2 - 91.4)	7 (19.4)	29 (80.6)	1.96 (1.28 - 2.99)	1.21 (0.79 - 1.85)
Bradford Royal	59 (8.2)	70.5 (17.5 - 89.3)	17 (28.8)	42 (71.2)	1.84 (1.27 - 2.67)	1.49 (1.02 - 2.16)
Calderdale & Huddersfield	58 (8.1)	71.2 (24.6 - 90.9)	18 (31.0)	40 (69.0)	1.56 (1.07 - 2.27)	1.09 (0.75 - 1.59)
Leeds Teaching	162 (22.6)	58.8 (0.5 - 94.9)	80 (49.4)	82 (50.6)	1	1
Harrogate & District	28 (3.9)	73.0 (55.2 - 96.3)	6 (21.4)	22 (78.6)	1.92 (1.20 - 3.07)	1.05 (0.66 - 1.69)
York Teaching	54 (7.5)	70.8 (17.7 - 90.7)	25 (46.3)	29 (53.7)	1.02 (0.67 - 1.56)	0.64 (0.42 - 0.98)
Dewsbury & District	25 (3.5)	77.0 (25.8 - 97.2)	8 (32.0)	17 (68.0)	1.64 (0.97 - 2.77)	1.04 (0.61 - 1.76)
Pinderfields General	38 (5.3)	64.8 (17.0 - 86.4)	19 (50.0)	19 (50.0)	1.03 (0.62 - 1.69)	0.98 (0.59 - 1.62)
Pontefract General	32 (4.5)	74.3 (22.5 - 94.3)	12 (37.5)	20 (62.5)	1.44 (0.88 - 2.34)	0.93 (0.57 - 1.52)
Hull & East Yorkshire	125 (17.5)	65.3 (16.9 - 93.9)	54 (43.2)	71 (56.8)	1.17 (0.85 - 1.61)	0.94 (0.69 - 1.30)
Scarborough	21 (2.9)	76.7 (17.4 - 95.7)	5 (23.8)	16 (76.2)	1.88 (1.10 - 3.21)	1.02 (0.59 - 1.75)
Grimsby (DPOW)	24 (3.4)	73.7 (34.4 - 86.7)	7 (29.2)	17 (70.8)	1.61 (0.95 - 2.71)	1.11 (0.67 - 1.87)
Scunthorpe General	53 (7.4)	76.3 (13.9 - 89.8)	11 (20.8)	42 (79.3)	2.26 (1.56 - 3.29)	1.36 (0.94 - 1.99)
Multi-Disciplinary Team:						
Airedale/Bradford	95 (13.3)	71.2 (0.2 - 91.4)	24 (25.3)	71 (74.7)	1.27 (0.95 - 1.68)	1.27 (0.96 - 1.69)
Leeds	220 (30.7)	63.3 (0.5 - 94.9)	98 (44.6)	122 (55.5)	0.76 (0.60 - 0.97)	0.97 (0.76 - 1.23)
Harrogate/York	82 (11.5)	71.2 (17.7 - 96.3)	31 (37.8)	51 (62.2)	0.86 (0.63 - 1.18)	0.72 (0.52 - 0.99)
Mid-Yorks	95 (13.3)	70.2 (17.0 - 97.2)	39 (41.1)	56 (59.0)	0.88 (0.65 - 1.20)	0.92 (0.67 - 1.25)
HYCCN ³	223 (31.2)	70.5 (13.9 - 95.7)	77 (34.5)	146 (65.5)	1	1

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 47: AML 1-year Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	717 (100)	68.8 (0.2 - 97.2)	270 (37.7)	447 (62.3)		
Hospital:						
Airedale	30 (4.2)	74.0 (37.6 - 91.4)	4 (13.3)	26 (86.7)	2.52 (1.63-3.91)	1.31 (0.84-2.04)
Bradford Royal	64 (8.9)	69.1 (17.5 - 89.3)	21 (32.8)	43 (67.2)	1.84 (1.28-2.64)	1.41 (0.98-2.03)
Calderdale & Huddersfield	41 (5.7)	73.8 (51.8 - 90.9)	6 (14.6)	35 (85.4)	2.61 (1.76-3.86)	1.33 (0.90-1.98)
Leeds Teaching	187 (26.1)	57.3 (0.2 - 94.9)	98 (52.4)	89 (47.6)	1	1
Harrogate & District	23 (3.2)	77.4 (59.3 - 96.3)	3 (13.0)	20 (87.0)	2.69 (1.65-4.37)	1.22 (0.74-1.99)
York Teaching	52 (7.3)	71.1 (22.1 - 90.7)	23 (44.2)	29 (55.8)	1.19 (0.78-1.80)	0.67 (0.44-1.03)
Mid-Yorks	93 (13.0)	71.4 (17.9 - 97.2)	37 (39.8)	56 (60.2)	1.50 (1.07-2.10)	1.04 (0.74-1.47)
Hull & East Yorkshire	141 (19.7)	65.3 (16.9 - 93.9)	60 (42.6)	81 (57.5)	1.30 (1.07-2.10)	1.01 (0.75-1.36)
Scarborough	16 (2.2)	79.0 (70.1 - 95.7)	2 (12.5)	14 (87.5)	2.92 (1.66-5.14)	1.19 (0.67-2.10)
Grimsby (DPOW)	16 (2.2)	77.4 (55.6 - 86.7)	3 (18.8)	13 (81.3)	2.48 (1.38-4.44)	1.35 (0.75-2.42)
Scunthorpe General	42 (5.9)	79.2 (30.6 - 89.8)	8 (19.1)	34 (80.9)	2.69 (1.81-3.99)	1.30 (0.87-1.95)
No Haematology Referral ³	11 (1.5)	62.6 (13.9 - 83.9)	4 (36.4)	7 (63.6)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³No referral to haematology or treated outside the network




Figure 20: AML Overall Survival




Figure 21: AML Relative Survival




Figure 22: AML Survival by Age at Diagnosis (Years)




Figure 23: AML Survival by Subtype

Precursor Acute Lymphoblastic Leukaemia (ALL)




Figure 24: ALL Subtypes

Table 48: ALL Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	217 (100)	137 (63.1)	80 (36.9)		
Follow up (years):					
Median (range)	3.0 (0 - 6.6)	4.1 (1.6-6.6)	0.8 (0-4.8)	-	-
Sex:					
Male	118 (54.4)	75 (63.6)	43 (36.4)	1	1
Female	99 (45.6)	62 (62.6)	37 (37.4)	1.11 (0.72 - 1.73)	1.16 (0.74 - 1.81)
Survival (years):					
Median (95%CI)	-				
Age at Diagnosis (Years):					
Mean (sd)	25.9 (24.9)	14.4 (16.4)	45.6 (24.7)	-	-
Median (range)	15.1 (0.04 - 90.5)	8.6 (0.2 - 80.2)	47.9 (0.04 - 90.5)	-	-
Age group					
<5	159 (73.3)	128 (80.5)	31 (19.5)	1	1
5 to 14	12 (5.5)	1 (8.3)	11 (91.7)	0.60 (0.19 - 1.90)	0.62 (0.20 - 1.94)
15 to 24	13 (6.0)	1 (7.7)	12 (92.3)	1.83 (0.64 - 5.22)	2.00 (0.69 - 5.74)
25 to 39	19 (8.8)	5 (26.3)	14 (73.7)	4.41 (1.74 - 11.25)	4.54 (1.78 - 11.56)
40 to 59	7 (3.2)	1 (14.3)	6 (85.7)	14.79 (6.24 - 35.06)	15.74 (6.60 - 37.51)
60+	7 (3.2)	1 (14.3)	6 (85.7)	13.10 (5.58 - 30.72)	13.61 (5.79 - 31.97)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 49: ALL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	217 (100)	15.1 (0.04 - 90.5)	137 (63.1)	80 (36.9)	-	-
Hospital:						
Airedale	6 (2.8)	10.3 (1.0 - 65.2)	6 (100)	-	-	-
Bradford Royal	11 (5.1)	38.2 (2.0 - 79.1)	5 (45.5)	6 (54.6)	2.71 (1.11 - 6.59)	0.87 (0.34 - 2.26)
Calderdale & Huddersfield	15 (6.9)	42.6 (0.3 - 85.1)	7 (46.7)	8 (53.3)	2.87 (1.30 - 6.34)	1.16 (0.49 - 2.70)
Leeds Teaching	110 (50.7)	8.6 (0.04 - 74.2)	84 (76.4)	26 (23.6)	1	1
York Teaching	12 (5.5)	19.4 (2.7 - 71.5)	8 (66.7)	4 (33.3)	1.52 (0.53 - 4.35)	1.00 (0.35 - 2.87)
Dewsbury & District	3 (1.4)	5.1 (3.8 - 29.2)	3 (100)	-	-	-
Pinderfields General	9 (4.2)	39.8 (2.0 - 79.1)	1 (11.1)	8 (88.9)	-	2.01 (0.87 - 4.66)
Pontefract General	4 (1.8)	20.0 (1.8 - 60.5)	2 (50.0)	2 (50.0)	-	2.02 (0.47 - 8.62)
Hull & East Yorkshire	28 (12.9)	38.6 (2.1 - 90.5)	15 (53.6)	13 (46.4)	2.34 (1.20 - 4.56)	0.81 (0.40 - 1.68)
Scarborough	3 (1.4)	77.3 (57.2 - 83.4)	-	3 (100)	-	-
Grimsby (DPOW)	6 (2.8)	41.5 (16.7 - 84.6)	1 (16.7)	5 (83.3)	-	-
Scunthorpe General	9 (4.2)	19.6 (2.6 - 59.5)	4 (44.4)	5 (55.6)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	17 (7.8)	27.4 (2.0 - 79.1)	11 (64.7)	6 (35.3)	0.52 (0.21 - 1.25)	0.47 (0.20 - 1.15)
Leeds	125 (57.6)	8.9 (0.04 - 85.1)	91 (72.8)	34 (27.2)	0.39 (0.23 - 0.65)	0.76 (0.46 - 1.30)
Harrogate/York	13 (6.0)	19.1 (2.7 - 71.5)	9 (69.2)	4 (30.8)	0.46 (0.16 - 1.31)	0.71 (0.25 - 2.04)
Mid-Yorks	16 (7.4)	31.6 (1.8 - 79.1)	6 (37.5)	10 (62.5)	1.23 (0.59 - 2.55)	1.29 (0.62 - 2.68)
HYCCN ³	46 (21.2)	35.7 (2.1 - 90.5)	20 (43.5)	26 (56.5)	1	1

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 50: ALL Overall Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	217 (100)	15.1 (0.04 - 90.5)	137 (63.1)	80 (36.9)	-	-
Hospital:						
Airedale	-	-	-	-	-	-
Bradford Royal	11 (5.1)	59.3 (18.1 - 79.1)	4 (36.4)	7 (63.6)	3.98 (1.74 - 9.11)	1.10 (0.44 - 2.77)
Calderdale & Huddersfield	6 (2.8)	71.5 (47.7 - 85.1)	-	6 (100)	-	-
Leeds Teaching	145 (66.8)	7.70 (0.05 - 74.2)	116 (80.0)	29 (20.0)	1	1
Harrogate & District	-	-	-	-	-	-
York Teaching	5 (2.3)	55.6 (19.6 - 71.5)	2 (40.0)	3 (60.0)	-	-
Mid-Yorks	12 (5.5)	37.7 (18.6 - 79.1)	3 (25.0)	9 (75.0)	5.64 (2.66 - 11.97)	2.17 (0.97 - 4.86)
Hull & East Yorkshire	23 (10.6)	54.6 (17.5 - 90.5)	8 (34.8)	15 (65.2)	4.46 (2.39 - 8.33)	1.40 (0.68 - 2.91)
Scarborough	2 (2.3)	80.3 (77.3 - 83.4)	-	2 (100)	-	-
Grimsby (DPOW)	5 (2.3)	63.3 (19.2 - 84.7)	-	5 (100)	-	-
Scunthorpe General	4 (1.8)	35.1 (20.0 - 59.5)	2 (50.0)	2 (50.0)	-	-
Sheffield Children's Hospital	4 (1.8)	9.4 (2.6 - 23.5)	2 (50.0)	2 (50.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex




Figure 25: ALL Overall Survival




Figure 26: ALL Relative Survival




Figure 27: ALL Survival by Age at Diagnosis (Years)




Figure 28: ALL Survival by Age at Diagnosis (Years)

Monoclonal B-cell lymphocytosis (MBL)

Table 51: MBL Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	445 (100)	369 (82.4)	76 (17.6)		
Follow up (years):					
Median (range)	3.7 (0 - 6.5)	3.9 (1.6-6.5)	1.9 (0-6.2)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	234 (52.6)	188 (80.3)	46 (19.7)	1	1
Female	211 (47.4)	181 (85.8)	30 (14.2)	0.72 (0.45 - 1.17)	0.52 (0.32 - 0.85)
Age at Diagnosis (Years):					
Mean (sd)	71.5 (10.4)	69.8 (9.8)	79.9 (8.7)	-	-
Median (range)	71.7 (42.6 - 98.4)	70.2 (42.6 - 93.0)	80.1 (48.2 - 98.4)	-	-
Age group					
<40	-	-	-	-	-
40 to 49	12 (2.7)	11 (91.7)	1 (8.3)	4.62 (0.29 - 73.94)	3.99 (0.25 - 63.89)
50 to 59	50 (11.3)	49 (98.0)	1 (2.0)	1	1
60 to 69	128 (28.8)	122 (95.3)	6 (4.7)	2.35 (0.28 - 19.51)	2.21 (0.27 - 18.35)
70 to 79	152 (34.2)	124 (81.6)	28 (18.4)	9.64 (1.31 - 70.84)	9.93 (1.34 - 72.98)
80+	103 (23.2)	63 (61.2)	40 (38.8)	25.93 (3.56 - 188.78)	27.22 (3.74 - 198.25)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 52: MBL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	445 (100)	71.7 (42.6 - 98.4)	369 (82.4)	76 (17.6)	-	-
Hospital:						
Airedale	33 (7.4)	74.2 (48.9 - 90.9)	25 (75.8)	8 (24.2)	1.29 (0.51 - 3.27)	0.99 (0.38 - 2.53)
Bradford Royal	12 (2.7)	74.2 (60.3 - 83.0)	10 (83.3)	2 (16.7)	0.84 (0.18 - 3.85)	0.74 (0.16 - 3.43)
Calderdale & Huddersfield	28 (6.3)	74.2 (51.1 - 98.4)	21 (75.0)	7 (25.0)	1.20 (0.46 - 3.15)	1.25 (0.47 - 3.31)
Leeds Teaching	51 (11.5)	72.3 (49.2 - 90.6)	41 (80.4)	10 (19.6)	1	1
Harrogate & District	14 (3.2)	72.1 (55.1 - 85.1)	13 (92.9)	1 (7.1)	0.29 (0.04 - 2.23)	0.36 (0.05 - 2.83)
York Teaching	70 (15.7)	74.3 (48.6 - 89.8)	61 (87.1)	9 (12.9)	0.63 (0.25 - 1.54)	0.64 (0.26 - 1.58)
Dewsbury & District	19 (4.3)	70.8 (49.4 - 86.6)	15 (79.0)	4 (21.1)	1.22 (0.38 - 3.88)	1.21 (0.38 - 3.86)
Pinderfields General	27 (6.1)	74.3 (51.0 - 96.5)	21 (77.8)	6 (22.2)	1.11 (0.40 - 3.05)	0.92 (0.33 - 2.53)
Pontefract General	32 (7.2)	68.2 (42.6 - 88.4)	25 (78.1)	7 (21.9)	1.02 (0.39 - 2.68)	1.40 (0.53 - 3.71)
Hull & East Yorkshire	82 (18.4)	69.2 (48.3 - 94.6)	69 (84.2)	13 (15.9)	0.77 (0.34 - 1.76)	0.72 (0.32 - 1.65)
Scarborough	22 (4.9)	66.7 (48.2 - 85.6)	21 (95.5)	1 (4.6)	0.20 (0.03 - 1.54)	0.19 (0.02 - 1.50)
Grimsby (DPOW)	8 (1.8)	63.4 (47.7 - 82.1)	8 (100)	-	-	-
Scunthorpe General	13 (2.9)	74.3 (67.8 - 84.5)	10 (76.9)	3 (23.1)	0.96 (0.26 - 3.49)	0.75 (0.21 - 2.73)
Private	4 (0.9)	72.7 (65.8 - 94.8)	3 (75.0)	1 (25.0)	-	-
General Practice	30 (6.7)	74.8 (49.4 - 86.6)	26 (86.7)	4 (13.3)	0.92 (0.29 - 2.96)	0.85 (0.26 - 2.74)
Multi-Disciplinary Team:						
Airedale/Bradford	45 (10.1)	74.1 (48.9 - 90.9)	35 (77.8)	10 (22.2)	1.84 (0.84 - 4.02)	1.59 (0.72 - 3.50)
Leeds	79 (17.8)	73.9 (49.2 - 98.4)	62 (78.5)	17 (21.5)	1.69 (0.86 - 3.32)	1.84 (0.94 - 3.62)
Harrogate/York	84 (18.9)	73.5 (48.6 - 89.8)	74 (88.1)	10 (11.9)	0.90 (0.41 - 1.96)	1.01 (0.46 - 2.22)
Mid-Yorks	78 (17.5)	70.7 (42.6 - 96.5)	61 (78.2)	17 (21.8)	1.73 (0.88 - 3.38)	1.94 (0.99 - 3.81)
HYCCN ³	125 (28.1)	69.1 (47.7 - 94.6)	108 (86.4)	17 (13.6)	1	1
Private	4 (0.9)	72.7 (65.8 - 94.8)	3 (75.0)	1 (25.0)	2.45 (0.32-18.51)	1.20 (0.16-9.16)
General Practice	30 (6.7)	74.8 (49.4 - 86.6)	26 (86.7)	4 (13.3)	1.45 (0.49-4.34)	1.44 (0.48-4.33)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 29: MBL Overall Survival




Figure 30: MBL Relative Survival




Figure 31: MBL Survival by Age at Diagnosis (Years)

Chronic Lymphocytic Leukaemia

Table 53: CLL Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1144 (100)	774 (67.7)	369 (32.3)	-	-
Follow up (years):					
Median (range)	3.1 (0 - 6.6)	3.7 (1.6-6.6)	1.6 (2.0-6.4)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	702 (61.4)	480 (68.4)	222 (31.6)	1	1
Female	441 (38.6)	294 (66.7)	147 (33.3)	1.08 (0.88 - 1.33)	0.81 (0.65 - 1.00)
Age at Diagnosis (Years):					
Mean (sd)	70.7 (11.4)	67.6 (10.9)	77.1 (9.6)	-	-
Median (range)	71.6 (26.1 - 97.1)	68.1 (26.1 - 95.0)	78.6 (36.0 - 97.1)	-	-
Age group					
<40	7 (0.6)	6 (85.7)	1 (14.3)	-	-
40 to 49	36 (3.2)	34 (94.4)	2 (5.6)	0.59 (0.14 - 2.58)	0.58 (0.13 - 2.54)
50 to 59	169 (14.8)	153 (90.5)	16 (9.5)	1	1
60 to 69	299 (26.1)	240 (80.3)	59 (19.7)	2.21 (1.27 - 3.84)	2.18 (1.25 - 3.78)
70 to 79	386 (33.7)	248 (64.3)	138 (35.8)	4.46 (2.66 - 7.48)	4.55 (2.71 - 7.64)
80+	247 (21.6)	94 (38.1)	153 (61.9)	10.72 (6.40 - 17.97)	11.14 (6.64 - 18.70)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 54: CLL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1144 (100)	71.6 (26.1 - 97.1)	775 (67.7)	369 (32.3)	-	-
Hospital:						
Airedale	69 (6.0)	72.8 (43.0 - 97.1)	43 (62.3)	26 (37.7)	1.20 (0.75 - 1.91)	1.02 (0.64 - 1.63)
Bradford Royal	82 (7.2)	72.9 (26.1 - 92.5)	56 (68.3)	26 (31.7)	1.04 (0.65 - 1.66)	1.03 (0.64 - 1.65)
Calderdale & Huddersfield	94 (8.2)	72.5 (44.9 - 95.4)	66 (70.2)	28 (29.8)	1.03 (0.65 - 1.62)	1.03 (0.65 - 1.62)
Leeds Teaching	170 (14.9)	71.5 (40.0 - 96.3)	116 (68.2)	54 (31.8)	1	1
Harrogate & District	65 (5.7)	70.2 (43.5 - 88.1)	50 (76.9)	15 (23.1)	0.80 (0.45 - 1.41)	0.85 (0.48 - 1.50)
York Teaching	109 (9.5)	71.3 (38.2 - 92.5)	74 (67.9)	35 (32.1)	0.97 (0.63 - 1.49)	0.93 (0.61 - 1.42)
Dewsbury & District	48 (4.2)	71.0 (42.3 - 91.1)	31 (64.6)	17 (35.4)	1.15 (0.66 - 1.98)	1.26 (0.73 - 2.17)
Pinderfields General	70 (6.1)	74.1 (43.9 - 92.3)	46 (65.7)	24 (34.3)	1.18 (0.73 - 1.91)	1.13 (0.70 - 1.83)
Pontefract General	52 (4.6)	72.7 (45.7 - 91.7)	36 (69.2)	16 (30.8)	0.97 (0.56 - 1.69)	1.10 (0.63 - 1.92)
Hull & East Yorkshire	144 (12.6)	70.7 (30.5 - 94.8)	98 (68.1)	46 (31.9)	0.98 (0.66 - 1.45)	1.12 (0.75 - 1.66)
Scarborough	81 (7.1)	72.5 (41.9 - 94.9)	46 (56.8)	35 (43.2)	1.33 (0.87 - 2.04)	1.16 (0.76 - 1.78)
Grimsby (DPOW)	65 (5.7)	69.7 (48.8 - 88.8)	48 (73.9)	17 (26.2)	0.86 (0.50 - 1.48)	0.95 (0.55 - 1.64)
Scunthorpe General	58 (5.1)	70.8 (35.8 - 96.9)	38 (65.5)	20 (34.5)	1.11 (0.66 - 1.85)	0.96 (0.57 - 1.61)
Private	14 (1.2)	60.3 (45.0 - 79.3)	12 (85.7)	2 (14.3)	0.33 (0.08 - 1.34)	0.59 (0.14 - 2.41)
General Practice	23 (4.2)	73.2 (43.9 - 95.0)	15 (65.2)	8 (34.8)	1.87 (0.89 - 3.96)	1.19 (0.53 - 2.63)
Multi-Disciplinary Team:						
Airedale/Bradford	151 (13.2)	72.8 (26.1 - 97.1)	99 (65.6)	52 (34.4)	1.06 (0.76 - 1.46)	0.96 (0.69 - 1.32)
Leeds	264 (23.1)	71.7 (40.0 - 96.3)	182 (68.9)	82 (31.1)	0.96 (0.73 - 1.28)	0.94 (0.71 - 1.25)
Harrogate/York	174 (15.2)	71.1 (38.2 - 92.5)	124 (71.3)	50 (28.7)	0.85 (0.61 - 1.19)	0.84 (0.60 - 1.17)
Mid-Yorks	170 (14.9)	72.9 (42.3 - 92.3)	113 (66.5)	57 (33.5)	1.05 (0.76 - 1.44)	1.08 (0.78 - 1.48)
HYCCN ³	348 (30.5)	70.8 (30.5 - 96.9)	230 (66.1)	118 (33.9)	1	1
Private	14 (1.2)	60.3 (45.0 - 79.3)	12 (85.7)	2 (14.3)	0.31 (0.08 - 1.24)	0.55 (0.13 - 2.22)
General Practice	23 (4.2)	73.2 (43.9 - 95.0)	15 (65.2)	8 (34.8)	1.58 (0.73-3.39)	1.11 (0.51-2.39)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 32: CLL Overall Survival




Figure 33: CLL Relative Survival




Figure 34: CLL Survival by Age at Diagnosis (Years)




Figure 35: CLL Survival by Binet Score

Hairy Cell Leukaemia (HCL)

Table 55: HCL Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	55 (100)	49 (89.1)	6 (10.9)	-	-
Follow up (years):					
Median (range)	3.8 (0 - 6.4)	3.9 (1.6-6.4)	0.2 (0-3.3)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	42 (76.4)	37 (88.1)	5 (11.9)	1	1
Female	13 (23.6)	12 (92.3)	1 (7.7)	0.61 (0.07 - 5.23)	0.33 (0.04 - 3.00)
Age at Diagnosis (Years):					
Mean (sd)	64.8 (14.8)	63.4 (14.1)	75.9 (16.9)	-	-
Median (range)	65.7 (28.9 - 90.9)	65.2 (28.9 - 90.9)	81.6 (42.0 - 86.4)	-	-
Age group					
<40	3 (5.5)	3 (100)	-	-	-
40 to 49	8 (14.6)	7 (87.5)	1 (12.5)	-	-
50 to 59	7 (12.7)	7 (100)	-	-	-
60 to 69	12 (21.8)	12 (100)	-	-	-
70 to 79	18 (32.7)	16 (88.9)	2 (11.1)	-	-
80+	7 (12.7)	4 (57.1)	3 (42.9)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 56: HCL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	55 (100)	65.7 (28.9 - 90.9)	49 (89.1)	6 (10.9)	-	-
Hospital:						
Airedale	-	-	-	-	-	-
Calderdale & Huddersfield	7 (12.7)	63.6 (49.0 - 84.8)	6 (85.7)	1 (14.3)	-	-
Leeds Teaching	7 (12.7)	68.0 (63.0 - 83.8)	6 (85.7)	1 (14.3)	-	-
Harrogate & District	2 (3.6)	70.0 (63.5 - 76.6)	2 (100)	-	-	-
York Teaching	4 (7.3)	48.5 (28.9 - 72.8)	4 (100)	-	-	-
Dewsbury & District	3 (5.5)	75.8 (42.0 - 85.7)	2 (66.7)	1 (33.3)	-	-
Pinderfields General	4 (7.3)	71.0 (60.2 - 86.4)	4 (100)	-	-	-
Pontefract General	2 (3.6)	81.3 (79.1 - 83.5)	1 (50.0)	1 (50.0)	-	-
Hull & East Yorkshire	14 (25.5)	65.9 (45.8 - 90.9)	14 (100)	-	-	-
Scarborough	3 (5.5)	79.4 (71.3 - 86.4)	1 (33.3)	2 (66.7)	-	-
Grimsby (DPOW)	3 (5.5)	55.1 (43.2 - 70.5)	3 (100)	-	-	-
Scunthorpe General	4 (7.3)	51.2 (42.0 - 61.9)	4 (100)	-	-	-
Multi-Disciplinary Team:						
Leeds	14 (25.5)	65.6 (49.0 - 84.8)	12 (85.7)	2 (14.3)	-	-
Harrogate/York	6 (10.9)	60.2 (28.9 - 76.6)	6 (100)	-	-	-
Mid-Yorks	9 (16.4)	75.8 (42.0 - 86.4)	7 (77.8)	2 (22.2)	-	-
HYCCN ³	24 (43.6)	65.0 (42.0 - 90.9)	22 (91.7)	2 (8.3)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 36: HCL Overall Survival




Figure 37: HCL Relative Survival

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Table 57: MGUS Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1135 (100)	814 (71.7)	321 (28.3)		
Follow up (years):					
Median (range)	3.3 (0 - 6.6)	3.8 (1.6-6.6)	1.9 (0-6.3)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	641 (56.5)	431 (67.3)	210 (32.7)	1	1
Female	494 (43.5)	383 (77.5)	111 (22.5)	0.63 (0.50 - 0.80)	0.63 (0.50 - 0.79)
Age at Diagnosis (Years):					
Mean (sd)	70.1 (11.7)	67.5 (11.7)	76.8 (9.0)	-	-
Median (range)	72.2 (27.7 - 95.7)	69.2 (29.9 - 89.1)	78.1 (27.7 - 95.7)	-	-
Age group					
<40	14 (1.2)	13 (92.9)	1 (7.1)	1.02 (0.13 - 8.00)	1.13 (0.15 - 8.86)
40 to 49	65 (5.7)	63 (96.9)	2 (3.1)	0.46 (0.10 - 2.11)	0.46 (0.10 - 2.09)
50 to 59	147 (13.0)	137 (93.2)	10 (6.8)	1	1
60 to 69	260 (22.9)	215 (82.7)	45 (17.3)	2.58 (1.30 - 5.12)	2.44 (1.23 - 4.85)
70 to 79	406 (35.8)	270 (66.5)	136 (33.5)	5.81 (3.05 - 11.03)	5.62 (2.95 - 10.68)
80+	243 (21.4)	116 (47.7)	127 (52.3)	10.50 (5.51 - 20.00)	10.52 (5.52 - 20.04)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 58: MGUS Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1135 (100)	72.2 (27.7 - 95.7)	814 (71.7)	321 (28.3)	-	-
Hospital:						
Airedale	61 (5.4)	76.0 (42.3 - 94.3)	45 (73.8)	16 (26.2)	0.93 (0.54 - 1.62)	0.77 (0.44 - 1.34)
Bradford Royal	84 (7.4)	71.9 (41.7 - 92.2)	65 (77.4)	19 (22.6)	0.82 (0.49 - 1.37)	0.78 (0.47 - 1.32)
Calderdale & Huddersfield	59 (5.2)	75.8 (44.1 - 87.4)	35 (59.3)	24 (40.7)	1.50 (0.93 - 2.41)	1.38 (0.85 - 2.22)
Leeds Teaching	200 (17.6)	71.1 (27.7 - 92.6)	142 (71.0)	58 (29.0)	1	1
Harrogate & District	33 (2.9)	73.4 (30.7 - 88.6)	27 (81.8)	6 (18.2)	0.54 (0.23 - 1.26)	0.48 (0.21 - 1.12)
York Teaching	138 (12.2)	72.0 (29.9 - 95.7)	101 (73.2)	37 (26.8)	0.86 (0.57 - 1.30)	0.83 (0.55 - 1.25)
Dewsbury & District	24 (2.1)	73.3 (40.5 - 87.2)	15 (62.5)	9 (37.5)	1.49 (0.74 - 3.02)	1.64 (0.81 - 3.32)
Pinderfields General	83 (7.3)	72.3 (34.6 - 92.4)	63 (75.9)	20 (24.1)	0.87 (0.52 - 1.45)	0.78 (0.47 - 1.30)
Pontefract General	57 (5.0)	72.8 (38.2 - 89.1)	36 (63.2)	21 (36.8)	1.38 (0.84 - 2.28)	1.24 (0.75 - 2.05)
Hull & East Yorkshire	208 (18.3)	70.7 (35.4 - 89.5)	147 (70.7)	61 (29.3)	0.98 (0.68 - 1.40)	1.01 (0.71 - 1.45)
Scarborough	45 (4.0)	75.0 (55.0 - 88.8)	26 (57.8)	19 (42.2)	1.77 (1.05 - 2.97)	1.43 (0.85 - 2.40)
Grimsby (DPOW)	89 (7.8)	71.4 (38.6 - 90.1)	68 (76.4)	21 (23.6)	0.83 (0.50 - 1.37)	0.87 (0.53 - 1.43)
Scunthorpe General	42 (3.7)	72.1 (42.8 - 85.7)	33 (78.6)	9 (21.4)	0.67 (0.33 - 1.34)	0.67 (0.33 - 1.35)
Private	12 (1.1)	67.9 (38.3 - 80.1)	11 (91.7)	1 (8.3)	0.26 (0.04 - 1.90)	0.34 (0.05 - 2.46)
Multi-Disciplinary Team:						
Airedale/Bradford	145 (12.8)	73.5 (41.7 - 94.3)	110 (75.9)	35 (24.1)	0.88 (0.60 - 1.29)	0.78 (0.54 - 1.15)
Leeds	259 (22.8)	72.4 (27.7 - 92.6)	177 (68.3)	82 (31.7)	1.13 (0.85 - 1.50)	1.10 (0.82 - 1.46)
Harrogate/York	171 (15.1)	72.4 (29.9 - 95.7)	128 (74.9)	43 (25.2)	0.81 (0.57 - 1.15)	0.77 (0.54 - 1.09)
Mid-Yorks	164 (14.5)	73.0 (34.6 - 92.4)	114 (69.5)	50 (30.5)	1.15 (0.83 - 1.61)	1.05 (0.75 - 1.47)
HYCCN ³	384 (33.8)	71.9 (35.4 - 90.1)	274 (71.4)	110 (28.7)	1	1
Private	12 (1.1)	67.9 (38.3 - 80.1)	11 (91.7)	1 (8.3)	0.27 (0.04 - 1.92)	0.34 (0.05 - 2.47)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 38: MGUS Overall Survival




Figure 39: MGUS Relative Survival




Figure 40: MGUS Survival by Age at Diagnosis (Years)

Myeloma

Table 59: Myeloma Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1127 (100)	421 (37.3)	706 (62.7)	-	-
Follow up (years): Median (range)	1.9 (0 - 6.6)	3.3 (1.6-6.6)	0.9 (0-6.1)	-	-
Survival (years): Median (95%CI)	2.4 (2.1 – 2.7)				
Sex:					
Male	646 (57.3)	246 (38.1)	400 (61.9)	1	1
Female	481 (42.7)	175 (36.4)	306 (63.6)	1.07 (0.92 - 1.24)	0.97 (0.83 - 1.13)
Age at Diagnosis (Years):					
Mean (sd)	71.4 (11.5)	66.3 (11.6)	74.5 (10.2)	-	-
Median (range)	73.0 (30.6 - 95.5)	66.4 (30.6 - 94.7)	76.0 (39.9 - 95.7)	-	-
Age group					
<40	10 (0.9)	9 (90.0)	1 (10.0)	0.18 (0.03 - 1.31)	0.18 (0.02 - 1.30)
40 to 49	40 (3.6)	28 (70.0)	12 (30.0)	0.69 (0.37 - 1.28)	0.69 (0.37 - 1.28)
50 to 59	147 (13.0)	88 (59.9)	59 (40.1)	1	1
60 to 69	260 (23.1)	125 (48.1)	135 (51.9)	1.47 (1.08 - 2.00)	1.47 (1.08 - 1.99)
70 to 79	379 (33.6)	118 (31.1)	261 (68.9)	2.49 (1.87 - 3.30)	2.49 (1.87 - 3.31)
80+	291 (25.8)	53 (18.2)	238 (81.8)	3.99 (2.99 - 5.33)	4.00 (3.00 - 5.34)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 60: Myeloma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1127 (100)	73.0 (30.6 - 95.5)	421 (37.3)	706 (62.7)	-	-
Hospital:						
Airedale	63 (5.6)	73.7 (39.4 - 90.8)	20 (31.8)	43 (68.3)	1.37 (0.96 - 1.93)	1.21 (0.86 - 1.72)
Bradford Royal	80 (7.1)	74.0 (30.6 - 91.1)	31 (38.8)	49 (61.3)	1.15 (0.82 - 1.60)	0.95 (0.68 - 1.32)
Calderdale & Huddersfield	93 (8.3)	74.6 (44.6 - 94.7)	32 (34.4)	61 (65.6)	1.31 (0.96 - 1.78)	1.09 (0.80 - 1.49)
Leeds Teaching	212 (18.8)	71.1 (34.0 - 93.5)	91 (42.9)	121 (57.1)	1	1
Harrogate & District	49 (4.4)	76.2 (49.9 - 93.9)	19 (38.8)	30 (61.2)	1.04 (0.69 - 1.55)	0.81 (0.54 - 1.20)
York Teaching	120 (10.7)	73.5 (46.6 - 91.8)	49 (40.8)	71 (59.2)	1.12 (0.83 - 1.50)	0.94 (0.70 - 1.26)
Dewsbury & District	42 (3.7)	72.7 (45.1 - 89.8)	15 (35.7)	27 (64.3)	1.08 (0.71 - 1.64)	1.11 (0.73 - 1.68)
Pinderfields General	43 (3.8)	70.8 (47.7 - 88.3)	18 (41.9)	25 (58.1)	0.99 (0.64 - 1.52)	1.03 (0.67 - 1.58)
Pontefract General	35 (3.1)	77.3 (49.7 - 90.9)	5 (14.3)	30 (85.7)	2.26 (1.52 - 3.38)	2.05 (1.37 - 3.07)
Hull & East Yorkshire	200 (17.8)	71.9 (35.6 - 93.2)	71 (35.5)	129 (64.5)	1.16 (0.90 - 1.48)	1.13 (0.88 - 1.45)
Scarborough	40 (3.6)	76.3 (45.3 - 91.4)	11 (27.5)	29 (72.5)	1.28 (0.85 - 1.92)	0.99 (0.66 - 1.49)
Grimsby (DPOW)	88 (7.8)	74.2 (33.4 - 95.5)	40 (45.5)	48 (54.6)	0.93 (0.67 - 1.30)	0.78 (0.55 - 1.09)
Scunthorpe General	56 (5.0)	72.8 (48.5 - 93.2)	16 (28.6)	40 (71.4)	1.77 (1.24 - 2.54)	1.61 (1.13 - 2.31)
Private	5 (0.4)	64.8 (47.6 - 70.2)	2 (40.0)	3 (60.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	143 (12.7)	73.8 (30.6 - 91.1)	51 (35.7)	92 (64.3)	1.05 (0.83 - 1.34)	0.99 (0.78 - 1.26)
Leeds	305 (27.1)	71.9 (34.0 - 94.7)	123 (40.3)	182 (59.7)	0.93 (0.77 - 1.12)	0.97 (0.80 - 1.17)
Harrogate/York	169 (15.0)	74.4 (46.6 - 93.9)	68 (40.2)	101 (59.8)	0.93 (0.73 - 1.17)	0.84 (0.67 - 1.06)
Mid-Yorks	120 (10.7)	72.5 (45.1 - 90.9)	38 (31.7)	82 (68.3)	1.09 (0.85 - 1.40)	1.21 (0.94 - 1.56)
HYCCN ³	384 (34.1)	72.9 (33.4 - 95.5)	138 (35.9)	246 (64.1)	1	1
Private	5 (0.4)	64.8 (47.6 - 70.2)	2 (40.0)	3 (60.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 61: Myeloma Overall Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1127 (100)	73.0 (30.6 - 95.5)	421 (37.3)	706 (62.7)	-	-
Hospital:						
Airedale	58 (5.2)	73.3 (39.4-90.8)	20 (34.5)	38 (65.5)	1.19 (0.83-1.71)	1.06 (0.74-1.52)
Bradford Royal	79 (7.0)	74.8 (30.6-91.1)	31 (39.2)	48 (60.8)	1.09 (0.78-1.51)	0.88 (0.63-1.23)
Calderdale & Huddersfield	89 (7.9)	74.4 (44.6-94.7)	33 (37.1)	56 (62.9)	1.16 (0.85-1.58)	0.97 (0.71-1.33)
Leeds Teaching	228 (20.2)	71.1 (34.0-93.5)	94 (41.2)	134 (58.8)	1	1
Harrogate & District	46 (4.1)	76.2 (49.9-93.9)	17 (37.0)	29 (63.0)	1.03 (0.69-1.54)	0.80 (0.54-1.20)
York Teaching	115 (10.2)	73.7 (46.6-91.8)	48 (41.7)	67 (58.3)	1.05 (0.78-1.41)	0.87 (0.65-1.17)
Mid-Yorks	120 (10.7)	72.7 (45.1-90.9)	37 (30.8)	83 (69.2)	1.23 (0.94-1.62)	1.23 (0.94-1.62)
Hull & East Yorkshire	198 (17.6)	71.7 (35.6-93.2)	71 (35.9)	127 (64.1)	1.09 (0.86-1.39)	1.08 (0.85-1.37)
Scarborough	41 (3.6)	77.7 (45.3-91.4)	10 (24.4)	31 (75.6)	1.27 (0.86-1.87)	0.93 (0.63-1.37)
Grimsby (DPOW)	87 (7.7)	74.3 (33.4-95.5)	39 (44.8)	48 (55.2)	0.92 (0.66-1.28)	0.74 (0.53-1.03)
Scunthorpe General	57 (5.1)	72.1 (48.5-93.2)	18 (31.6)	39 (68.4)	1.52 (1.07-2.18)	1.45 (1.07-2.08)
Private	5 (0.4)	64.8 (47.6-70.2)	2 (40.0)	3 (60.0)	-	-
No Haematology Referral ³	4 (0.4)	65.8 (59.2-73.5)	1 (25.0)	3 (75.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³No referral to haematology or treated outside the network

Table 62: Myeloma Patient Demographics and 1 - Year Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1127 (100)	762 (67.6)	365 (32.4)	-	-
Sex:					
Male	646 (57.3)	441 (68.3)	205 (31.7)	1	1
Female	481 (42.7)	321 (66.7)	160 (33.26)	1.08 (0.88 - 1.32)	0.98 (0.80 - 1.21)
Age at Diagnosis (Years):					
Mean (sd)	71.4 (11.5)	69.3 (11.4)	78.0 (10.2)	-	-
Median (Range)	73.0 (30.6 - 95.5)	70.8 (30.6-95.5)	78.0 (39.9-93.9)	-	-
Age group					
<40	10 (0.9)	9 (90.0)	1 (10.0)	0.61 (0.08 - 4.49)	0.60 (0.08-4.48)
40 to 49	40 (3.6)	34 (85.0)	6 (15.0)	0.91 (0.37 - 2.24)	0.91 (0.37-2.23)
50 to 59	147 (13.0)	123 (83.7)	24 (16.3)	1	1
60 to 69	260 (23.1)	205 (78.9)	55 (21.2)	1.32 (0.81 - 2.12)	1.31 (0.81-2.12)
70 to 79	379 (33.6)	246 (64.9)	133 (35.1)	2.38 (1.54 - 3.68)	2.38 (1.54-3.68)
80+	291 (25.8)	145 (49.8)	146 (50.2)	3.91 (2.54 - 6.02)	3.91 (2.54-6.03)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 63: Myeloma - 1-Year Survival by Diagnostic Hospital and MDT

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1127 (100)	73.0 (30.6 - 95.5)	762 (67.6)	365 (32.4)	-	-
Hospital:						
Airedale	63 (5.6)	73.7 (39.4 - 90.8)	38 (60.3)	25 (39.7)	1.20 (0.76 - 1.89)	1.07 (0.68 - 1.69)
Bradford Royal	80 (7.1)	74.0 (30.6 - 91.1)	56 (70.0)	24 (30.0)	0.86 (0.54 - 1.37)	0.76 (0.48 - 1.20)
Calderdale & Huddersfield	93 (8.3)	74.6 (44.6 - 94.7)	62 (66.7)	31 (33.3)	0.97 (0.64 - 1.48)	0.85 (0.56 - 1.29)
Leeds Teaching	212 (18.8)	71.1 (34.0 - 93.5)	141 (66.5)	71 (33.5)	1	1
Harrogate & District	49 (4.4)	76.2 (49.9 - 93.9)	33 (67.4)	16 (32.7)	0.90 (0.52 - 1.55)	0.73 (0.42 - 1.25)
York Teaching	120 (10.7)	73.5 (46.6 - 91.8)	83 (69.2)	37 (30.8)	0.90 (0.60 - 1.34)	0.82 (0.55 - 1.22)
Dewsbury & District	42 (3.7)	72.7 (45.1 - 89.8)	30 (71.4)	12 (28.6)	0.78 (0.42 - 1.44)	0.79 (0.43 - 1.47)
Pinderfields General	43 (3.8)	70.8 (47.7 - 88.3)	33 (76.7)	10 (23.3)	0.64 (0.33 - 1.23)	0.69 (0.36 - 1.35)
Pontefract General	35 (3.1)	77.3 (49.7 - 90.9)	17 (48.6)	18 (51.4)	1.78 (1.06 - 2.99)	1.60 (0.96 - 2.69)
Hull & East Yorkshire	200 (17.8)	71.9 (35.6 - 93.2)	142 (71.0)	58 (29.0)	0.81 (0.57 - 1.14)	0.81 (0.57 - 1.14)
Scarborough	40 (3.6)	76.3 (45.3 - 91.4)	29 (72.5)	11 (27.5)	0.80 (0.42 - 1.51)	0.66 (0.35 - 1.25)
Grimsby (DPOW)	88 (7.8)	74.2 (33.4 - 95.5)	65 (73.9)	23 (26.1)	0.73 (0.46 - 1.17)	0.63 (0.39 - 1.01)
Scunthorpe General	56 (5.0)	72.8 (48.5 - 93.2)	28 (50.0)	28 (50.0)	1.64 (1.06 - 2.53)	1.52 (0.98 - 2.35)
Private	5 (0.4)	64.8 (47.6 - 70.2)	4 (80.0)	1 (20.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	143 (12.7)	73.8 (30.6 - 91.1)	94 (65.7)	49 (34.3)	1.13 (0.81 - 1.57)	1.06 (0.76 - 1.48)
Leeds	303 (26.9)	71.9 (34.0 - 94.7)	201 (66.3)	102 (33.7)	1.12 (0.86 - 1.45)	1.14 (0.88 - 1.49)
Harrogate/York	169 (15.0)	74.4 (46.6 - 93.9)	116 (68.6)	53 (31.4)	1.01 (0.73 - 1.39)	0.95 (0.68 - 1.31)
Mid-Yorks	120 (10.7)	72.5 (45.1 - 90.9)	80 (66.7)	40 (33.3)	1.09 (0.76 - 1.56)	1.17 (0.82 - 1.68)
HYCCN ³	384 (34.1)	72.9 (33.4 - 95.5)	264 (68.8)	120 (31.3)	1	1
Private	5 (0.4)	64.8 (47.6 - 70.2)	4 (80.0)	1 (20.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 64: Myeloma 1- Year Overall Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1127 (100)	73.0 (30.6 - 95.5)	762 (67.6)	365 (32.4)	-	-
Hospital:						
Airedale	58 (5.2)	73.3 (39.4-90.8)	37 (63.8)	21 (36.2)	1.05 (0.65-1.71)	0.93 (0.58-1.51)
Bradford Royal	79 (7.0)	74.8 (30.6-91.1)	55 (69.6)	24 (30.4)	0.88 (0.55-1.38)	0.74 (0.47-1.17)
Calderdale & Huddersfield	89 (7.9)	74.4 (44.6-94.7)	61 (68.5)	28 (31.5)	0.90 (0.52-1.57)	0.78 (0.51-1.21)
Leeds Teaching	228 (20.2)	71.1 (34.0-93.5)	151 (66.2)	77 (33.8)	0.90 (0.61-1.34)	0.72 (0.41-1.25)
Harrogate & District	46 (4.1)	76.2 (49.9-93.9)	31 (67.4)	15 (32.6)	1	1
York Teaching	115 (10.2)	73.7 (46.6-91.8)	79 (68.7)	36 (31.3)	0.90 (0.61-1.34)	0.81 (0.55-1.21)
Mid-Yorks	120 (10.7)	72.7 (45.1-90.9)	79 (65.8)	41 (34.2)	0.99 (0.68-1.45)	0.99 (0.68-1.44)
Hull & East Yorkshire	198 (17.6)	71.7 (35.6-93.2)	140 (70.7)	58 (29.3)	0.81 (0.58-1.14)	0.81 (0.57-1.14)
Scarborough	41 (3.6)	77.7 (45.3-91.4)	30 (73.2)	11 (26.8)	0.77 (0.41-1.45)	0.60 (0.32-1.13)
Grimsby (DPOW)	87 (7.7)	74.3 (33.4-95.5)	64 (73.6)	23 (26.4)	0.73 (0.46-1.17)	0.62 (0.39-0.99)
Scunthorpe General	57 (5.1)	72.1 (48.5-93.2)	30 (52.6)	27 (47.4)	1.53 (0.99-2.37)	1.46 (0.94-2.26)
Private	5 (0.4)	64.8 (47.6-70.2)	4 (80.0)	1 (20.0)	-	-
No Haematology Referral ³	4 (0.4)	65.8 (59.2-73.5)	1 (25.0)	3 (75.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³No referral to haematology or treated outside the network




Figure 41: Myeloma Overall Survival




Figure 42: Myeloma Relative Survival




Figure 43: Myeloma Survival by Age




Figure 44: Myeloma Relative Survival by Age




Figure 45: Myeloma Survival by B²M (mg/L)

The establishment of HMRN predates the publication of the International Staging System (ISS). Albumin is now routinely collected and the ISS will be calculated for patients diagnosed post 2010.

Plasmacytoma

Table 65: Plasmacytoma Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	99 (100)	56 (56.6)	43 (43.4)	-	-
Follow up (years):					
Median (range)	2.4 (0 - 6.5)	3.1 (1.6-6.5)	1.2 (0.-5.7)	-	-
Survival (years):					
Median (95%CI)	5.7 (3.1 - -)				
Sex:					
Male	65 (65.7)	35 (53.9)	30 (46.1)	1	1
Female	34 (34.3)	21 (61.8)	13 (38.2)	0.76 (0.40 - 1.49)	0.70 (0.36 - 1.36)
Age at Diagnosis (Years):					
Mean (sd)	66.5 (12.2)	62.9 (12.3)	71.3 (10.4)	-	-
Median (range)	69.2 (36.6 - 94.5)	61.7 (36.6-85.4)	71.8 (40.6-94.5)	-	-
Age group					
<40	2 (2.0)	2 (100)	-	-	-
40 to 49	13 (13.1)	10 (76.9)	3 (23.1)	0.33 (0.90-1.19)	0.37 (0.10-1.36)
50 to 59	14 (14.1)	13 (92.9)	1 (7.1)	0.10 (0.01-0.77)	0.11 (0.01-0.85)
60 to 69	22 (22.2)	11 (50.0)	11 (50.0)	1	1
70 to 79	37 (37.4)	16 (43.2)	21 (56.8)	1.38 (0.66-2.87)	1.47 (0.70-3.10)
80+	11 (11.1)	4 (36.4)	7 (63.6)	2.17 (0.83-5.68)	2.58 (0.90-7.41)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 66: Plasmacytoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	99 (100)	69.2 (36.6 - 94.5)	56 (56.6)	43 (43.4)	-	-
Hospital:						
Airedale	8 (8.1)	70.1 (36.6 - 79.4)	7 (87.5)	1 (12.5)	-	-
Bradford Royal	6 (6.1)	71.3 (44.7 - 81.5)	4 (66.7)	2 (33.3)	-	-
Calderdale & Huddersfield	9 (9.1)	71.3 (45.1 - 77.0)	6 (66.7)	3 (33.3)	-	-
Leeds Teaching	31 (31.3)	65.3 (38.7 - 83.3)	14 (45.2)	17 (54.8)	-	-
Harrogate & District	6 (6.1)	77.3 (59.6 - 91.0)	2 (33.3)	4 (66.7)	-	-
York Teaching	12 (12.2)	71.9 (59.9 - 94.5)	7 (58.3)	5 (41.7)	-	-
Dewsbury & District	2 (2.0)	59.7 (50.2 - 69.2)	1 (50.0)	1 (50.0)	-	-
Pinderfields General	2 (2.0)	61.0 (49.2 - 72.8)	2 (100)	-	-	-
Hull & East Yorkshire	15 (15.3)	65.0 (43.5 - 78.3)	7 (46.7)	8 (53.3)	-	-
Scarborough	2 (2.0)	68.7 (58.1 - 79.3)	1 (50.0)	1 (50.0)	-	-
Grimsby (DPOW)	2 (2.0)	72.8 (60.2 - 85.4)	2 (100)	-	-	-
Scunthorpe General	2 (2.0)	65.8 (48.5 - 83.0)	1 (50.0)	1 (50.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	14 (14.3)	71.1 (36.6 - 81.5)	11 (78.6)	3 (21.4)	0.43 (0.12 - 1.56)	0.45 (0.12 - 1.64)
Leeds	40 (40.8)	65.9 (38.7 - 83.3)	20 (50.0)	20 (50.0)	1.10 (0.51 - 2.35)	1.36 (0.63 - 2.94)
Harrogate/York	18 (18.4)	73.4 (59.6 - 94.5)	9 (50.0)	9 (50.0)	1.32 (0.54 - 3.27)	0.99 (0.39 - 2.47)
Mid-Yorks	5 (5.1)	65.1 (49.2 - 72.8)	4 (80.0)	1 (20.0)	-	-
HYCCN ³	21 (21.4)	65.0 (43.5 - 85.4)	11 (52.4)	10 (47.6)	1	1

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 46: Plasmacytoma Overall Survival




Figure 47: Plasmacytoma Relative Survival




Figure 48: Plasmacytoma Survival by Age at Diagnosis

Follicular Lymphoma

Table 67: Follicular Lymphoma Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	546 (100)	425 (77.8)	121 (22.2)	-	-
Follow up (years):					
Median (range)	3.3 (0 - 6.6)	3.7 (1.6-6.6)	1.7 (0-5.8)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	253 (46.3)	201 (79.5)	52 (20.5)	1	1
Female	293 (53.7)	224 (76.2)	69 (23.5)	1.13 (0.78 - 1.63)	0.96 (0.66 - 1.38)
Age at Diagnosis (Years):					
Mean (sd)	63.6 (12.9)	60.8 (12.1)	73.5 (10.8)	-	-
Median (range)	64.6 (19.6 - 95.2)	61.5 (19.6-92.1)	74.6 (43.8-95.2)	-	-
Age group					
<40	25 (4.6)	25 (100)	0	-	-
40 to 49	54 (9.9)	49 (90.7)	5 (9.3)	1.54 (0.50 - 4.70)	1.52 (0.50-4.65)
50 to 59	122 (22.3)	114 (93.4)	8 (6.6)	1	1
60 to 69	159 (29.1)	129 (81.1)	30 (18.9)	3.15 (1.44 - 6.86)	3.15 (1.44 - 6.89)
70 to 79	135 (24.7)	94 (69.6)	41 (30.4)	5.76 (2.70 - 12.30)	5.73 (2.68 - 12.20)
80+	51 (9.3)	14 (27.5)	37 (72.6)	20.15 (9.36 - 43.37)	20.39 (9.45 - 43.99)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 68: Follicular Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	546 (100)	64.6 (19.6 - 95.2)	425 (77.8)	121 (22.2)		
Hospital:						
Airedale	23 (4.2)	66.0 (42.6 - 79.8)	18 (78.3)	5 (21.7)	0.78 (0.30 - 2.06)	1.08 (0.40 - 2.88)
Bradford Royal	67 (12.3)	65.5 (27.0 - 83.1)	50 (74.6)	17 (25.4)	0.86 (0.46 - 1.62)	1.01 (0.53 - 1.92)
Calderdale & Huddersfield	55 (10.1)	62.7 (30.0 - 86.9)	44 (80.0)	11 (20.0)	0.64 (0.31 - 1.31)	0.90 (0.43 - 1.86)
Leeds Teaching	82 (15.1)	64.4 (19.6 - 95.2)	60 (73.2)	22 (26.8)	1	1
Harrogate & District	21 (3.9)	68.2 (45.1 - 92.1)	16 (76.2)	5 (23.8)	0.82 (0.31 - 2.17)	0.62 (0.23 - 1.65)
York Teaching	65 (11.9)	66.5 (37.5 - 90.2)	53 (81.5)	12 (18.5)	0.64 (0.32 - 1.29)	0.72 (0.35 - 1.46)
Dewsbury & District	23 (4.2)	64.2 (29.0 - 87.6)	18 (78.3)	5 (21.7)	0.75 (0.28 - 1.98)	0.86 (0.33 - 2.29)
Pinderfields General	23 (4.2)	56.3 (32.8 - 77.6)	22 (95.7)	1 (4.3)	0.13 (0.02 - 0.95)	0.34 (0.05 - 2.62)
Pontefract General	13 (2.4)	67.3 (46.3 - 87.7)	8 (61.5)	5 (38.5)	1.63 (0.62 - 4.31)	2.34 (0.88 - 6.23)
Hull & East Yorkshire	83 (15.2)	65.6 (28.6 - 87.9)	63 (75.9)	20 (24.1)	0.83 (0.45 - 1.52)	0.96 (0.52 - 1.77)
Scarborough	24 (4.4)	66.1 (36.6 - 88.0)	16 (66.7)	8 (33.3)	1.22 (0.54 - 2.75)	1.19 (0.53 - 2.69)
Grimsby (DPOW)	26 (4.8)	64.6 (39.2 - 91.9)	21 (80.8)	5 (19.2)	0.57 (0.22 - 1.50)	0.58 (0.22 - 1.54)
Scunthorpe General	29 (5.3)	61.5 (38.0 - 91.8)	25 (86.2)	4 (13.8)	0.54 (0.19 - 1.56)	0.72 (0.25 - 2.11)
Private	11 (2.0)	52.8 (37.1 - 72.3)	11 (100)	0	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	90 (16.5)	65.6 (27.0 - 83.1)	68 (75.6)	22 (24.4)	1.06 (0.63 - 1.80)	1.15 (0.68 - 1.96)
Leeds	137 (25.1)	64.1 (19.6 - 95.2)	104 (75.9)	33 (24.1)	1.06 (0.67 - 1.70)	1.06 (0.66 - 1.71)
Harrogate/York	86 (15.8)	66.8 (37.5 - 92.1)	69 (80.2)	17 (19.8)	0.87 (0.49 - 1.54)	0.75 (0.41 - 1.35)
Mid-Yorks	59 (10.8)	59.7 (29.0 - 87.8)	48 (81.4)	11 (18.6)	0.80 (0.41 - 1.56)	1.12 (0.57 - 2.21)
HYCCN ³	162 (29.7)	65.1 (28.6 - 91.9)	125 (77.2)	37 (22.8)	1	1
Private	11 (2.0)	52.8 (37.1 - 72.3)	11 (100)	0	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 49: Follicular Lymphoma Overall Survival




Figure 50: Follicular Lymphoma Relative Survival




Figure 51: Follicular Lymphoma Survival by Age at Diagnosis (Years)

Marginal Zone Lymphoma (MZL)




Figure 52: MZL Subtypes

Table 69: Total MZL Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	530 (100)	346 (65.3)	184 (34.7)	-	-
Follow up (years): Median (range)	2.7 (0 - 6.6)	3.5 (1.6-6.6)	1.40 (0-5.9)	-	-
Survival (years): Median (95%CI)	-	-	-	-	-
Sex:					
Male	298 (56.2)	191 (64.1)	107 (35.9)	1	1
Female	232 (43.8)	155 (66.8)	77 (33.2)	0.89 (0.66 - 1.20)	0.80 (0.60 - 1.08)
Age at Diagnosis (Years):					
Mean (sd)	69.7 (12.6)	66.9 (12.7)	75.2 (10.4)	-	-
Median (range)	71.5 (20.4 - 97.7)	68.2 (20.4-93.4)	76.4 (28.8-97.7)	-	-
Age group					
<40	12 (2.3)	11 (91.7)	1 (8.3)	0.56 (0.07 - 4.36)	0.52 (0.07-4.04)
40 to 49	25 (4.7)	22 (88.0)	3 (12.0)	0.73 (0.20 - 2.61)	0.73 (0.20-2.60)
50 to 59	72 (13.6)	61 (84.7)	11 (15.3)	1	1
60 to 69	133 (25.1)	103 (77.4)	30 (22.6)	1.52 (0.76 - 3.03)	1.48 (0.74-2.95)
70 to 79	183 (34.5)	106 (57.9)	77 (42.1)	3.21 (1.71 - 6.04)	3.17 (1.69-5.97)
80+	105 (19.8)	43 (41.0)	62 (59.1)	5.52 (2.90 - 10.50)	5.57 (2.93-10.59)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 70: Systemic MZL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	400 (100)	72.0 (22.5-97.7)	248 (62.0)	152 (38.0)	-	-
Hospital:						
Airedale	30 (7.5)	77.3 (48.1-92.9)	22 (73.3)	8 (26.7)	0.57 (0.26-1.24)	0.47 (0.21-1.02)
Bradford Royal	31 (7.7)	70.5 (44.4-90.9)	23 (74.2)	8 (25.8)	0.54 (0.25-1.17)	0.53 (0.25-1.16)
Calderdale & Huddersfield	24 (6.0)	72.6 (47.0-84.3)	13 (54.2)	11 (45.8)	1.24 (0.63-2.47)	1.29 (0.65-2.57)
Leeds Teaching	76 (19.0)	69.8 (33.7-93.4)	44 (57.9)	32 (42.1)	1	1
Harrogate & District	25 (6.3)	75.4 (37.5-93.4)	18 (72.0)	7 (28.0)	0.61 (0.27-1.37)	0.49 (0.21-1.10)
York Teaching	49 (12.3)	73.5 (44.1-91.1)	36 (73.5)	13 (26.5)	0.58 (0.31-1.11)	0.55 (0.29-1.05)
Dewsbury & District	9 (2.3)	73.6 (67.0-85.7)	3 (33.3)	6 (66.7)	-	-
Pinderfields General	21 (5.3)	72.7 (22.5-87.8)	10 (47.6)	11 (52.4)	1.43 (0.72-2.84)	1.59 (0.80-3.15)
Pontefract General	8 (2.0)	64.0 (51.6-77.9)	4 (50.0)	4 (50.0)	1.45 (0.51-4.10)	1.72 (0.60-4.93)
Hull & East Yorkshire	61 (15.3)	68.3 (48.4-97.7)	38 (62.3)	23 (37.7)	0.89 (0.52-1.53)	0.98 (0.57-1.67)
Scarborough	12 (3.0)	71.9 (45.1-87.7)	7 (58.3)	5 (41.7)	1.17 (0.46-3.02)	1.00 (0.48-2.13)
Grimsby (DPOW)	21 (5.3)	71.8 (47.6-89.8)	12 (57.1)	9 (42.9)	0.91 (0.44-1.91)	1.01 (0.48-2.13)
Scunthorpe General	27 (6.8)	71.7 (51.6-88.6)	13 (48.2)	14 (51.9)	1.32 (0.70-2.47)	1.11 (0.59-2.10)
Private	6 (1.5)	69.1 (56.8-78.0)	5 (83.3)	1 (16.7)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	61 (15.3)	75.6 (44.4-92.9)	45 (73.8)	16 (26.2)	0.55 (0.31-0.96)	0.49 (0.28-0.86)
Leeds	100 (25.0)	71.5 (33.7-93.4)	57 (57.0)	43 (43.0)	1.04 (0.70-1.56)	1.04 (0.69-1.57)
Harrogate/York	74 (18.5)	73.9 (37.5-93.4)	54 (73.0)	20 (27.0)	0.58 (0.35-0.98)	0.52 (0.31-0.87)
Mid-Yorks	38 (9.5)	72.8 (22.5-87.8)	17 (44.7)	21 (55.3)	1.62 (0.97-2.70)	1.66 (1.00-2.78)
HYCCN ³	121 (30.3)	69.8 (45.1-97.7)	70 (57.9)	51 (42.2)	1	1
Private	6 (1.5)		5 (83.3)	1 (16.7)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex, ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 71: Extranodal MZL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	130	70.0 (20.4-96.2)	98 (75.4)	32 (24.6)		
Hospital:						
Airedale	5 (3.9)	79.5 (59.7-81.9)	4 (80.0)	1 (20.0)	-	-
Bradford Royal	11 (8.5)	50.3 (29.6-96.2)	9 (81.8)	2 (18.2)	0.85 (0.17-4.26)	1.63 (0.32-8.18)
Calderdale & Huddersfield	12 (9.2)	66.6 (37.3-85.0)	8 (66.7)	4 (33.3)	1.61 (0.45-5.69)	1.94 (0.50-7.46)
Leeds Teaching	30 (23.1)	71.5 (36.3-84.4)	24 (80.0)	6 (20.0)	1	1
Harrogate & District	5 (3.9)	76.9 (58.3-88.8)	2 (40.0)	3 (60.0)	-	-
York Teaching	10 (7.7)	77.9 (58.3-91.8)	9 (90.0)	1 (10.0)	0.43 (0.05-3.58)	0.32 (0.04-2.71)
Dewsbury & District	2 (1.5)	73.3 (65.9-80.8)	2 (100)	-	-	-
Pinderfields General	5 (3.9)	70.2 (20.4-87.8)	2 (40.0)	3 (60.0)	-	-
Hull & East Yorkshire	19 (14.6)	70.3 (20.4-87.8)	13 (68.4)	6 (31.6)	1.54 (0.49-4.78)	1.45 (0.46-4.57)
Scarborough	5 (3.9)	62.9 (39.4-83.0)	5 (100)	-	-	-
Grimsby (DPOW)	10 (7.7)	68.5 (52.5-81.8)	8 (80.0)	2 (20.0)	0.82 (0.16-4.06)	0.89 (0.17-4.59)
Scunthorpe General	8 (6.2)	66.1 (41.4-91.0)	7 (87.5)	1 (12.5)	-	-
Private	5 (3.9)	63.4 (31.1-77.1)	5 (100)	-	-	-
Pathlinks	2 (1.5)	65.8 (53.8- 77.6)	-	2 (100)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	16 (12.3)	62.4 (29.6-96.2)	13 (81.3)	3 (18.7)	0.95 (0.26-3.52)	1.33 (0.35-4.96)
Leeds	42 (32.3)	70.7 (36.3-85.0)	32 (76.2)	10 (23.8)	1.19 (0.48-2.94)	1.18 (0.48-2.93)
Harrogate/York	15 (11.5)	77.0 (58.3-91.8)	11 (73.3)	4 (26.7)	1.42 (0.44-4.63)	0.96 (0.29-3.20)
Mid-Yorks	8 (6.2)	75.0 (49.9-93.4)	4 (50.0)	4 (50.0)	-	-
HYCCN ³	42 (32.3)	68.1 (20.4-91.0)	33 (78.6)	9 (21.4)	1	1
Private	5 (3.9)	63.4 (31.1-77.1)	5 (100)	-	-	-
Pathlinks	2 (1.5)	65.8 (53.8-77.8)	-	2 (100)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex, ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 53: MZL Overall Survival




Figure 54: MZL Survival by Disease Subtype




Figure 55: MZL Relative Survival




Figure 56: Systemic MZL Relative Survival




Figure 57: Extranodal MZL Relative Survival




Figure 58: MZL Survival by Age (Years)

Mantle Cell Lymphoma

Table 72: MCL Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	144 (100)	43 (29.9)	101 (70.1)	-	-
Follow up (years):					
Median (range)	1.7 (0 - 6.3)	2.7 (1.6-6.3)	1.1 (0-5.9)	-	-
Survival (years):					
Median (95%CI)	1.9 (1.5 – 2.7)				
Sex:					
Male	92 (63.9)	32 (34.2)	60 (65.2)	1	1
Female	52 (36.1)	11 (21.1)	41 (78.9)	1.16 (0.79 - 1.76)	0.97 (0.64 - 1.47)
Age at Diagnosis (Years):					
Mean (sd)	72.7 (10.1)	68.2 (9.2)	75.7 (9.9)	-	-
Median (range)	74.0 (47.7 - 96.3)	68.6 (47.7-84.3)	76.0 (49.8-92.3)	-	-
Age group					
<40	-	-	-	-	-
40 to 49	2 (1.4)	1 (50.0)	1 (50.0)	0.90 (0.11 - 7.31)	0.90 (0.11 - 7.34)
50 to 59	17 (11.8)	10 (58.8)	7 (41.2)	1	1
60 to 69	39 (27.1)	13 (33.3)	26 (66.7)	1.82 (0.79 - 4.24)	1.82 (0.78 - 4.23)
70 to 79	47 (32.6)	15 (31.9)	32 (68.1)	1.99 (0.87 - 4.51)	1.98 (0.86 - 4.54)
80+	39 (27.1)	4 (10.3)	35 (89.7)	4.08 (1.79 - 9.29)	4.10 (1.77 - 9.34)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 73: MCL Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	144 (100)	74.0 (47.7 - 96.3)	43 (29.9)	101 (70.1)	-	-
Hospital:						
Airedale	2 (1.4)	71.5 (67.0 - 76.0)	-	2 (100)	-	-
Bradford Royal	10 (6.9)	78.7 (69.0 - 85.8)	4 (40.0)	6 (60.0)	0.55 (0.22 - 1.36)	0.40 (0.16 - 1.01)
Calderdale & Huddersfield	14 (9.7)	67.7 (53.5 - 82.2)	3 (21.4)	11 (78.6)	0.85 (0.41 - 1.76)	1.11 (0.52 - 2.36)
Leeds Teaching	34 (23.6)	69.7 (51.4 - 87.5)	8 (23.5)	26 (76.5)	1	1
Harrogate & District	8 (5.6)	75.4 (47.7 - 93.0)	4 (50.0)	4 (50.0)	-	-
York Teaching	14 (9.7)	74.0 (51.6 - 92.4)	6 (42.9)	8 (57.1)	0.67 (0.30 - 1.50)	0.65 (0.29 - 1.47)
Dewsbury & District	3 (2.1)	68.6 (62.1 - 80.5)	1 (33.3)	2 (66.7)	-	-
Pinderfields General	9 (6.3)	74.2 (58.5 - 85.5)	2 (22.2)	7 (77.8)	-	-
Pontefract General	2 (1.4)	75.0 (66.8 - 83.1)	-	2 (100)	-	-
Hull & East Yorkshire	23 (16.0)	76.1 (49.8 - 96.3)	7 (30.4)	16 (69.6)	0.89 (0.48 - 1.67)	0.76 (0.41 - 1.43)
Scarborough	7 (4.9)	75.0 (61.4 - 90.9)	3 (42.9)	4 (57.1)	-	-
Grimsby (DPOW)	11 (7.6)	76.1 (63.9 - 84.0)	2 (18.2)	9 (81.8)	0.79 (0.36 - 1.72)	0.72 (0.33 - 1.57)
Scunthorpe General	6 (4.2)	70.1 (60.8 - 80.4)	2 (33.3)	4 (66.7)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	12 (8.3)	77.2 (67.0 - 85.8)	4 (33.3)	8 (66.7)	0.81 (0.37 - 1.75)	0.66 (0.30 - 1.45)
Leeds	48 (33.3)	68.3 (51.4 - 87.5)	11 (22.9)	37 (77.1)	1.12 (0.70 - 1.79)	1.31 (0.82 - 2.10)
Harrogate/York	22 (15.3)	74.0 (47.7 - 93.0)	10 (45.5)	12 (54.6)	0.83 (0.43 - 1.62)	0.88 (0.49 - 1.71)
Mid-Yorks	14 (9.7)	74.1 (58.5 - 85.5)	3 (21.4)	11 (78.6)	1.48 (0.74 - 2.94)	1.48 (0.74 - 2.96)
HYCCN ³	47 (32.6)	76.0 (49.8 - 96.3)	14 (29.8)	33 (70.2)	1	1

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 59: MCL Overall Survival




Figure 60: MCL Relative Survival




Figure 61: MCL Survival by Age at Diagnosis (Years)

Diffuse Large B - Cell Lymphoma (DLBCL)




Figure 62: DLBCL Subtypes

Table 74: DLBCL Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	1419 (100)	691 (48.7)	728 (51.3)	-	-
Follow up (years):					
Median (range)	2.0 (0-6.6)	3.7 (1.6-6.6)	0.3 (0-6.2)	-	-
Survival (years):					
Median (95%CI)	3.9 (2.8 – 5.3)				
Sex:					
Male	730 (51.4)	359 (49.2)	371 (50.8)	1	1
Female	689 (48.6)	332 (48.2)	357 (51.8)	1.03 (0.89 - 1.19)	0.94 (0.81 - 1.09)
Age at Diagnosis (Years):					
Mean (sd)	67.6 (15.2)	62.2 (15.8)	72.6 (12.7)	-	-
Median (range)	70.4 (1.6 - 97.0)	65.5 (1.6-93.5)	74.7 (17.7-97.0)	-	-
Age group					
<40	80 (5.6)	66 (82.5)	14 (17.5)	0.40 (0.22 - 0.70)	0.40 (0.22-0.70)
40 to 49	101 (7.1)	76 (75.3)	25 (24.8)	0.60 (0.38 - 0.94)	0.60 (0.38-0.94)
50 to 59	189 (13.3)	115 (60.9)	74 (39.2)	1	1
60 to 69	326 (23.0)	186 (57.1)	140 (42.9)	1.15 (0.87 - 1.53)	1.15 (0.87-1.53)
70 to 79	445 (31.4)	185 (41.6)	260 (58.4)	1.90 (1.47 - 2.46)	1.91 (1.47-2.47)
80+	278 (19.6)	63 (22.7)	215 (77.3)	3.13 (2.40 - 4.08)	3.15 (0.83-1.11)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex

Table 75: DLBCL Overall Survival by Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²	Adjusted HR (95%CI) ³	Adjusted HR (95%CI) ⁴
Total	1419 (100)	70.4 (1.6 - 97.0)	691 (48.7)	728 (51.3)	-	-		
Airedale	51 (3.6)	69.8 (27.7 - 86.9)	30 (58.8)	21 (41.2)	0.63 (0.40 - 0.99)	0.61 (0.39 - 0.96)	0.70 (0.44 -1.02)	0.90 (0.57 – 1.42)
Bradford Royal	127 (9.0)	70.4 (17.7 - 97.0)	54 (42.5)	73 (57.5)	1.03 (0.79 - 1.36)	0.88 (0.67 - 1.16)	0.99 (0.74 -1.30)	0.92 (0.69-1.21)
Calderdale & Huddersfield	128 (9.0)	72.5 (20.0 - 94.3)	62 (48.4)	66 (51.6)	0.89 (0.67 - 1.18)	0.80 (0.60 - 1.06)	0.91 (0.68-1.21)	0.90 (0.68-1.20)
Leeds Teaching	305 (21.5)	70.0 (1.6 - 96.3)	134 (43.9)	171 (56.1)	1	1	1	1
Harrogate & District	77 (5.4)	73.5 (31.1 - 90.4)	38 (49.4)	39 (50.7)	0.86 (0.60 - 1.21)	0.73 (0.52 - 1.04)	0.83 (0.58-1.18)	0.96 (0.67-1.36)
York Teaching	145 (10.2)	71.4 (13.5 - 95.7)	73 (50.3)	72 (49.7)	0.83 (0.63 - 1.09)	0.70 (0.53 - 0.92)	0.77 (0.58-1.01)	0.84 (0.64-1.11)
Dewsbury & District	60 (4.2)	69.8 (37.7 - 92.4)	28 (46.7)	32 (53.3)	1.01 (0.69 - 1.47)	0.95 (0.65 - 1.38)	1.08 (0.74-1.58)	1.06 (0.72-1.55)
Pinderfields General	72 (5.1)	67.7 (7.5 - 87.7)	39 (54.2)	33 (45.8)	0.69 (0.48 - 1.01)	0.67 (0.50 - 0.97)	0.74 (0.51-1.07)	0.78 (0.54-1.14)
Pontefract General	18 (1.3)	59.8 (42.3 - 88.5)	12 (66.7)	6 (33.3)	0.48 (0.21 - 1.08)	0.56 (0.25 - 1.26)	0.63 (0.28-1.43)	0.69 (0.30-1.56)
Hull & East Yorkshire	240 (16.9)	68.8 (19.2 - 92.0)	114 (47.5)	126 (52.5)	0.90 (0.72 - 1.14)	0.85 (0.68 - 1.07)	0.91 (0.72-1.14)	1.01 (0.81-1.28)
Scarborough	59 (4.2)	75.4 (23.6 - 92.0)	25 (42.4)	34 (57.6)	1.07 (0.74 - 1.55)	0.85 (0.59 - 1.23)	0.96 (0.66-1.40)	1.16 (0.80-1.28)
Grimsby (DPOW)	63 (4.4)	70.9 (22.9 - 89.8)	37 (58.7)	26 (41.3)	0.65 (0.43 - 0.98)	0.57 (0.40 - 0.87)	0.65 (0.43-0.99)	0.57 (0.37-0.86)
Scunthorpe General	61 (4.3)	68.3 (28.8 - 93.9)	37 (60.7)	24 (39.3)	0.65 (0.42 - 1.00)	0.62 (0.40 - 0.96)	0.71 (0.46-1.10)	0.78 (0.51-1.22)
Private	10 (0.7)	60.6 (44.4 - 92.1)	7 (70.0)	3 (30.0)	-	-	-	-
Pathlinks	3 (0.2)	76.2 (61.4-94.7)	1 (33.3)	2 (66.7)	-	-	-	-
Multi-Disciplinary Team:								
Airedale/Bradford	178 (12.6)	70.0 (17.7 - 97.0)	84 (47.2)	94 (52.8)	1.07 (0.84 - 1.37)	1.04 (0.81 - 1.32)	1.06 (0.83—1.36)	1.00 (0.78-1.28)
Leeds	433 (30.6)	70.8 (1.6 - 96.3)	195 (45.3)	237 (54.7)	1.14 (0.96 - 1.38)	1.21 (1.00 - 1.46)	1.14 (0.95-1.38)	1.06 (0.88-1.28)
Harrogate/York	222 (15.7)	72.5 (13.5 - 95.7)	111 (50.0)	111 (50.0)	1.00 (0.79 - 1.24)	0.92 (0.73 - 1.16)	0.93 (0.74-1.17)	0.96 (0.76-1.21)
Mid-Yorks	150 (10.6)	67.5 (7.5 - 92.4)	79 (52.7)	71 (47.3)	0.92 (0.70 - 1.20)	0.98 (0.75 - 1.28)	1.00 (0.76-1.31)	0.96 (0.73-1.26)
HYCCN⁵	423 (29.9)	70.3 (19.2 - 93.9)	213 (50.4)	210 (49.6)	1	1	1	1
Private	10 (0.7)	60.6 (44.4 - 92.1)	7 (70.0)	3 (30.0)	-	-	-	-
Pathlinks	3 (0.2)	76.2 (61.4-94.7)	1 (33.3)	2 (66.7)	-	-	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex, ³adjusted for age, sex and CNS Involvement. ⁴adjusted for age, sex, CNS Involvement and IPI Score. ⁵Hull & Yorkshire Coastline Cancer Network (HYCCN). CNS Involvement: Bradford Royal (n=2), Leeds Teaching (n=38), Harrogate & District (n=1), York (n=4), Pinderfields (n=1), Pontefract (n=1), Hull & East Yorkshire (n=20)

Table 76: DLBCL Overall Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²	Adjusted HR (95%CI) ³	Adjusted HR (95%CI) ⁴
Total	1419 (100)	70.4 (1.6 - 97.0)	691 (48.7)	728 (51.3)	-	-	-	-
Hospital:								
Airedale	60 (4.2)	69.9 (27.7 - 86.9)	34 (56.7)	26 (43.3)	0.68 (0.45 - 1.03)	0.66 (0.43 - 0.99)	0.72 (0.47-1.09)	0.92 (0.61-1.40)
Bradford Royal	116 (8.2)	69.4 (17.7 - 97.0)	45 (38.8)	71 (61.2)	1.15 (0.87 - 1.52)	1.10 (0.83 - 1.45)	1.06 (0.81-1.40)	0.98 (0.74-1.30)
Calderdale & Huddersfield	127 (9.0)	72.0 (20.1 - 94.3)	64 (50.4)	63 (49.6)	0.85 (0.63 - 1.13)	0.80 (0.60 - 1.07)	0.86 (0.64-1.15)	0.84 (0.63-1.12)
Leeds Teaching	305 (21.4)	70.6 (1.6 - 96.3)	135 (44.3)	170 (55.0)	1	1	1	1
Harrogate & District	83 (5.9)	73.2 (31.1 - 90.4)	41 (49.4)	42 (50.6)	0.85 (0.61 - 1.20)	0.77 (0.55 - 1.09)	0.83 (0.59-1.16)	0.96 (0.68-1.34)
York Teaching	146 (10.3)	71.1 (13.5 - 95.7)	71 (48.6)	75 (51.4)	0.89 (0.68 - 1.16)	0.80 (0.61 - 1.04)	0.83 (0.63-1.10)	0.88 (0.67-1.15)
Mid-Yorks	149 (10.5)	67.4 (7.5 - 92.4)	81 (54.4)	68 (45.6)	0.75 (0.57 - 0.99)	0.78 (0.59 - 1.03)	0.81 (0.61-1.07)	0.82 (0.62-1.09)
Hull & East Yorkshire	239 (16.8)	69.3 (19.2 - 92.0)	113 (47.3)	126 (52.7)	0.91 (0.73 - 1.15)	0.88 (0.70 - 1.12)	0.91 (0.72-1.15)	1.03 (0.81-1.29)
Scarborough	44 (3.1)	75.5 (37.4 - 92.0)	21 (47.7)	23 (52.3)	0.94 (0.61 - 1.47)	0.76 (0.49 - 1.18)	0.82 (0.53-1.27)	1.01 (0.65-1.29)
Grimsby (DPOW)	68 (4.8)	71.4 (22.9 - 89.8)	39 (57.4)	29 (42.7)	0.68 (0.46 - 1.01)	0.63 (0.43 - 0.94)	0.69 (0.46-1.02)	0.60 (0.40-0.89)
Scunthorpe General	62 (4.4)	67.8 (28.8 - 93.9)	38 (61.3)	24 (38.7)	0.65 (0.42 - 1.00)	0.64 (0.42 - 0.99)	0.69 (0.45-1.07)	0.75 (0.48-1.16)
Private	9 (0.6)	60.0 (44.4 - 92.1)	6 (66.7)	3 (33.3)	-	-	-	-
Not Treated/Non Network Hospital	11 (0.8)	72.2 (21.3 - 94.7)	3 (27.3)	8 (72.7)	-	-	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex, ³adjusted for age, sex and CNS Involvement, ⁴adjusted for age, sex, CNS Involvement and IPI Score. CNS Involvement: Bradford Royal (n=11), Leeds Teaching (n=28), Harrogate & District (n=1), York (n=4), Mid-Yorks (n=5), Hull & East Yorkshire (n=17), Scunthorpe (n=1)

Table 77: DLBCL by International Prognostic Index (IPI)

	Diagnostic N (%)	International Prognostics Index (IPI)					HR (95%CI) ¹	HR (95%CI) ²
		Low	Low/ Intermediate	Intermediate/ High	High	Not Known		
Hospital:	1419 (100)	289 (27.7)	245 (23.5)	254 (24.4)	255 (24.4)	376	-	-
Airedale	51 (3.6)	16 (34.8)	13 (28.3)	9 (19.6)	8 (17.4)	5	0.63 (0.40 - 0.99)	0.91 (0.58 – 1.44)
Bradford Royal	127 (9.0)	24 (29.3)	16 (19.5)	15 (18.3)	27 (32.9)	45	1.03 (0.79 - 1.36)	0.98 (0.74 – 1.29)
Calderdale & Huddersfield	128 (9.0)	21 (24.7)	21 (24.7)	20 (23.5)	23 (27.1)	43	0.89 (0.67 - 1.18)	0.88 (0.66 – 1.17)
Leeds Teaching	305 (21.5)	65 (30.8)	36 (17.1)	65 (30.8)	45 (21.3)	94	1	1
Harrogate & District	77 (5.4)	10 (14.7)	20 (29.4)	18 (26.5)	20 (29.4)	9	0.86 (0.60 - 1.21)	1.01 (0.71 – 1.43)
York Teaching	145 (10.2)	32 (28.6)	28 (25.0)	24 (21.4)	28 (25.0)	33	0.83 (0.63 - 1.09)	0.94 (0.72 – 1.24)
Dewsbury & District	60 (4.2)	15 (38.5)	8 (20.5)	5 (12.8)	11 (28.2)	21	1.01 (0.69 - 1.47)	1.04 (0.71 – 1.52)
Pinderfields General	72 (5.1)	20 (37.0)	12 (22.2)	5 (9.3)	17 (31.5)	18	0.69 (0.48 - 1.01)	0.73 (0.50 – 1.06)
Pontefract General	18 (1.3)	7 (43.8)	2 (12.5)	2 (12.5)	5 (31.3)	2	0.48 (0.21 - 1.08)	0.60 (0.26 – 1.35)
Hull & East Yorkshire	240 (16.9)	36 (18.3)	60 (30.5)	56 (28.4)	45 (22.8)	43	0.90 (0.72 - 1.14)	1.08 (0.86 – 1.36)
Scarborough	59 (4.2)	16 (36.4)	8 (18.2)	12 (27.8)	8 (18.2)	15	1.07 (0.74 - 1.55)	1.36 (0.94 – 1.97)
Grimsby (DPOW)	63 (4.4)	13 (31.7)	10 (24.4)	10 (24.4)	8 (19.5)	22	0.65 (0.43 - 0.98)	0.58 (0.38 – 0.87)
Scunthorpe General	61 (4.3)	14 (29.2)	11 (22.9)	13 (27.1)	10 (20.8)	13	0.65 (0.42 - 1.00)	0.76 (0.49 – 1.16)
Private	10 (0.7)	-	-	-	-	10	-	-
Pathlinks	3 (0.2)	-	-	-	-	3	-	-
Multi-Disciplinary Team:								
Airedale/Bradford	178 (12.6)	40 (31.3)	29 (22.7)	34 (18.8)	35 (27.3)	50	1.08 (0.84 - 1.37)	0.97 (0.76 – 1.24)
Leeds	432 (30.6)	86 (29.1)	57 (19.3)	85 (28.7)	68 (23.0)	137	1.16 (0.96 - 1.40)	1.09 (0.91 – 1.32)
Harrogate/York	221 (15.6)	42 (23.3)	48 (26.7)	42 (23.3)	48 (26.6)	42	1.00 (0.79 - 1.26)	0.95 (0.76 – 1.20)
Mid-Yorks	150 (10.6)	42 (38.5)	22 (20.2)	12 (11.0)	33 (30.3)	41	0.92 (0.70 - 1.21)	0.94 (0.72 – 1.23)
HYCCN ³	421 (29.8)	79 (23.9)	89 (27.0)	91 (27.6)	71 (21.5)	93	1	1
Private	10 (0.7)	-	-	-	-	10	-	-
Pathlinks	3 (0.2)	-	-	-	-	3	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for sex and IPI. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 78: DLBCL 1-Year Survival by Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²	Adjusted HR (95%CI) ³	Adjusted HR (95%CI) ⁴
Total	1419 (100)	70.4 (1.6 - 97.0)	875 (61.7)	542 (38.3)	-	-	-	-
Hospital:								
Airedale	51 (3.6)	69.8 (27.7 - 86.9)	37 (72.6)	14 (27.5)	0.55 (0.32 - 0.96)	0.56 (0.32 - 0.96)	0.65 (0.37-1.13)	0.84 (0.49-1.48)
Bradford Royal	127 (9.0)	70.4 (17.7 - 97.0)	70 (55.1)	57 (44.9)	1.02 (0.75 - 1.40)	0.89 (0.66 - 1.22)	1.01 (0.74-1.38)	0.92 (0.67-1.26)
Calderdale & Huddersfield	128 (9.0)	72.5 (20.0 - 94.3)	81 (63.3)	45 (36.7)	0.79 (0.53 - 1.18)	0.72 (0.51 - 1.00)	0.83 (0.59-1.16)	0.81 (0.58-1.13)
Leeds Teaching	305 (21.5)	70.0 (1.6 - 96.3)	166 (54.4)	139 (45.7)	1	1	1	1
Harrogate & District	77 (5.4)	73.5 (31.1 - 90.4)	48 (62.3)	29 (37.7)	0.79 (0.53 - 1.18)	0.71 (0.51 - 1.00)	0.79 (0.53-1.19)	0.94 (0.63-1.42)
York Teaching	145 (10.2)	71.4 (13.5 - 95.7)	95 (65.5)	50 (34.5)	0.74 (0.53 - 1.02)	0.63 (0.46 - 0.87)	0.69 (0.50-0.96)	0.77 (0.56-1.07)
Dewsbury & District	60 (4.2)	69.8 (37.7 - 92.4)	38 (63.3)	22 (36.7)	0.81 (0.52 - 1.27)	0.78 (0.50 - 1.22)	0.90 (0.57-1.42)	0.86 (0.55-1.35)
Pinderfields General	72 (5.1)	67.7 (7.5 - 87.7)	50 (69.4)	22 (30.6)	0.61 (0.39 - 0.95)	0.60 (0.38 - 0.93)	0.68 (0.43-1.06)	0.73 (0.47-1.15)
Pontefract General	18 (1.3)	59.8 (42.3 - 88.5)	15 (83.3)	3 (16.7)	0.32 (0.10 - 1.00)	0.40 (0.13 - 1.26)	0.45 (0.15-1.44)	0.49 (0.16-1.56)
Hull & East Yorkshire	240 (17.0)	68.8 (19.2 - 92.0)	149 (62.1)	91 (37.9)	0.81 (0.62 - 1.06)	0.79 (0.61 - 1.03)	0.84 (0.65-1.10)	0.96 (0.74-1.26)
Scarborough	59 (4.2)	75.4 (23.6 - 92.0)	31 (52.5)	28 (47.5)	1.09 (0.73 - 1.64)	0.86 (0.57 - 1.29)	0.98 (0.65-1.49)	1.15 (0.76-1.74)
Grimsby (DPOW)	63 (4.5)	70.9 (22.9 - 89.8)	47 (74.6)	16 (25.4)	0.50 (0.30 - 0.84)	0.46 (0.28 - 0.78)	0.54 (0.32-0.91)	0.47 (0.28-0.80)
Scunthorpe General	61 (4.3)	68.3 (28.8 - 93.9)	40 (65.6)	21 (34.4)	0.72 (0.45 - 1.14)	0.67 (0.42 - 1.07)	0.78 (0.49-1.26)	0.90 (0.56-1.45)
Private	10 (0.7)	60.6 (44.4 - 92.1)	7 (70.0)	3 (30.0)	-	-	-	-
Pathlinks	3 (0.2)	76.2 (61.4-94.7)	1 (33.3)	2 (66.7)	-	-	-	-
Multi-Disciplinary Team:								
Airedale/Bradford	178 (12.6)	67.0 (17.7 - 97.0)	107 (60.1)	71 (39.9)	1.13 (0.85 - 1.49)	1.10 (0.83 - 1.47)	1.14 (0.86-1.51)	1.04 (0.78-1.38)
Leeds	432 (30.6)	70.8 (1.6 - 96.3)	246 (57.0)	186 (43.1)	1.21 (0.98 - 1.50)	1.24 (1.02 - 1.54)	1.19 (0.96-1.47)	1.08 (0.87-1.34)
Harrogate/York	221 (15.6)	72.1 (13.5 - 95.7)	142 (64.2)	79 (35.8)	0.98 (0.75 - 1.29)	0.91 (0.69 - 1.19)	0.91 (0.70-1.20)	0.96 (0.73-1.26)
Mid-Yorks	150 (10.6)	67.5 (7.5 - 92.4)	103 (68.7)	47 (31.3)	0.83 (0.60 - 1.16)	0.90 (0.65 - 1.25)	0.93 (0.67-1.29)	0.87 (0.63-1.21)
HYCCN ⁵	421 (29.8)	70.3 (19.2 - 93.9)	267 (63.4)	154 (36.6)	1	1	1	1
Private	10 (0.7)	60.6 (44.4 - 92.1)	7 (70.0)	3 (30.0)	-	-	-	-
Pathlinks	3 (0.2)	76.2 (61.4-94.7)	1 (33.3)	2 (66.7)	-	-	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex, ³adjusted for age, ⁴sex and subtype, ⁵adjusted for age, sex and IPI. ⁵Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 79: DLBCL 1-Year Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²	Adjusted HR (95%CI) ³	Adjusted HR (95%CI) ⁴
Total	1419 (100)	70.4 (1.6 - 97.0)	875 (61.7)	544 (38.3)	-	-	-	-
Hospital:								
Airedale	60 (4.2)	69.9 (27.7 - 86.9)	42 (70.0)	18 (30.0)	0.62 (0.38-1.02)	0.62 (0.38-1.01)	0.69 (0.42-1.13)	0.90 (0.55-1.47)
Bradford Royal	116 (8.2)	69.4 (17.7 - 97.0)	61 (52.6)	55 (47.4)	1.14 (0.83-1.56)	1.12 (0.82-1.53)	1.07 (0.78-1.46)	0.98 (0.71-1.34)
Calderdale & Huddersfield	128 (9.0)	71.4 (20.1 - 94.3)	82 (64.1)	46 (35.9)	0.79 (0.57-1.11)	0.75 (0.53-1.04)	0.82 (0.58-1.15)	0.78 (0.56-1.10)
Leeds Teaching	304 (21.4)	70.6 (1.6 - 96.3)	168 (55.3)	136 (44.7)	1	1	1	1
Harrogate & District	83 (5.9)	73.2 (31.1 - 90.4)	54 (65.1)	29 (34.9)	0.75 (0.50-1.12)	0.69 (0.46-1.03)	0.75 (0.50-1.18)	0.90 (0.60-1.34)
York Teaching	146 (10.3)	71.1 (13.5 - 95.7)	92 (63.0)	54 (37.0)	0.82 (0.60-1.13)	0.74 (0.54-1.02)	0.77 (0.56-1.06)	0.82 (0.60-1.13)
Mid-Yorks	149 (10.5)	67.4 (7.5 - 92.4)	103 (69.1)	46 (30.9)	0.65 (0.47-0.91)	0.68 (0.49-0.95)	0.73 (0.52-1.03)	0.74 (0.53-1.04)
Hull & East Yorkshire	239 (16.8)	66.7 (19.2 - 92.0)	151 (63.2)	88 (36.8)	0.80 (0.62-1.05)	0.80 (0.61-1.04)	0.82 (0.63-1.08)	0.96 (0.73-1.25)
Scarborough	44 (3.1)	75.5 (37.4 - 92.0)	23 (52.3)	21 (47.7)	1.13 (0.71-1.78)	0.90 (0.57-1.42)	0.98 (0.62-1.56)	1.15 (0.72-1.83)
Grimsby (DPOW)	68 (4.8)	71.4 (22.9 - 89.8)	50 (73.5)	18 (26.5)	0.54 (0.33-0.88)	0.52 (0.32-0.85)	0.57 (0.35-0.94)	0.50 (0.30-0.82)
Scunthorpe General	62 (4.4)	67.8 (28.8 - 93.9)	40 (64.5)	22 (35.5)	0.76 (0.49-1.20)	0.74 (0.47-1.17)	0.81 (0.51-1.28)	0.90 (0.57-1.43)
Private	9 (0.6)	60.0 (44.4 - 92.1)	6 (66.7)	3 (33.3)	-	-	-	-
Not Treated/Not Known	11 (0.8)	79.0 (21.3 - 94.70)	3 (27.3)	8 (72.7)	-	-	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex, ³adjusted for age, sex and subtype, ⁴adjusted for age, sex and IPI




Figure 63: DLBCL Overall Survival




Figure 64: DLBCL Relative Survival




Figure 65: DLBCL Survival by Age at Diagnosis (Years)




Figure 66: DLBCL Relative Survival by Age at Diagnosis (Years)




Figure 67: DLBCL Survival by IPI Score




Figure 68: DLBCL Survival by CNS Involvement

Burkitt Lymphoma

Table 80: Burkitt Lymphoma Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	66 (100)	33 (50.0)	33 (50.0)	-	-
Follow up (years):					
Median (Range)	1.4 (0 - 6.5)	3.7 (1.6-6.5)	0.2 (0-1.2)	-	-
Survival (years):					
Median (95%CI)	1.2 (0.4 - -)				
Sex:					
Male	50 (75.6)	26 (52.0)	24 (48.0)	1	1
Female	16 (24.2)	7 (43.8)	9 (56.2)	1.38 (0.64 - 2.96)	1.01 (0.46 - 2.17)
Age at Diagnosis (Years):					
Mean (sd)	43.3 (26.4)	29.2 (23.3)	57.4 (21.6)	-	-
Median (range)	52.2 (3.1 - 88.2)	21.3 (3.4-73.8)	59.8 (3.1-88.2)	-	-
Age group					
<40	29 (43.9)	24 (82.8)	5 (17.2)	0.12 (0.04 - 0.37)	0.12 (0.04 - 0.37)
40 to 49	3 (4.6)	-	3 (100)	0.93 (0.25 - 3.47)	0.95 (0.25 - 3.56)
50 to 59	11 (16.7)	2 (18.2)	9 (81.8)	1	1
60 to 69	10 (15.2)	5 (50.0)	5 (50.0)	0.42 (0.14 - 1.26)	0.42 (0.14 - 1.27)
70 to 79	11 (16.7)	2 (18.2)	9 (81.8)	1.41 (0.55 - 3.57)	1.42 (0.56 - 3.61)
80+	2 (3.0)	-	2 (100)	1.35 (0.29 - 6.29)	1.32 (0.28 - 6.22)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 81: Burkitt Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	66 (100)	52.2 (3.1 - 88.2)	33 (50.0)	33 (50.0)	-	-
Hospital:						
Airedale	2 (3.0)	68.0 (58.3 - 77.6)	-	2 (100)	-	-
Bradford Royal	3 (4.6)	52.2 (52.1 - 64.8)	2 (66.7)	1 (33.3)	-	-
Calderdale & Huddersfield	5 (7.6)	61.4 (37.9 - 88.2)	2 (40.0)	3 (60.0)	-	-
Leeds Teaching	28 (42.4)	17.1 (37.9 - 84.3)	19 (67.9)	9 (32.1)	-	-
Harrogate & District	3 (4.6)	59.8 (55.3 - 69.2)	1 (33.3)	2 (66.7)	-	-
York Teaching	4 (6.1)	54.9 (3.4 - 70.0)	2 (50.0)	2 (50.0)	-	-
Dewsbury & District	2 (3.0)	69.5 (61.4 - 77.6)	-	2 (100)	-	-
Pinderfields General	4 (6.1)	20.3 (7.4 - 78.7)	3 (75.0)	1 (25.0)	-	-
Hull & East Yorkshire	9 (13.6)	53.3 (10.5 - 72.5)	3 (33.3)	6 (66.7)	-	-
Scarborough	3 (4.6)	71.4 (66.1 - 74.3)	1 (33.3)	2 (66.7)	-	-
Grimsby (DPOW)	-	-	-	-	-	-
Scunthorpe General	2 (3.0)	53.3 (47.9 - 58.7)	-	2 (100)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	5 (7.6)	58.3 (52.1 - 77.6)	2 (40.0)	3 (60.0)	-	-
Leeds	33 (50.0)	23.5 (3.1 - 88.2)	21 (63.6)	12 (36.4)	-	-
Harrogate/York	7 (10.6)	56.8 (3.4 - 70.0)	3 (42.9)	4 (57.1)	-	-
Mid-Yorks	7 (10.6)	57.6 (7.4 - 78.7)	3 (42.9)	4 (57.1)	-	-
HYCCN ³	14 (21.2)	60.9 (10.5 - 74.3)	4 (28.9)	10 (71.4)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 82: Burkitt Lymphoma Overall Survival by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	66 (100)	52.2 (3.1 - 88.2)	33 (50.0)	33 (50.0)	-	-
Hospital:						
Bradford Royal	4 (6.1)	55.3 (52.1 - 64.8)	2 (50.0)	2 (50.0)	-	-
Calderdale & Huddersfield	3 (4.6)	61.4 (56.7 - 88.2)	-	3 (100)	-	-
Leeds Teaching	33 (50.0)	21.3 (3.1 - 84.3)	23 (69.7)	10 (30.3)	-	-
York Teaching	4 (6.1)	54.9 (3.4 - 70.0)	2 (50.0)	2 (50.0)	-	-
Mid-Yorks	5 (7.6)	57.6 (16.9 - 78.3)	2 (40.0)	3 (60.0)	-	-
Hull & East Yorkshire	11 (16.7)	58.7 (10.5 - 72.5)	4 (36.4)	7 (63.6)	-	-
Scarborough	2 (3.0)	72.8 (71.4 - 74.3)	-	2 (100)	-	-
Grimsby (DPOW)	-	-	-	-	-	-
Private	-	-	-	-	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex




Figure 69: Burkitt Lymphoma Overall Survival




Figure 70: Burkitt Lymphoma Survival by Age at Diagnosis (Years)

Lymphoproliferative Disorder, NOS

Table 83: LPD NOS Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	330 (100)	194 (58.8)	136 (41.2)	-	-
Follow up (years):					
Median (Range)	3.2 (0-6.6)	4.1 (1.6-6.6)	1.5 (0-5.8)	-	-
Survival (years):					
Median (95%CI)	-	-	-	-	-
Sex:					
Male	174 (52.7)	103 (59.2)	71 (40.8)	1	1
Female	156 (47.3)	91 (58.3)	65 (41.7)	1.01 (0.72 - 1.41)	0.79 (0.57 - 1.12)
Age at Diagnosis (Years):					
Mean (sd)	74.5 (11.5)	71.2 (10.7)	79.2 (11.0)	-	-
Median (range)	76.9 (4.1 - 96.6)	71.5 (21.2-92.9)	80.6 (4.0-96.6)	-	-
Age group					
<40	3 (0.9)	2 (66.7)	1 (33.3)	2.49 (0.33-19.98)	2.44 (0.32-18.59)
40 to 49	6 (1.8)	6 (100)	-	-	-
50 to 59	23 (7.0)	18 (78.3)	5 (21.7)	1.19 (0.43-3.30)	1.21 (0.44-3.36)
60 to 69	76 (23.0)	62 (81.6)	14 (18.4)	1	1
70 to 79	104 (31.5)	61 (58.7)	43 (41.4)	2.79 (1.52 - 5.10)	2.94 (1.60-5.40)
80+	118 (35.8)	45 (38.1)	73 (61.9)	5.29 (2.98 - 9.40)	5.69 (3.19-10.18)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 84: LPD NOS Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	330 (100)	76.9 (4.1 - 96.6)	194 (58.8)	136 (41.2)	-	-
Hospital:						
Airedale	24 (7.3)	80.2 (54.4 - 90.9)	15 (62.5)	9 (37.5)	0.71 (0.33 - 1.52)	0.52 (0.24 - 1.14)
Bradford Royal	24 (7.3)	79.1 (49.5 - 90.1)	15 (62.5)	9 (37.5)	0.77 (0.36 - 1.66)	0.77 (0.36 - 1.67)
Calderdale & Huddersfield	24 (7.3)	77.0 (21.2 - 86.5)	15 (62.5)	9 (37.5)	0.75 (0.35 - 1.61)	0.69 (0.32 - 1.47)
Leeds Teaching	57 (17.3)	78.0 (34.8 - 96.6)	32 (56.1)	25 (43.9)	1	1
Harrogate & District	15 (4.6)	71.1 (61.1 - 85.9)	9 (60.0)	6 (40.0)	0.71 (0.29 - 1.72)	0.66 (0.27 - 1.63)
York Teaching	32 (9.7)	74.5 (56.2 - 94.6)	19 (59.4)	13 (40.6)	0.72 (0.37 - 1.41)	0.58 (0.30 - 1.15)
Dewsbury & District	13 (3.9)	77.5 (59.1 - 87.9)	9 (69.2)	4 (30.8)	0.78 (0.27 - 2.23)	0.67 (0.23 - 1.94)
Pinderfields General	23 (7.0)	77.8 (55.1 - 92.3)	9 (39.1)	14 (60.9)	1.36 (0.70 - 2.61)	1.14 (0.59 - 2.21)
Pontefract General	12 (3.6)	79.8 (69.5 - 92.9)	4 (33.3)	8 (66.7)	1.60 (0.72 - 3.55)	0.93 (0.42 - 2.10)
Hull & East Yorkshire	52 (15.8)	76.0 (45.9 - 95.0)	35 (67.3)	17 (32.7)	0.58 (0.31 - 1.07)	0.54 (0.29 - 1.00)
Scarborough	14 (4.2)	71.2 (57.9 - 96.3)	6 (42.9)	8 (57.1)	1.27 (0.57 - 2.82)	1.22 (0.55 - 2.71)
Grimsby (DPOW)	13 (3.9)	78.6 (4.1 - 88.8)	5 (38.5)	8 (61.5)	1.58 (0.71 - 3.50)	1.38 (0.62 - 3.09)
Scunthorpe General	13 (3.9)	68.7 (61.9 - 85.9)	11 (84.6)	2 (15.4)	0.24 (0.06 - 1.02)	0.24 (0.06 - 1.02)
Private	6 (1.8)	74.0 (60.4 - 85.0)	4 (66.7)	2 (33.3)	-	-
General Practice	8 (2.4)	77.0 (64.9-91.5)	6 (75.0)	2 (25.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	48 (15.6)	79.1 (49.5 - 90.9)	30 (62.5)	18 (37.5)	1.04 (0.59 - 1.84)	0.95 (0.53 - 1.68)
Leeds	81 (24.6)	77.3 (21.2 - 96.6)	47 (58.0)	34 (42.0)	1.29 (0.80 - 2.07)	1.33 (0.83 - 2.13)
Harrogate/York	47 (14.2)	73.1 (56.2 - 94.6)	28 (59.6)	19 (40.4)	1.01 (0.58 - 1.76)	0.90 (0.51 - 1.58)
Mid-Yorks	48 (15.6)	78.2 (55.1 - 92.9)	22 (45.8)	26 (54.2)	1.78 (1.07 - 2.96)	1.45 (0.88 - 2.41)
HYCCN ³	92 (27.9)	74.6 (4.1 - 96.3)	57 (62.0)	35 (38.0)	1	1
Private	6 (1.8)	74.0 (60.4 - 85.0)	4 (66.7)	2 (33.3)	-	-
General Practice	8 (2.4)	77.0 (64.9-91.5)	6 (75.0)	2 (25.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 71: LPD NOS Overall Survival




Figure 72: LPD NOS Relative Survival




Figure 73: LPD NOS Survival by Age at Diagnosis (Years)

Hodgkin Lymphoma




Figure 74: Hodgkin Lymphoma Subtypes

Table 85: Hodgkin Lymphoma Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	514 (100)	401 (78.0)	113 (22.0)	-	-
Follow up (years):					
Median (Range)	3.3 (0-6.6)	3.9 (1.6-6.6)	0.6 (0-5.6)	-	-
Survival (years):					
Median (95%CI)	-	-	-	-	-
Sex:					
Male	282 (54.9)	215 (76.2)	67 (23.8)	1	1
Female	232 (45.1)	186 (80.2)	46 (19.7)	0.78 (0.54-1.14)	0.69 (0.47-1.00)
Age at Diagnosis (years):					
Mean (sd)	45.3 (21.4)	39.9 (18.6)	64.6 (19.2)	-	-
Median (range)	41.4 (4.0-89.4)	35.7 (4.0-84.5)	70.8 (5.1-89.4)	-	-
Age group					
<40	249 (48.4)	230 (92.4)	19 (7.6)	0.39 (0.18-0.85)	0.40 (0.19-0.86)
40 to 49	52 (10.1)	51 (98.1)	1 (1.9)	0.10 (0.01-0.78)	0.09 (0.01-0.74)
50 to 59	55 (10.7)	45 (81.8)	10 (18.2)	1	1
60 to 69	63 (12.3)	41 (65.1)	22 (34.9)	2.23 (1.05-4.71)	2.28 (1.08-4.81)
70 to 79	69 (13.4)	28 (40.6)	41 (59.4)	4.78 (2.39-9.57)	5.00 (2.49-10.01)
80+	26 (5.1)	6 (23.1)	20 (76.9)	8.37 (3.89-17.99)	8.53 (3.97-18.32)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 86: Hodgkin Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	514 (100)	41.4 (4.0-89.4)	401 (78.0)	113 (22.0)	-	-
Hospital:						
Airedale	20 (3.9)	53.3 (19.4-89.0)	11 (55.0)	9 (45.0)	3.32 (1.53-7.22)	1.71 (0.78-3.76)
Bradford Royal	60 (11.7)	43.5 (10.7-80.9)	45 (75.0)	15 (25.0)	1.46 (0.76-2.81)	0.92 (0.47-1.80)
Calderdale & Huddersfield	43 (8.4)	50.2 (17.1-83.3)	33 (76.7)	10 (23.3)	1.54 (0.73-3.25)	0.84 (0.39-1.78)
Leeds Teaching	130 (25.3)	32.7 (4.0-82.1)	108 (83.1)	22 (16.9)	1	1
Harrogate & District	17 (3.3)	39.8 (16.8-89.4)	14 (82.4)	3 (17.6)	1.10 (0.33-3.67)	0.83 (0.25-2.80)
York Teaching	52 (10.1)	44.5 (12.4-82.3)	43 (82.7)	9 (17.3)	1.05 (0.48-2.29)	0.81 (0.37-1.76)
Dewsbury & District	10 (2.0)	43.4 (18.9-74.0)	7 (70.0)	3 (30.0)	1.89 (0.57-6.31)	1.02 (0.30-3.43)
Pinderfields General	34 (6.6)	37.4 (17.6-82.5)	28 (82.4)	6 (17.6)	1.04 (0.42-2.58)	0.76 (0.31-1.88)
Pontefract General	8 (1.6)	49.7 (17.4-79.1)	5 (62.5)	3 (37.5)	-	-
Hull & East Yorkshire	89 (17.5)	46.8 (13.4-88.0)	69 (77.5)	20 (22.5)	1.33 (0.72-2.43)	0.69 (0.37-1.28)
Scarborough	14 (2.7)	63.2 (21.2-81.4)	9 (64.3)	5 (35.7)	2.31 (0.88-6.11)	0.96 (0.36-2.55)
Grimsby (DPOW)	12 (2.3)	38.5 (16.6-71.9)	10 (83.3)	2 (16.7)	0.97 (0.23-4.14)	0.85 (0.20-3.61)
Scunthorpe General	18 (3.5)	38.2 (18.5-83.3)	13 (72.2)	5 (27.8)	1.69 (0.64-4.47)	1.36 (0.51-3.60)
Private	6 (1.2)	45.0 (40.9-75.2)	5 (83.3)	1 (16.7)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	80 (15.6)	45.4 (10.7-89.0)	56 (70.0)	24 (30.0)	1.28 (0.75-2.18)	1.40 (0.82-2.38)
Leeds	173 (33.7)	36.0 (4.0-83.3)	141 (81.5)	32 (18.5)	0.78 (0.48-1.27)	1.18 (0.72-1.94)
Harrogate/York	69 (13.5)	43.2 (12.4-89.4)	57 (82.6)	12 (17.4)	0.74 (0.38-1.44)	1.02 (0.52-1.99)
Mid-Yorks	52 (10.1)	40.4 (17.4-82.5)	40 (76.9)	12 (23.1)	0.96 (0.50-1.87)	1.19 (0.61-2.32)
HYCCN ³	133 (25.9)	47.6 (13.4-88.0)	101 (75.9)	32 (24.1)	1	1
Private	6 (1.2)	45.0 (40.9-75.2)	5 (83.3)	1 (16.7)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 87: Classical Hodgkin Lymphoma Patient Demographics and Overall Survival

	N (%)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	464 (100)	352 (75.9)	112 (24.1)	-	-
Follow up (years):					
Median (Range)	3.23 (0 - 6.6)	3.86 (1.59-4.57)	0.64 (0-5.59)	-	-
Survival (years):					
Median (95%CI)	-				
Sex:					
Male	249 (53.7)	183 (73.5)	66 (26.5)	1	1
Female	215 (46.3)	169 (78.6)	46 (21.4)	0.75 (0.52 - 1.10)	0.69 (0.47 - 1.01)
Age at Diagnosis (Years):					
Mean (sd)	45.4 (21.6)	39.2 (18.6)	64.5 (19.3)	-	-
Median (range)	41.2 (4.0 - 89.4)	34.9 (4.0 - 84.5)	70.7 (5.1 - 89.4)	-	-
Age group					
<40	226 (48.7)	207 (91.6)	19 (8.4)	0.40 (0.19 - 0.86)	0.41 (0.19 - 0.89)
40 to 49	43 (9.3)	42 (97.7)	1 (2.3)	-	-
50 to 59	51 (11.0)	41 (80.4)	10 (19.6)	0.11 (0.14 - 0.86)	0.11 (0.01 - 0.83)
60 to 69	57 (12.3)	35 (61.4)	22 (38.6)	2.32 (1.10 - 4.91)	2.33 (1.10 - 4.93)
70 to 79	62 (13.4)	22 (35.5)	40 (64.5)	4.99 (2.49 - 10.00)	5.30 (2.64 - 10.65)
80+	25 (5.4)	5 (20.0)	20 (80.0)	8.45 (3.93 - 18.18)	8.46 (3.93 - 18.18)

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.

Table 88: Classical Hodgkin Lymphoma Overall Survival by Diagnostic Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	464 (100)	41.2 (4.0 - 89.4)	352 (75.9)	112 (24.1)	-	-
Hospital:	18 (3.9)	59.0 (19.4 - 89.0)	9 (50.0)	9 (50.0)	3.50 (1.61 - 7.61)	1.46 (0.66 - 3.23)
Bradford Royal	52 (11.2)	46.1 (10.7 - 80.9)	38 (73.1)	14 (26.9)	1.40 (0.72 - 2.74)	0.78 (0.40 - 1.52)
Calderdale & Huddersfield	43 (9.3)	50.2 (17.1 - 83.3)	33 (76.7)	10 (23.3)	1.38 (0.65 - 2.91)	0.69 (0.32 - 1.46)
Leeds Teaching	118 (25.4)	31.7 (3.4 - 82.1)	96 (81.4)	22 (18.6)	1	1
Harrogate & District	15 (3.2)	32.3 (16.8 - 89.4)	12 (80.0)	3 (20.0)	1.13 (0.34 - 3.76)	1.04 (0.31 - 3.50)
York Teaching	45 (9.7)	42.4 (12.4 - 82.3)	36 (80.0)	9 (20.0)	1.12 (0.52 - 2.43)	0.86 (0.40 - 1.88)
Dewsbury & District	10 (2.2)	43.4 (18.9 - 74.0)	7 (70.0)	3 (30.0)	1.70 (0.50 - 5.70)	0.83 (0.24 - 2.80)
Pinderfields General	32 (6.9)	37.4 (17.6 - 82.5)	26 (81.2)	6 (18.8)	1.00 (0.40 - 2.50)	0.71 (0.28 - 1.75)
Pontefract General	6 (1.3)	59.3 (17.4 - 79.1)	3 (50.0)	3 (50.0)	2.90 (0.86 - 9.66)	1.62 (0.47 - 5.53)
Hull & East Yorkshire	79 (17.0)	51.7 (17.0 - 88.0)	59 (74.7)	20 (25.3)	1.37 (0.75 - 2.52)	0.63 (0.34 - 1.16)
Scarborough	13 (2.8)	63.1 (21.2 - 81.4)	8 (61.5)	5 (38.5)	2.24 (0.85 - 5.92)	0.84 (0.31 - 2.24)
Grimsby (DPOW)	10 (2.2)	38.5 (16.6 - 71.9)	8 (80.0)	2 (20.0)	1.01 (0.24 - 4.28)	0.76 (0.18 - 3.23)
Scunthorpe General	17 (3.7)	39.3 (18.5 - 83.3)	12 (70.6)	5 (29.4)	1.63 (0.62 - 4.30)	1.14 (0.43 - 3.03)
Private	5 (1.1)	45.0 (40.9 - 75.2)	4 (80.0)	1 (20.0)	-	-
Multi-Disciplinary Team:						
Airedale/Bradford	70 (15.1)	48.3 (10.7 - 89.0)	47 (67.1)	23 (32.9)	1.25 (0.73 - 2.14)	1.33 (0.80 - 2.29)
Leeds	161 (34.7)	34.9 (4.0 - 83.3)	129 (80.1)	32 (19.9)	1	1
Harrogate/York	60 (12.9)	41.1 (12.4 - 89.4)	48 (80.0)	12 (20.0)	0.75 (0.46 - 1.22)	1.22 (0.75 - 2.00)
Mid-Yorks	48 (10.3)	44.9 (17.4 - 82.5)	36 (75.0)	12 (25.0)	0.77 (0.39 - 1.49)	1.26 (0.64 - 2.45)
HYCCN ³	119 (25.7)	51.3 (16.6 - 88.0)	87 (73.1)	32 (26.9)	0.93 (0.48 - 1.80)	1.20 (0.61 - 2.33)
Private	5 (1.1)	45.0 (40.9 - 75.2)	4 (80.0)	1 (20.0)	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex. ³Hull & York Yorkshire Coastline Cancer Network (HYCCN)

Table 89: Classical Hodgkin Lymphoma by Treating Hospital

	Treating N (%)	Age at Diagnosis (years) Median (range)	Alive N (%)	Dead N (%)	HR (95%CI) ¹	Adjusted HR (95%CI) ²
Total	464 (100)	41.2 (4.0 - 89.4)	352 (75.9)	112 (24.1)	-	-
Hospital:						
Airedale	24 (5.2)	45.3 (19.4-89.0)	15 (62.5)	9 (37.5)	2.27 (1.06-4.90)	1.20 (0.55-2.60)
Bradford Royal	46 (9.9)	46.1 (18.3-80.9)	32 (69.6)	14 (30.4)	1.52 (0.78-2.93)	0.79 (0.41-1.53)
Calderdale & Huddersfield	41 (8.8)	50.7 (17.1-83.3)	30 (73.2)	11 (26.8)	1.54 (0.75-3.15)	0.70 (0.34-1.43)
Leeds Teaching	122 (26.3)	27.9 (4.0-82.1)	98 (80.3)	24 (19.7)	1	1
Harrogate & District	19 (4.1)	39.8 (16.8-89.4)	16 (84.2)	3 (15.8)	0.78 (0.24-2.60)	0.63 (0.19-2.10)
York Teaching	36 (7.8)	47.8 (22.2-82.3)	28 (77.8)	8 (22.2)	1.24 (0.56-2.76)	0.79 (0.35-1.77)
Mid-Yorks	51 (11.0)	37.8 (17.4-82.5)	40 (78.4)	11 (21.6)	1.13 (0.56-2.76)	0.79 (0.38-1.61)
Hull & East Yorkshire	73 (15.7)	53.3 (17.0-88.0)	54 (74.0)	19 (26.0)	1.33 (0.73-2.43)	0.54 (0.30-1.00)
Scarborough	13 (2.8)	63.1 (21.2-81.4)	9 (69.2)	4 (30.8)	1.70 (0.59-4.89)	0.69 (0.24-2.01)
Grimsby (DPOW)	12 (2.6)	42.8 (20.0-71.9)	9 (75.0)	3 (25.0)	1.23 (0.37-4.10)	0.84 (0.25-2.81)
Scunthorpe General	18 (3.9)	36.7 (18.5-83.3)	13 (72.2)	5 (27.8)	1.48 (0.56-3.87)	1.14 (0.43-2.99)
Private	7 (1.5)	42.5 (29.3-75.2)	6 (85.7)	1 (14.3)	-	-
Not Treated/Non Network Hospital	2 (0.4)	48.2 (22.2-74.2)	2 (100)	-	-	-

¹Hazard Ratio (HR) & 95% Confidence Intervals (95%CI), ²adjusted for age and sex.




Figure 75: Hodgkin Lymphoma Overall Survival




Figure 76: Hodgkin Lymphoma Relative Survival




Figure 77: Hodgkin Lymphoma Survival by Age (Years)




Figure 78: Hodgkin Lymphoma Survival by IPI Score




Figure 79: Hodgkin Lymphoma Survival by Disease Subtype

T-cell Disorders




Figure 80: T-cell Disorders

Table 90: T-cell Disorders Patient Demographics

	N (%)
Total	252 (100)
Follow up (years): Median (Range)	2.4 (0 - 6.5)
Survival (years): Median (95%CI)	3.7 (2.5 - -)
Sex:	
Male	138 (54.8)
Female	114 (45.2)
Age at Diagnosis (Years):	
Mean (sd)	64.7 (17.0)
Median (range)	67.7 (2.9 - 95.6)
Age group	
<40	20 (7.9)
40 to 49	29 (11.5)
50 to 59	37 (14.7)
60 to 69	51 (20.2)
70 to 79	65 (25.8)
80+	50 (19.8)

Table 91: T-cell Disorders by Diagnostic, Treating Hospital and Multi-Disciplinary Team

	Diagnostic N (%)	Treating N (%)
Total		
Hospital:		
Airedale	16 (6.4)	16 (6.4)
Bradford Royal	24 (9.6)	18 (7.1)
Calderdale & Huddersfield	25 (10.0)	25 (9.9)
Leeds Teaching	42 (16.7)	44 (17.5)
Harrogate & District	17 (6.8)	13 (5.2)
York Teaching	17 (6.8)	15 (6.0)
Mid York Yorkshire	-	25 (9.9)
Dewsbury & District	10 (4.0)	-
Pinderfields General	14 (5.6)	-
Pontefract General	8 (3.2)	-
Hull & East Yorkshire	38 (15.1)	39 (15.5)
Scarborough	12 (4.8)	11 (4.4)
Grimsby (DPOW)	8 (3.2)	6 (2.4)
Scunthorpe General	16 (6.4)	17 (6.8)
Private	2 (0.8)	2 (0.8)
Not Treated/Not Known	-	21 (8.3)
Multi-Disciplinary Team:		
Airedale/Bradford	40 (15.9)	-
Leeds	67 (26.7)	-
Harrogate/York	34 (13.6)	-
Mid-Yorks	32 (12.8)	-
HYCCN ¹	74 (29.5)	-
Private	2 (0.8)	-

¹Hull & York Yorkshire Coastline Cancer Network (HYCCN)




Figure 81: T-cell Disorders Overall Survival




Figure 82: T-cell Disorders Relative Survival




Figure 83: T-cell Prolymphocytic Leukaemia Overall Survival




Figure 84: T-cell or NK - cell Large Granular Lymphocytosis Overall Survival




Figure 85: Extranodal NK/T-cell Lymphoma, Nasal Type Overall Survival




Figure 86: Enteropathy - type T-cell Lymphoma Overall Survival




Figure 87: Mycosis Fungoides Overall Survival




Figure 88: Primary Cutaneous CD30 Positive T-cell Overall Survival




Figure 89: Anaplastic Large Cell Lymphoma of T/Null Type Overall Survival




Figure 90: Peripheral T-cell Lymphoma - Common; Unspecified Overall Survival




Figure 91: Angioimmunoblastic T-cell Lymphoma Overall Survival